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General introduction 
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Platelet transfusions 
Patients treated for hematological illnesses frequently experience prolonged periods of 
thrombocytopenia. The causes of thrombocytopenia are numerous and can be 
multifactorial, such as: therapy related aplasia (chemotherapy, immunotherapie or 
radiation), the repression of healthy bone marrow by an underlying illness, primary 
bone marrow aplasia, graft failure after bone marrow transplantation and graft versus 
host disease. Severe thrombocytopenia can result in mild to life-threatening bleeding 
complications1, which can be largely prevented by the timely application of donor 
platelet transfusions2•3 . Prophylactic donor platelet transfusions often consist of a 
mixture of platelets from different random volunteer donors. They are administered 
when platelet count is less than 10 x 1 09/L 4-9 or at higher counts during interventions 
or in patients with an increased bleeding risk (e.g. concomitant administration of 
anticoagulant drugs and acute promyelocytic leukemia). The efficacy of platelet 
transfusions can be deducted from the increase in platelet count after transfusion. More 
exact methods of measuring the efficacy of platelet transfusions are platelet recovery, 
fractory increase of platelet count corrected by the blood volume, or corrected count 
increment (CCI), fractory increase of platelet count corrected by the body surface 
area10-12. In this thesis we used the platelet recovery as standardized measurement for 
efficacy of platelet transfusions and is defined as: 
Platelet increment (109/L) x blood volume (l) 
%recovery=------------------- X 100 
Number of transfused platelets (1011) 
The platelet recovery is regarded as successful when 2: 20% at 1 hour after platelet 
transfusion and 2: 10% at 16 hours after platelet transfusion. 
Platelet refractoriness 
Twentyfour to 44% of random donor platelet transfusions fail to reach the desired 
platelet recovery after 1 or 16 hours13-16, which is called a platelet transfusion failure. 
Platelet transfusion failures are caused by immune or non-immune factors interfering 
with the survival of transfused donor platelets in vivo. Immune causes of transfusion 
failure are alloantibodies directed against class I human leukocyte antigens (HLA-class 
I), the only HLA-antigens that are present on platelets, against platelet specific 
antigens (HP A), against antigens of the ABO-blood group system, autoantibodies 
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against platelets or circulating immune complexes17-19. Many non-immune factors 
have been described of which the most frequently encountered factors are: 
splenomegaly, fever, concomitant medication (e.g. antibiotics, fungizone, 
cyclosporine, tacrolimus, ciprofloxacin, vancomycin, heparin, ticlopidine ), 
disseminated intravascular coagulation, radiotherapy and active blood loss. Regularly 
patients do not show any increase in platelet count inspite of repetitive random donor 
platelet transfusions resulting in platelet transfusion refractoriness and causing 
persistent severe thrombocytopenia13~16 •20-23 . It is important to prevent and, if possible, 
to eliminate the cause of the refractoriness. Therefore, alloantibody tests are used to 
detect the presence of immune causes of platelet refractoriness. 
Prevention of alloimmunization 
HLA-antigens are the most immunogenic antigens in platelet transfusions. These 
HLA-antigens are present not only on platelets but also on lymphocytes, monocytes 
and granulocytes. The presence of the latter cells in transfusion products ( erytrocyte 
and platelet concentrates and fresh frozen plasma) play an important role in 
alloantibody formation in the patient. It is shown that the overall incidence of 
alloantibodies against HLA-class I antigens can be reduced by administrating 
leukodepleted blood products to patients10•11'24'25-33 . Leukodepletion is obtained by 
applying commercially available white blood cell filters to all blood products, 
erythrocyte and platelet concentrates. Saarinen et al. demonstrated that filtrating blood 
products reduces refractoriness of patients against donor platelets from 6-93% to 0-
24%30. Especially when filtered blood products contained no more than 5 x 106 
leukocytes per transfused unit of blood refractoriness against random platelet 
transfusions was reduced to an average 3% of patients (Table 1). The patients who are 
demonstrated in Table 1 have not been prospectively studied according to similar in-
and exclusion criteria. These data, however, are a summary of the available data that 
might give an estimation of the reduction in the prevalence of refractory patients to 
random donor platelet transfusions according to the amount ofleukodepletion. 
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Table 1. Historicai overview from different studies: the number 
"'""'"''n'"c in relation to the amount of ieukodepletion 
No 
Yes 
Total 
No A 
235 (76%) 
96 (24%) 
331 
Leukodepletion 
n (%) 
MildB 
473 (84%) 
91 (16%) 
564 
Total 
n 
Rigorous c 
207 (97%) 915 
7 (3%) 194 
214 1109 
No leukodepletion means an arerage 6-1 -- 1,060 x 106 leuko(vtes per unit blood. mild 
average 5-60 x per unit blood, and 
crveraf5""e < 5 .Y uni! blood 
.-1 2-+. 25. 26, 28. 30, 31. 32. 33. 3-f. 
E 2-1, 25, 26. ]8, 31, 31 
c 
Transfusions in alloimmunized patients 
The most frequently encountered alloantibodies in patients, refractory for random 
donor platelet transfusions who are treated for hematological illnesses, are directed 
against HLA-class I antigens35 . HLA-class I matched single donor platelet transfusions 
(HLA-matched platelet transfusions) can overcome the refractoriness to transfused 
platelets. HLA-matched platelet transfusions are derived as a single donor apheresis 
product from volunteer donors who have been typed for their HLA-class I antigens. 
The HLA-matched platelet transfusions are classified as compatible, when donor and 
recipient share all HLA-A and B antigens or when the donor expresses less HLA-A 
and B antigens than the recipient (the donor is phenotypically homozygous for HLA-A 
and/or B loci). HLA-matched platelet transfusions are classified as crossreacti.ng, 
when cross-reactive HLA-mismatches between the donor and recipient HLA-A orB 
antigens are present36. HLA-class C antigens have been thought to be of little 
significance in HLA-matching of transfused platelets37. Recently, however, a case 
series has demonstrated an improvement of the recovery of HLA-matched platelet 
transfusions if donor platelets are matched for the HLA-C locus too38 . Further study is 
needed to clarify this issue. 
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Antibody detecting tests 
In the past decades many different techniques that can detect alloantibodies against 
HLA-class I antigens have been developed (Table 2). All these techniques detect the 
presence of alloantibodies against HLA-class I antigens, but some techniques 
demonstrate other immune causes of enhanced platelet destruction too (platelet 
specific antibodies, autoantibodies or immune complexes). 
Table 2. Different to detect aUoantibodies HLA-dass 
cells 
Test principle Type of antibodies References 
lymphocytotoxicity 
test (LCT) 
Complement mediated lysis of 
donor lymphocytes 
HLA 39-41 
microscopic platelet Microscopic detection of donor HLA, platelet specific, 42 
suspension platelets with fluorescence 
immunofluorescence labeled anti-1gG 
test (PSIFT) 
enzyme-linked absorbance reading of donor 
immunosorbent assay platelets with enzyme labeled 
(ELISA) anti-1gG 
monoclonal antibody- absorbance reading oflysated 
specific donor platelets with enzyme 
immobilization of 
platelet antigens 
assay (MAIPA) 
labeled anti-1gG after 
immobilization by a monoclonal 
antibody 
radioactivity counting of donor 
platelets with 1251-labeled anti-
autoantibodies, immune 
complexes 
HLA, platelet specific, 
autoantibodies, immune 
complexes 
Depending on the 
specificity ofthe 
monoclonal antibody 
HLAorHPA 
HLA, platelet specific, 
autoantibodies, immune 
monoclonal _,1-
labeled anti-1gG 
assay 1gG complexes 
flow cytometric 
platelet 
immunofluorescence 
test (P1FT) 
flow cytometric 
lymphocyte 
immunofluorescence 
test (LIFT) 
, Cr platelet lysis 
assay 
platelet radioactive 
antiglobulin test 
(PRAT) 
flowcytometric detection of donor HLA, platelet specific, 
platelets with fluorescence 
labelled anti-1gG or anti-1gM 
autoantibodies, immune 
complexes 
flowcytometric detection of donor HLA 
lymphocytes with fluorescence 
labelled anti-1gG or anti-1gM 
radioactivity counting of 
complement mediated lysis of 
51Cr-tagged donor platelets 
radioactivity counting of donor 
platelets with 1251-labeled anti-
1gG after filtrating a membrane 
HLA, platelet specific, 
autoantibodies, immune 
complexes 
HLA, platelet specific, 
autoantibodies, immune 
complexes 
43-46 
47-49 
50 
51-56 
53-56 
57 
58 
11 
The value of alloantibodies detected by lymphocytotoxicity, flowcytometric 
immunofluorescence tests, MAIP A and ELISA has been previously assessed in 
relation to the survival of transfused platelets13- 16'20-23 . Only 3 of these studies were 
performed in patients receiving filtered blood products from random donors. The study 
by Ishida was confined only to patients undergoing hematopoietic stem cell 
transplantations; the study by Fabris registered only immune causes of refractoriness; 
and the study of Legler described refractory periods of patients, but not a correlation of 
test results with the recovery of a subsequent platelet transfusion. 
Several new techniques have been introduced in recent years (Table 3). In these tests 
not panel cells are used as a target but HLA-antigens from a large volunteer donor 
group, which make these tests more standardized and more commercial. 
Table 3. to detect ali!oanl:ibodies 
standardized donor 
FlowPRA 
micro beads 
QuikScreen 
(renamed ELIHLA in 
our studies) 
Test principle Type of 
antibodies 
flowcytometric detection oflatex beads HLA 
coated with a broad range of purified 
HLA-class I with fluorescence labeled 
anti-IgG 
absorbance reading of a broad range of 
solubilized HLA class I antigens with 
enzyme labeled anti-IgG 
HLA 
HLA-dass 
References 
59,60 
61-64 
The value of these new techniques in relation the recovery of a subsequent 
leukodepleted platelet transfusion is not clear. Altogether, the contribution of immune 
and non-immune factors influencing platelet recovery in hematological patients 
receiving leukodepleted blood products still remains unclear despite previous studies. 
Alloantibody detection m patients receiving leukodepleted blood 
products 
Despite the application of leukodepletion to all blood products resulting in a reduction 
of the prevalence of immune-caused refractoriness to donor platelet transfusions, 
refractoriness by alloimmunization is still encountered (Table 1 ). The relative 
importance between antibodies against HLA-class I antigen, antibodies against platelet 
specific antigens (HP A) and non-immunological causes of platelet refractoriness have 
changed after the use ofleukodepleted blood products16 . It is not clear, however, what 
1 I 
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percentage of platelet transfusion failures are caused by immunological or non-
immunological factors in patients receiving leukodepleted blood products. When test 
characteristics of routinely used tests, e.g. LCT with a false positive result rate of 
30%13 as demonstrated in Table 4, are applied to a patient population which exhibits a 
diminished prevalence of alloantibodies against HLA-class I, because of the 
administration of leukodepleted blood products, it is to be expected that an increased 
rate of false positive test results will be encountered. 
Table 4. Number of 
poor corrected COILmil: increments 
test 
Lymphocytotoxicity test Corrected count increment Total 
negative 
positive 
Total 
n 
Good 
377 
69 
446 
Poor 
265 
161 
426 
n 
642 
230 
872 
when CCI;? iO or poor when CCI< 10. 
389{; 
In order to estimate the rate of false positive test results, according to the test 
characteristics of the LCT13 , in patients receiving random leukodepleted donor platelet 
transfusions, we combined the results of Table 1 and 4: 
(1-sensitivity) x not refractory patients 
False positive = 
(1-sensitivity) x not refractory patients + specificity x refractory patients 
False positivity= 0.15 x 207 I (0.15 x 207 + 0.38 x 7) = 0.91 = 91% 
This figure of 91% is a high number and is only a theoretical deduction from the 
available data. This number is susceptable to selection bias in the studies demonstrated 
in Table 1 and to the number oftransfusions per patient in Table 4. It is, however, very 
probable that the problem of false positivity will be large in clinics treating patients 
receiving leukodepleted platelet transfusions. The increased rate of false positive test 
I 
results may be lessened by (i) using a test that exhibits better test characteristics, 
increased sensitivity and specificity, or (ii) applying these tests to selected refractory 
patients at risk of immunological causes of platelet refractoriness. 
Rationale of the thesis 
In this thesis we deal with two aspects of alloantibody assays: (i) test characteristics 
and (ii) performance of tests in different patient populations. The :first part of this 
thesis focuses on the technical aspects of antibody detection guided by the following 
questions: 
1. Is a technique using standardized antigens (ELIHLA) as sensitive as techniques 
using panel cells (LCT, LIFT, PIFT) and are the results of these 4 different 
techniques related? 
2. Are the results of a technique that detects IgG bound to transfused platelets in vivo 
(IVBI-PIFT) related to those of an in vitro technique using panel cells ( crossmatch-
PIFT) or using standardized platelet antigens (ELIHLA)? 
3. Is binding of IgG to transfused platelets in vivo related to poor platelet recovery? 
4. Can the visual scoring method of the IVBI-PIFT reliably be objectivated by a 
mathematical method of histogram subtraction? 
The second part of the thesis deals with the predictive value of alloantibody tests on 
platelet recovery of random platelet transfusions in a non-selected patient population 
and of HLA-matched platelet transfusions in a heavely selected patient population. In 
some of the studies non-immunological factors jeopardizing the survival of platelets 
were taking into account too. These value of alloantibody assays were studied by the 
following questions: 
1. What is the prevalence of immune and non-immune causes of platelet transfusion 
failures in a non-selected patient population? 
2. Which alloantibody tests and what non-immune causes are best related to platelet 
transfusion failures in a non-selected patient population? 
14 
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3. Are the results of alloantibody tests influenced by incubation factors (in vitro 
versus in vivo) and panel cell composition, and what is the impact of these two 
factors on the relation of test results with platelet recovery? 
4. Are alloantibody tests predictive for the recovery of HLA-matched platelet 
transfusions in patients refractory for random platelet transfusions in the absence of 
non-immunological factors? 
15 
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Abstract 
Typically, immunofluorescence-based assays to detect antibodies against blood cells 
consist of separate tests on cell suspensions enriched for the individual populations. Here, 
we present a 3-color flow cytometric assay that allows the simultaneous detection of IgM 
and IgG antibodies against platelets, lymphocytes and granulocytes using a mixed 
suspension of these 3 cell populations. 
l\vlethods arnd materiaJs 
Platelets, lymphocytes and granulocytes are isolated and reconstituted in equal 
proportions, followed by incubation steps with serum and anti-human IgM and IgG 
conjugates. A mixture oflaser dye solution 751 and propidiumiodide is added to the cells 
10 min prior to flow cytometry to exclude residual erythrocytes and damaged and/or 
dead nucleated cells during data analysis on the basis of their nonreactivity, respectively 
very strong reactivity with these red-fluorescent dyes. Predefined, fixed light scatter and 
fluorescence (FL) region and marker settings, or definitions for cluster algorithms, are 
used in all experiments to identify the individual cell populations and to discriminate 
positive from negative immunofluorescence. This approach obviates the need for 
subjective adjustments of marker settings. 
R.esuilts 
We demonstrate the application of this assay using conventional list mode data analysis 
software (Cell Quest™) and cluster analysis software (Attractors™). This flow cytometric 
assay is more sensitive than conventional assays (e.g., complement-dependent 
cytotoxicity or microscopic immunofluorescence assays) for the detection of 
alloantibodies against platelets, lymphocytes and granulocytes. 
The simultaneous flow cytometric detection of IgM and IgG antibodies against platelets, 
lymphocytes and granulocytes is a rapid, sensitive and objective assay which is useful for 
detection of alloantibodies and crossmatching in transfusion medicine. 
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Introduction 
The detection of antibodies against platelets, lymphocytes and granulocytes is important 
in hematological diagnosis and therapy. Demonstration of autoantibodies on platelets or 
granulocytes is helpful in establishing the autoimmune nature of thrombocytopenia and 
granulocytopenia1. Detection and specificity assessment of alloantibodies against 
platelets is crucial for the analysis of refractoriness to platelet transfusions. Antibodies 
against HLA antigens are reactive with platelets, lymphocytes and granulocytes, whilst 
platelet-specific antibodies react only with platelets. Serological crossmatching is useful 
for the selection of compatible donors for platelet transfusion therapy?-4. 
A wide variety of techniques has been developed to detect antibodies to platelets, 
lymphocytes and granulocytes5-10. During the last 2 decades the focus has been on 
antibody detection using conjugated anti-human antibodies. Radioactive isotopes, 
enzymes or fluorochromes have been used as tracer molecules in such assays. The assay 
presented here is based on immunofluorescence. 
Direct and indirect immunofluorescence assays allow the detection of autoantibodies and 
alloantibodies, respectively. Direct assays include a single incubation step of cells with 
conjugated anti-human antibodies, followed by washing and reading. Indirect assays 
comprise 2 incubation steps: first, incubation of cells with patient (or control) serum, 
followed by washing; second, incubation with conjugated anti-human antibodies, 
followed by washing and reading. Such assays are typically performed on purified 
suspensions of platelets, lymphocytes and granulocytes. Microscopic 
immunofluorescence reading of cells in suspension requires that these suspensions are 
processed separately. These procedures are subjective and time-consuming. 
With the use of flow cytometry there is no need for separate incubations of platelets, 
lymphocytes and granulocytes, as these cell types can be distinguished simultaneously on 
the basis of their forward (FSC) and sideward (SSC) light scatter characteristics in flow 
cytometric analyses. We have developed such an assay and present now several improve-
ments in comparison to our previous report11 . First, simultaneous detection of IgM and 
IgG antibodies is achieved by the use of a mixture of anti-human IgG and IgM antibodies 
labeled with fluorescein isothiocyanate (FITC) and phycoerythrin (PE), respectively. 
Second, residual erythrocytes and damaged and/or dead nucleated cells are excluded 
from further analyses based on their nonreactivity, respectively very strong reactivity 
with a mixture of laser dye solution (LDS)-751 and propidiumiodide (PI). Third, we 
show the analysis of list mode data from this assay using automated cluster-defining 
software (Attractors™; Becton Dickinson [BDIS], San Jose, CA). 
7 
Methods and materials 
of 
Separate suspensions of platelets, mononuclear cells and granulocytes are prepared from 
a single EDT A-anticoagulated blood sample in order to prepare a test cell suspension in 
which the 3 cell populations are reconstituted in approximately equal proportions. This 
step is necessary to avoid the acquisition of too few list mode data of any of the 3 cell 
populations during flow cytometry. Platelet-rich plasma (PRP) is obtained by 
centrifugating the blood sample at 400 X g for 10 min. After removal of the PRP, residual 
platelets are harvested by reconstituting the cell pellet to the original volume of the blood 
sample using 0.027 M Naz-EDTA in 0.013 M phosphate-buffered 0.145 M NaCl, pH 7.4, 
containing 0.2% bovine serum albumin (EDTA-PBS-BSA), centrifugation and collection 
ofthe supernatant All centrifugation steps are carried out at room temperature (RT). The 
PRP and platelet-containing supernatant are pooled and centrifuged at 1200 X g for 20 
min to obtain a platelet pellet, which is washed twice using EDTA-PBS-BSA. To obtain 
granulocyte and mononuclear cell suspensions, the cell pellet that remained after platelet 
removal is diluted to approximately its original volume by the addition of a 0.2% 
methylcellulose solution in EDTA-PBS-BSA, followed by incubation for 30 to 45 min at 
37° C to allow gravity sedimentation of the erythrocytes. The leukocyte-containing 
supernatant is then harvested and the granulocytes are separated from the mononuclear 
cells by Ficoll density centrifugation at 1000 X g for 20 min. The interphase, containing 
the mononuclear cells, is collected and washed once with EDTA-PBS-BSA. Residual 
erythrocytes in the granulocyte pellet are lysed by precooled Nf4Cl solution for 5 min on 
melting ice, after which the granulocytes are washed once with EDTA-PBS-BSA. 
Thereafter, the mononuclear cells and the granulocytes each are washed once with 
EDTA-PBS without BSA (250 X g for 7 min) and fixed with 1% paraformaldehyde 
(PF A) in PBS for 5 min at RT, followed by 2 washes in EDTA-PBS-BSA. The platelets 
are then reconstituted to 150 X 109 cells/1 and the mononuclear cells and granulocytes to 
4.5 X 109 cell/l in EDTA-PBS-BSA. Finally, the test cell suspension is prepared by 
mixing equal volumes of the platelet, mononuclear cell and granulocyte suspensions. The 
use of mixed test cell suspensions yields similar results as obtained with separate 
suspensions of platelets, mononuclear cells and granulocytes11 . Unstained platelets and 
mononuclear cells can be stored unmixed for up to 4 days for immunofluorescence 
assays to obtain similar results as with freshly isolated cells, whilst storage of granulocy-
tes for >24 h results in increased background fluorescence. 
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Use LDS-751 and exdude 
Residual erythrocytes may have similar FSC and SSC characteristics as lymphocytes and 
granulocytes (violet stained events in Figure 1). The presence of erythrocytes within the 
lymphocyte and granulocyte regions (see below) interferes with the exclusive detection 
of reactivity patterns of these cells and, therefore, will lead to erroneous results. LDS-751 
stains DNA and RNA and hence allows discrimination between erythrocytes (negative) 
and nucleated cells (positive) on the basis of red fluorescence (FL). Damaged and dead 
nucleated cells, in particular granulocytes, may have increased autofluorescence and may 
bind antibodies nonspecifically. Thus, the presence of damaged and dead cells within the 
lymphocyte and granulocyte gates will hamper the sensitive and specific detection of 
antibodies on these cells. LDS-751 produces a signal of intermediate intensity in intact 
nucleated cells, but of very strong intensity in damaged cells12. Dead nucleated cells stain 
bright red with PI. Thus, the combined use of LDS-751 and PI allows the exclusion of 
erythrocytes on the basis of negativity, and the exclusion of damaged and dead cells on 
the basis ofbright red immunofluorescence (Figure 1). A working mixture ofLDS-751 
and PI (LDS-PI) is prepared for each assay by diluting 5 111 of PI (Sigma, St. Louis, MO) 
stock solution (4 mg/ml in PBS) and 5 111 LDS-751 (Exciton, Dayton, OH) stock solution 
(0.2 mg/ml in methanol) in 10 ml EDTA-PBS-BSA. 
Direct and indirect immunofluorescence assa:rs 
All incubations are performed in duplicate. 
Direct assay: 
50 111 of the test cell suspension are incubated with 50 111 of a mixture of equal volumes of 
goat-anti-human IgG conjugated with fluorescein isothiocyanate (GAHu!IgG/FITC; 
Nordic, Tilburg, the Netherlands) and goat-anti-human IgM conjugated with 
phycoerythrin (GAHullgM/PE; Southern Biotechnology Associates, Birmingham, AL) 
for 30 min in the dark at RT. The conjugated anti-human antibodies have been selected 
for their exclusive reactivity with human IgG and IgM, respectively, and titrated so as to 
obtain maximum discrimination between positive and negative signals. Following 
incubation the cells are washed three times using EDTA-PBS-BSA (250 x g for 7 min). 
After the last centrifugation step, the supernatant is removed so as to leave 25 111 buffer 
on the cell pellet. Following addition of 10 Ill LDS-PI mixture, the cells are resuspended 
and incubated for 10 min prior to flow cytometry. 
Indirect assay: 
50 111 serum are incubated with 50 111 test cell suspension for 30 min at RT, followed by 3 
washing steps. The cells are then incubated with 50 Ill of the conjugate mixture (see 
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above) for another 30 min in the dark at RT. The cells are then washed and incubated 
with LDS-PI as described above. 
Serum samples are harvested from whole blood that has been allowed to clot for 2 h at 
RT and stored at -70° C. A serum pool from multitransfused patients, reactive with 
platelets, lymphocytes and granulocytes from >90% of randomly selected cell donors, 
serves as positive control. Negative control sera are selected from sera obtained from 
untransfused males. The test cell suspensions must always chosen to be ABO compatible 
with the control and test sera, as anti-A and anti-B antibodies may react with platelets. 
This compatibility is easily realized by selecting only bloodgroup 0 donors for the cell 
panel. However, ABO-incompatible platelet crossmatches may be required for the 
selection ofHLA-matched, ABO-incompatible platelet donors. The possible contribution 
of anti-A and anti-B antibodies to positive crossmatches can be assessed in such cases by 
including in the assay a patient serum sample from which the anti-A and/or anti-B 
antibodies have been removed by adsorption. 
Data acquisition: 
We perform flow cytometry on a F ACScan instrument connected with a Macintosh 
Quadra 650 computer equipped with Cell Quest™ and Attractors™ software (BDIS). The 
appropriate instrument settings (FSC photodiode, SSC, FLl, FL2, FL3 photomultiplier 
tubes, FLl _ FL2 and FL2 _ FL3 color compensation) are verified prior to each 
experiment using QCWindows™ microbeads (Flow Cytometry Standards Corporation, 
San Juan, PR) and lymphocytes that are either unstained or stained with CD4/FITC or 
CD8/PE 13 . Careful instrument calibration is important in view of the use of predefined, 
fixed region and marker, or attractor, settings in all experiments (see below). Logarithmic 
scales are used for all parameters. Five-parameter (FSC, SSC, FLl[FITC], FL2[PE] and 
FL3[LDS/PI] list mode data of a minimum of 2,000 events per cell population, but at 
least 8,000 events, are acquired using CellQuest™ software. 
Data analysis using CellQuest™ software: 
Platelets, lymphocytes and granulocytes are selected by setting fixed regions in FSC vs. 
SSC, and SSC vs. FL3 dot plots. Platelets are FSC1ow, SSC1ow and FL31ow (green); 
lymphocytes are FSChigh,SSCintermediate and FL3int=ediate (red), whilst granulocytes are 
FSChigh, SSChigh and FL3intermediate (blue). Using CellQuest™, regions are placed similarly 
as the green, red and blue attractors in Figure 1 (upper 2 panels). 
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Fixed regions can be used throughout each experiment regardless of the number and type 
of cell donors (i.e., patient vs. blood bank donor) tested. FLI (GAHu/IgG/FITC) and FL2 
(GAHu/IgM!PE) immunofluorescence are analyzed using histograms and predefined 
marker settings that are kept constant throughout each experiment and between different 
experiments. These marker settings (Figure 2) have been defined for each cell population 
(i.e., platelets, lymphocytes and granulocytes), each anti-human Ig conjugate (i.e., IgM 
and IgG) and each assay type (direct and indirect immunofluorescence; see Results). 
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Data analysis using Attractors™ software: 
The analysis is based on the definition of a hierarchical set of attractors, i.e., once events 
have been clustered by one attractor they cannot be counted by subsequent attractors. 
Events are assigned to cell types by a set of flexible attractors. First, dead and damaged 
cells are excluded from further analyses by defining a 'black hole' attractor on the basis of 
strong FL3[LDS-751 +PI] positivity (orange events in Figure 1). Second, platelets are 
FSC10w, SSC1ow and FL31ow (green events). Third, residual erythrocytes (violet events) are 
excluded by their definition as remaining FL3 negative events. Fourth, monocytes are 
excluded on the basis of their FSC characteristics (higher than lymphocytes and 
granulocytes) and sse characteristics (intermediate between lymphocytes and granulo-
cytes; yellow events), in order to avoid their binding of human IgG antibodies through 
their high-affinity Type I Fc(IgG) receptors14. Fifth, lymphocytes are FSChigh,-
SSCintennediate and FL3intennediate (red). Sixth, granulocytes are FSChigh, SSChigh and FL3inter-
mediate (blue). 
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The binding of human IgG (FLl[FITC]) and IgM (FL2[PE]) antibodies is then analyzed 
as follows. Fixed attractors have been defined on the clusters defined by FL1 and FL2 
using 200 list mode data files ('negative' sera from 20 untransfused male donors tested 
against cells from 10 blood group 0 donors) in such a way that similar results were 
obtained as with conventional marker setting (see Results). These attractors have been 
defined for platelets, lymphocytes and granulocytes separately (Pneg, Lneg and Gneg in 
Figure 1 ). Another set of attractors encompasses the full range oflgG/FITC immunofluo-
rescence (PG, LG and GG) and a third set the whole range of IgMIPE immunofluores-
cence (PM, LM and GM). The percent cells with positive immunofluorescence for each 
cell type and Ig class is defined as the percent of events in the 'full FL range' attractor 
minus the percent of events in the corresponding 'negative population' attractor. 
Results 
and FL2 assays 
To define these markers to discriminate between positive and negative immunofluores-
cence in the indirect assays, cells from 10 blood bank donors (bloodgroup 0) were 
incubated with 20 sera from untransfused male blood bank donors (i.e., 'negative' sera) 
and the positive control serum. Examples of the reactivities of negative and positive 
control sera with platelets, lymphocytes and granulocytes as visualized with GAHu/IgG/-
FITC and GAHu/IgMIPE, are shown in Figure 3. 
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The resulting list mode data were analyzed using a series of marker settings. For each cell 
donor, cell population and marker setting the average of the percentages of positive cells 
after incubation with each of the 20 negative sera was calculated and subtracted from the 
corresponding percentage of positive cells after incubation with the positive control 
serum. The marker setting yielding the largest difference between these 2 values was 
then selected for each donor; from the 10 marker settings thus obtained, the median was 
chosen as the predefined marker setting for all subsequent experiments. 
A threshold level of percent positive cells was then defined to classify the reactivity of a 
given serum with a given cell population from a given donor as detected by a given anti-
human Ig conjugate as positive or negative. For each cell type and anti-human Ig 
conjugate, the 98th percentile of the percentage of positive cells obtained with the 
predefined marker setting on the list mode data of the 200 data points (20 sera x 10 cell 
donors) was assessed (Figure 3). Sera yielding percentages of cells exceeding that 
threshold are classified as positive for that cell population, that donor and that anti-human 
Ig conjugate. 
Performance 
The flow cytometric detection of alloantibodies against platelets and lymphocytes is 
more sensitive than detection by immunofluorescence microscopy, whilst both detection 
methods perform similarly in the detection of antibodies against granulocytes11. 
Expectedly, our flow cytometric assay (LIFT) is also more sensitive than the 
complement-cytotoxicity assay (LCT) in detecting lymphocyte-reactive antibodies, 
because the LCT does not detect antibodies that do not bind complement Of 26 sera that 
were positive in the LIFT, only 12 were also positive in the LCT, whilst 1 of26 sera that 
were negative in the LIFT, was positive in the LCT. 
The hands-on time for a series of 16 sera (plus 1 positive and 1 negative control serum) 
tested against a panel of 5 donors in duplicate is 3 h for preparation of cell suspensions, 3 
h for serum and conjugate incubations, 2 h for flow cytometric data acquisition and 1 h 
for processing the results of the automated flow cytometric data analysis. 
We have investigated the occurrence of IgM antibodies against platelets, lymphocytes 
and granulocytes in a longitudinal study of 13 patients which received platelet 
transfusions during and after chemotherapy for hematological malignancies and which 
developed IgG anti-HLA antibodies. Both classes of such antibodies could be detected in 
all patients. An example is shown in Figure 4. A 63-year old male received 
chemotherapy for refractory anemia with excess of blasts in transformation (RAEB-t). 
On 27/12 strongly reactive IgM and IgG antibodies against lymphocytes from all of 5 
panel donors became detectable, followed on 29/12 by IgM and IgG antibodies against 
platelets, indicating allosensitization against HLA At that time, 1-hour and 16-hour 
recoveries of random donor platelet transfusions had dropped to almost niL 
Administration of HLA-matched platelet transfusions on 31/12 and 6/1 led to improved 
recovenes. 
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Discussion 
The standardized isolation and staining procedures of the cells and the careful calibration 
of the flow cytometer settings allow, with conventional data analysis software (e.g., 
Cell Quest™), the use of :fixed region and marker settings throughout an experiment, no 
matter how large. The use of software using cluster analysis (i.e., Attractors™) has the 
advantage that the flexible attractors defining the cell types will move along with small 
variations in light scatter characteristics and FL3 staining of the cells. This is advanta-
geous in the case of LDS-751 which shows reversible binding to DNA/RNA as a 
function of dye concentration in the cell suspension12. This situation permits time-saving, 
walk-away, fully automated analysis of the list mode data. The results of these analyses 
can be transmitted electronically to a PC environment and processed to clinical reports 
using spreadsheets. In addition, we have developed an interface allowing the connection 
of the flow cytometry unit to our hospital information system LABZIS-2 (Hiscom, 
Leiden, The Netherlands). 
The combined detection of alloantibodies against platelets, lymphocytes and 
granulocytes provides a good indication of the specificities of such antibodies (Table 1). 
Table 1. 
Cell population 
Platelets 
Lymphocytes 
Granulocytes 
Platelets 
Lymphocytes 
Granulocytes 
Platelets 
Lymphocytes 
Granulocytes 
!hat cell 
detection of antibod.iies 
1 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Cell donor 
2 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
3 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
4 
+ 
+ 
of .results 
5 
+ 
+ 
Interpretation 
Platelet-specific antibodies 
anti-HLA antibodies 
anti-HLA and platelet-specific 
antibodies 
cells exceeding rhaz threshoid are classtfted as 
thea donor and rha! (.rJ?ri-lnunan Jg 
However, a reaction pattern exclusively with platelets may also be caused by antibodies 
against so-called cryptantigens. Such antigens are normally hidden in the cell membrane, 
but are exposed as a result of interaction between EDT A, PF A or a combination of both 
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compounds with the platelet membrane15. The binding of calcium ions by EDTA results 
in a change in conformation of the platelet glycoprotein Ilb!IIIa complex. The ability of 
PF A to interact in such a way with platelets has led us to abandon fixation of platelets in 
PFA (see above). EDTA-dependent, platelet-specific antibodies are clinically not 
relevant. Additional assays with platelets derived from citrate-anticoagulated blood are 
required as such antibodies hamper the interpretation of the test results. 
In conclusion, we have shown that using three-color flow cytometry, IgM and IgG 
antibodies against platelets, lymphocytes and granulocytes can be detected 
simultaneously in a sensitive, rapid and standardized assay of which data analysis and 
processing can be automated to a high degree. 
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Abstract 
For screenmg of alloimmunization in patients repeatedly receiving platelet 
transfusions different tests are used of which none is the standard. Here we describe a 
comparison of four tests most commonly used for detection of allo-immunization in a 
group of non-selected patients receiving platelet transfusions. 
Methods and materials 
In 99 patients with hematological malignancies who received platelet transfusions 192 
random serum samples were tested in the Enzyme-Linked Immunosorbent Assay 
(ELISA), the Lymphocytotoxic Test (LCT), the Lymphocyte Immunofluorescence 
Test (LIFT) and the Platelet Immunofluorescence Test (PIFT). Results of all tests 
were mutually compared. 
Results 
The results of all tests were significantly correlated with each other (P < 0.005). 
ELISA and LIFT were more often positive than LCT and PIFT. ELISA and LIFT 
showed the best correlation (x2 = 63.7; P < 0.001). 
Condusion 
ELISA, the least time consuming test, detects alloimmunization as often as LIFT and 
more often than LCT and PIFT. 
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Introduction 
Patients with hematological malignancies who receive intensified chemotherapy often 
need platelet support to prevent bleeding complications. Twenty-four to 44% of 
platelet transfusions fail to produce satisfactory response because of non-immune 
factors (63-67%), immune factors (18-25%) or both1-4 . In order to distinguish immune 
from non-immune factors different serological tests are routinely used. In the past 
decades the Lymphocytotoxic Test (LCT)5-7, microscopic Platelet Suspension 
Immunofluorescence Test (PSIFT)8, Enzyme - Linked Immunosorbent Assay 
(ELISA)9-12, Monoclonal Antibody - specific Immobilization of Platelet antigens 
Assay (MAIPA)13-15, monoclonal 125I-labeled anti-IgG assay C25I-MA)16, 
flowcytometric Platelet and Lymphocyte Immunofluorescence Test (PIFT respectively 
LIFT)17-22, 51Cr platelet lysis assal3 and Platelet Radioactive Antiglobulin Test 
(PRATi4 have been described. In recent years several new techniques have been 
introduced such as flowcytometry oflatex beads coated with HLA class I antigens25•26 , 
solubilized HLA class I antigens27 and commercially available ELISA tests with a 
broad range of HLA class I antigens28-30. Here we compare the test results obtained 
with a commercially available ELISA with a large panel of HLA class I antigens with 
those of the LCT and LIFT. In order to detect anti-platelet antibodies against other 
than HLA Class I antigens the PIFT was also performed in these serum samples. 
Methods and materials 
Patients 
From October 29th 1998 until August 1st 2000 192 serum samples from 99 random 
patients (Table 1), mean 1.9 transfusions per patient (range 1-8), who were treated for 
a malignant lymphoma or leukemia in our hospital were tested. Only one patient was 
treated with antithymocyte globulins; none with intravenous immunoglobulins. The 
serum samples were collected before the patients received a leucocyte depleted platelet 
transfusion, consisting of 5 random ABO-matched donors, prophylacticly when 
platelet count was less than 10 x 10911, before an intervention or because of clinical 
manifest bleeding at higher platelet counts. The median platelet count before platelet 
transfusion was 11 x 10911 (range 4-60 x 109/1). Of 192 serum samples the ELISA 
failed in 6 samples and LCT failed in 3 samples because of technical reasons. 
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Table 1. Patient characteristics 
Characteristics Category Results 
Gender Male 62 
Female 37 
Age in years Median 46 
Range 16-76 
Diagnosis ALL 5 
AML 43 
CLL 1 
CML 9 
MM 6 
NHL 18 
HL 4 
MDS 10 
Other 3 
Therapy Chemotherapy 61 
Auto BMT/SCT 10 
Allo BMT/SCT 23 
Other 5 
ALL ·= acwe Zvmphoblastic leukemia: AitiL = acute myeloid leukemia; CLL = chronic 
lymphoblastic leukemia; C'ML = chronic leukemia; Mlvf = 
non-Hodglcin 's Zvmphoma; HD = Hodg/.:in 's disease: it1DS = .>JndnHnes: 
Auto B/VfTISCT = bone marrow or peripheral stem cell 
Allo Bi\ITSCT = allogeneic bone marrow or peripheral stem 
ELISA 
QuikScreen™ was used according to manufacturer's instruction (GTI, Brookfield, WI, 
USA) by incubating patient's serum with HLA class I antigens obtained from a large 
pool of platelets from white, black and hispanic blood donors immobilized in a 
microwell strip. After adding alkaline phosphatase conjugated goat-antihuman-
immunoglobulin G (IgG) and a substrate of alkaline phosphatase p-nitrophenyl 
phosphate (PNPP) the absorbance was read at 405 nm. A result was considered to be 
positive when absorbance exceeded the absorbance of the negative control more than 2 
times. A result was rejected when dup1o results differed more than 20%. 
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LCT 
Five ml of citrate whole blood was incubated with 1-2 g Fe2+ and 2.5 m1 135 mmol/1 
NaCl, 9.0 mmol/1 Na2HP04.2H20, 2.6 mmol/1 NaH2P04.2H20, 0.05% NaN3 titrated 
up to pH= 7.2 (PBS) and was incubated for 30 minutes at 37 °C. After cooling for 10 
minutes 2.5 m1 of Lymphoprep (Pocas, Oslo, Norway) was injected beneath the 
suspension and centrifuged at 1000 G (Rotixa RP 4200, Hettich, Germany) for 20 
minutes. The interfase was washed 2 times with 11 m1 1% bovine serum albumin in 
PBS (1% BSA-PBS) and centrifuged at 450 G for 5 minutes. The cell pellet was 
suspended in 1 m1 RPMI1640/1 0% BCS (Bio Whittaker, Verviers, Belgium). Covered 
by a layer of Medinol oil 1 f!l of donor leukocyte suspension with a concentration of 3 
x 106/ml was incubated with 1 fll of patient serum for 30 minutes at room temperature 
and then 5 fll of rabbit complement was added to each well separate for 5 different 
donors. After incubating for 45 minutes 2 f!l of eosin was added for 3 minutes after 
which 10 f!l of formaldehyde was added. The wells were covered and left over night at 
4 °C . The next day dead cells were judged by phase contrast microscopy in triplet. If 2 
or 3 of the triplet showed a more than 50% lysis7 the reaction against the donor was 
considered to be positive. If 2 or more of 5 donors showed a positive reaction the 
patient was considered immunized against a broad range ofHLA-antigens. 
PIFT and LIFT 
In order to obtain platelet rich plasma (PRP) 10 m1 donor EDTA anticoagulated blood 
was centrifuged 10 minutes with 400 G. PRP was reincubated with a suspension of 10 
g ethyleendiamine-tetra-acetaat, 8.5 g NaCI, 1.61 g Na2HP04.2H20 and 0.2 g 
NaH2P04.2H20 in 1 liter Millipore H20, titrated up to pH= 7.35 with 10 mmol NaOH 
and mixed with 9 ml bovine serum albumin 22%, (EDT A-PBS 0.2% BSA) to a total of 
10 m1 and centrifuged at 1800 G for 10 minutes. After removing the supernatant 
platelets were resuspended to 7 m1 with EDTA-PBS 0.2% BSA and centrifuged at 
1800G for 10 minutes. After removing the supernatant platelets were resuspended with 
EDTA-PBS 0.2% BSA to reach a concentration of 100 x 106 per mi. To prepare a 
leukocyte cell suspension the suspension that remained after removal of PRP was 
resuspended to the original amount and lysated with precooled NH4Cl during 20 
minutes on ice and than centrifuged at 250 G for 10 minutes. After removing 
supernatant leukocytes were washed twice with EDTA-PBS 0.2% BSA at 250 G for 
10 minutes and brought to a concentration of 6 x 106/ml with EDT A-PBS 0.2% BSA. 
Finally a mixed cell suspension was prepared by mixing equal volumes of platelet and 
leukocyte suspensions. 
To 50 f!l of mixed cell suspension 50 fll of patient serum was added. After incubation 
for 30 minutes in the dark the suspension was three times resuspended with 850 fll 
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EDT A-PBS 0.2% BSA and centrifuged at 250 G for 7 minutes and incubated with 50 
fll diluted mixture of fluorescence-conjugated goat anti-IgG (FITC) (Nordic, Tilburg, 
The Netherlands). After incubation for 30 minutes in the dark the suspension was three 
times resuspended with 850 f.Ll EDTA-PBS 0.2% BSA and centrifuged at 250 G for 7 
minutes. Finally 10 f.Ll LDS-PI (5 f.Ll LDS stock (0.2 mg LDS 751 in 1 ml Methanol) 
(Applied Laser Technology, Maarheze, The Netherlands) together with 5 fll PI stock 
( 4 mg propidium iodide in 1 ml PBS) (Sigma Company, StLouis, MO, USA) in 10 ml 
EDTA-PBS 0.2% BSA) was added to the suspension and incubated for at least 15 
minutes. 
Four parameter flowcytometry was performed on a FACScan (Becton Dickinson 
Immunocytometry Systems, San Jose, CA) equipped with an air-cooled argon laser 
emitting 488 nm at 15 mW. Forward light scatter (FSC) was detected by a solid-state 
silicon detector, sideways light scatter (SSC) by one photomultiplier tube, FITC by a 
second photomultiplier tube and a 530 nm bandpass filter, Laser Dye Solution (LDS-
751) by a third photomultiplier tube and a >650 nm bandpass filter. During the 
analysis platelets and lymphocytes were discriminated by their FSC and SSC 
characteristics, while LDS-PI was used to diminish background interference of DNA 
and RNA renmants31 . Data were analyzed by a Macintosh G4 (Apple, Cupertino, CA, 
USA) in order to determine which percentage of total platelet or lymphocyte 
population exceeded a specific marker channel of fluorescence. A donor was 
considered to be positive if more than 17% and 36% of all platelets (PIFT) and 
leucocytes (LIFT) exceeded a specific marker for each cell population, respectively. 
These percentages resulted from the data of over 100 negative controls. A result per 
donor was rejected when duplo results differed more than 10%. The percentage 
positivity of all donors, thus less than 5 if a result of one donor was rejected, was 
reported. A patient was considered to be immunized against a broad range of HLA-
antigens if more than 25% of donors showed a positive result, as described 
. 1 19 21 preVIOUS y ' . 
Statistical 
The mean of the results of every test was classified as either negative or positive. For 
every combination of2 tests a 2x2 table was generated and Pearson's chi-squared was 
calculated to test for independence between two tests. All P-values are two-sided and 
P-values::;; 0.05 were considered statistically significant. 
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Results 
EUSA versus LCT 
Of 192 serum samples collected before patients received a random platelet transfusion 
185 could be analyzed in the ELISA and LCT. The results of the ELISA and LCT 
were significantly correlated (x2 = 8.6; P = 0.003)(Table 2a). Of the 19 serum samples 
that showed a positive ELISA and a negative LCT a positive LIFT and PIFT could be 
demonstrated in 12 (63%) and 5 (26%) respectively. Of the 10 serum samples that 
showed a negative ELISA and a positive LCT a positive LIFT and PIFT could be 
demonstrated in 1 (10%) and 0 (0%), respectively. 
Table 2. The 2 x 2 - tables show the of of ever)' combEnation 
of tests, Pearson~s test and the P-·'vallue 
a. 
Test LCT (n) 
Negative Positive Total 
ELISA 
Negative 150 10 160 
Positive 19 6 25 
Total 169 16 185 
b. 
Test LIFT (n) 
Negative Positive Total 
ELISA 
Negative 148 13 161 
Positive 7 18 25 
Total 155 31 186 
c. 
Test PIFT (n) 
Negative Positive Total 
ELISA 
Negative 155 6 161 
Positive 14 11 25 
Total 169 17 186 
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d. 
Test 
LCT 
Negative 
Positive 
Total 
e. 
Test 
LCT 
Negative 
Positive 
Total 
f 
Test 
LIFT 
Negative 
Positive 
Total 
Negative 
149 
9 
158 
Negative 
162 
10 
172 
Negative 
156 
19 
175 
a·~ ELISA rs. LCT: X= 8.6; P = OJJ03 
b = ELJ!J~-1 vs. LIFT: X= 63.7; P< 0.001 
c = ELI5~-1 vs. PJ1~T: X= -12.3; P "- 0.001 
d= LCTvs. LiFT: _i = 9.53; po~ 0.002 
e = LCT vs. P!FT: _i = !7.-!: P "- 0.001 
f= LJFTvs. PIFT: _i = -!0.8; P < 0.001 
ELISA versus LIFT 
LIFT (n) 
Positive 
24 
7 
31 
PIFT (n) 
Positive 
11 
6 
17 
PIFT (n) 
Positive 
5 
12 
17 
Total 
173 
16 
189 
Total 
173 
16 
189 
Total 
161 
31 
192 
ELISA and LIFT could be analyzed in 186 of 192 serum samples drawn before a 
platelet transfusion. The results of the ELISA and LIFT correlated significantly (x2 = 
63.7; P < 0.001) (Table 2b). Of the 7 serum samples that showed a positive ELISA 
and a negative LIFT a positive LCT and PIFT could be demonstrated in 0 (0%) and 1 
(14%), respectively. Of the 13 serum samples that showed a negative ELISA and a 
positive LIFT a positive LCT and PIFT could be demonstrated in 1 (7.7%) and 2 
(15%) platelet transfusions. 
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ELISA versus PJFT 
ELISA and PIFT were analyzed in 186 of 192 serum samples drawn before a platelet 
transfusion. The ELISA and PIFT correlated significantly (X2 = 42.3; P < 0.001) 
(Table 2c). Of the 14 serum samples that showed a positive ELISA and a negative 
PIFT a positive LCT and LIFT could be demonstrated in 0 (0%) and 8 (57%), 
respectively. Of the 6 serum samples that showed a negative ELISA and a positive 
PIFT a positive LCT and LIFT could be demonstrated in 0 (0%) and 2 (33%) platelet 
transfusions. 
LCT versus LIFT 
LCT was analyzed with LIFT in 189 serum samples drawn before a platelet 
transfusion. LCT and LIFT showed a significant correlation (X2 = 9.53; P = 0.002) 
(Table 2d). The LCT was positive in 9 (4.7%) samples when LIFT was negative, while 
the LIFT was positive in 24 (13%) when LCT was negative. 
LCT versus PlFT 
LCT was analyzed together with PIFT in 189 serum samples drawn before a platelet 
transfusion. 
LCT and PIFT were significantly correlated (x2 = 17.4; P < 0.001) (Table 2e). LCT 
was positive in 10 (5.3%) samples when PIFT was negative and PIFT was positive in 
11 (5.8%) when LCT was negative. 
LIFT versus PIFT 
Finally in 192 serum samples LIFT was analyzed with PIFT. LIFT and PIFT 
correlated significantly (x2 = 40.8; P < 0.001) (Table 2f). A positive LIFT was found 
in 19 (9.9%) samples when PIFT was negative and a positive PIFT was found in 5 
(2.6%) when LIFT was negative. 
Discussion 
In this study we compared three different techniques that are, with some modifications, 
commonly used for the detection of alloimmunization during platelet transfusion 
therapy. These techniques differ in several aspects: sensitivity, specificity, 
performance time, costs, materials and the necessity of recent donor blood. In the 
immunofluorescence tests (LIFT and PIFT) and in the LCT antibodies are detected 
reactive against lymphocytes or platelets, mostly against HLA antigens but not 
exclusively. For this reason PIFT and MAIPA, that also detect platelet specific 
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antibodies, are often added to LIFT and LCT. Here we used an immunofluorescence 
technique in which the detection of antibodies against lymphocytes and platelets are 
combined. The ELISA (Quikscreen™) only detects HLA class I antibodies, which 
could be a drawback, if platelet transfusion therapy did not very rarely produce 
antibodies against human platelet antigens (HP A) without the presence of antibodies 
- HLA . 3" 33 agarnst antrgens -- . 
With respect to the technical aspects, the ELISA (Quikscreen™) has several 
advantages. The average time to execute this test is 2 to 3 hours; no donor 
lymphocytes or platelets are needed and the test result is objectively generated by 
absorbometry, which results in lower costs. 
Most reports on this ELISA have been described in organ transplant patients26 - 28 most 
of whom do not receive platelet transfusion therapy. Only one report, to the best of our 
knowledge, describes the characteristics of this test in patients with hematological 
diseases30 . These patients, however, were known with refractoriness against platelets, 
experiencing febrile transfusion reactions or had in their sera nonspecific 
hemagglutination in an indirect antiglobulin test Our study was performed 
prospectively in 192 random serum samples collected in 99 patients with 
hematological malignancies without selection. We expected to :find either weaker 
antibodies or antibodies with more restricted specificity when sensibilisation occurred. 
In this way a better insight is generated in the concordance of these tests in a random 
population of patients with hematological malignancies without increased incidence of 
alloimmunization by patient selection. 
We showed that the ELISA was more frequently positive (19/185) than the LCT 
showing its superior sensitivity towards detecting alloimmunization, especially since 
the LIFT was positive in 63% of discordant serum samples. Only in 1 serum sample 
LCT was positive where ELISA was negative, probably caused by complement 
mediated cell lysis or by other toxic agents present in patient's serum. The ELISA 
showed a positive result in 7 samples while the LIFT was negative and the LIFT 
showed a positive result in 13 samples while the ELISA was negative, more probably 
pointing to a difference in antigen composition of these 2 tests than by a difference in 
sensitivity. Comparison of ELISA with PIFT showed a positive ELISA and negative 
PIFT in 14 samples, while LIFT was positive in 8 (57%). This is probably caused by 
greater sensitivity for HLA antibodies in ELISA and LIFT than in PIFT, HLA class I 
antigens being less expressed on platelets than on lymphocytes. In 4 of 6 samples that 
showed a positive PIFT (2.1% of all serum samples) a negative ELISA, LIFT and 
LCT was found. This could be caused by antibodies directed against platelet-specific 
antigens. 
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In conclusion we demonstrated that the ELISA detects alloantibodies as often as the 
LIFT and more often than the LCT. Platelet-specific antibodies are not detected in this 
test, but are infrequent in patients sensitized by random platelet transfusions without 
the presence of HLA-antibodies32· 33 . The ELISA, as a screening test, is a faster and 
cheaper than LIFT, LCT and PIFT without the need for preparation of donor cells and 
the use of elaborate equipment like a Facscan. 
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Platelet-bound immunoglobulins before and after 
platelet transfusion: measurement of in vivo binding 
397-402 
Abstract 
In routine tests to investigate immunological mechanisms as a cause for enhanced 
destruction of transfused platelets, serum from the patient is tested against a panel of 
donor lymphocytes and platelets to demonstrate the presence of antibodies against 
HLA or platelet specific antibodies. 
1\lethods and materua!s 
Here we describe a flow cytometric technique in which in v1vo binding of 
inlmunoglobulins (Ig) is measured. By comparing the histograms of the platelet 
suspensions before and after transfusion, four different patterns were obtained: no Ig 
binding before and after transfusion (pattern 1 ), pre-existent Ig binding (patterns 2 and 
3) or preferential Ig binding to the transfused platelets (pattern 4). 
Results 
This technique was tested in 164 random platelet transfusions and 34 HLA-matched 
platelet transfusions. A statistically significant association was found between pattern 
1 and a negative result of the indirect platelet immunofluorescence test for the 
detection of antibodies in the serum taken before the transfusion studied or a good 
platelet recovery and between pattern 4 and a positive indirect platelet 
inlmuno:fluorescence test or a low platelet recovery. 
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Introduction 
Patients who receive platelet transfusions are at risk of alloimmunization against HLA 
antigens or platelet-specific antigens1.2. These antibodies may interfere with the 
survival of the transfused platelets3.4 and may cause febrile transfusion reactions. The 
presence of alloantibodies against platelets and leucocytes are routinely measured by 
incubation of the serum of patients with a panel of donor cells (platelets, mononuclear 
cells and granulocytes). Several methods are used to detect the presence of these 
alloantibodies. The lymphocyte cytotoxic test (LCT) is based upon the complement-
binding capacities of antibodies and subsequent lysis of the panel cells. The enzyme-
linked immunosorbent assay (ELISA)5·6 and the monoclonal antibody-specific 
immobilization of platelet antigens (MAIP Af technique use enzymes bound to second 
antibodies and the addition of enzymedependent substrate. In the platelet, lymphocyte 
and granulocyte immunofluorescence test (PIFT, LIFT and GIFT respectively)8·9 
fluorescein-bound second antibodies are used. Although the sensitivity of these 
methods may differ, they all are based on the binding of antibodies under in vitro 
circumstances and to panel cells. In vivo circumstances, e.g. platelet-bound immune 
complexes or drug-dependent antibodies which may also jeopardize platelet survival, 
are ignored in these tests. Testing against panel cells, incubation under in vitro 
circumstances and the inability to detect platelet-bound immunoglobulins not related 
to alloantibody binding may be technical causes for the discrepancies that are found 
between the laboratory results and platelet recovery after transfusion in the clinic. Here 
we describe a technique which measured whether or not immunoglobulins (Ig) to 
platelets were bound in vivo irrespective of the platelet transfusion, as is the case with 
platelet-bound immune complexes or drug-dependent antibodies, or if binding occurs 
preferentially to the transfused platelets, as do alloantibodies. Furthermore we studied 
how these different patterns of Ig binding correlated with the indirect PIFT and with 
the platelet recovery after transfusion. 
Methods and materials 
Patients 
164 random platelet transfusions in non-refractory patients and 34 HLA-matched 
platelet transfusions in refractory patients were studied. All patients had 
haematological malignancies and were thrombocytopenic because of their disease or 
because of the therapy they received. In all patients a platelet transfusion9 was given 
prophylactically if the platelet count was 10 x 109/1 or less and at hi8gher counts in the 
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case of clinical bleeding or medical intervention. A random platelet transfusion 
consisted of five ABO-matched nylon-wool-filtered platelet units and consisted of a 
mean of 285 x 109 platelets per transfusion. 
Patients received HLA-matched transfusions if a low platelet recovery after at least 
two random platelet transfusions was found and anti-HLA antibodies were detectable 
in the indirect immunofluorescence test against a majority or all of the five panel 
lymphocytes and platelets. One unit of a HLA-matched platelet transfusion consisted 
of 289-595 x 109 platelets. 
Transfusion restnlilcs 
Before and after platelet transfusion the platelet concentration was measured. Of most 
platelet transfusions the platelet recovery (P.R.) was determined as follows 10.1 1: 
Platelet increment (1 09 /1) x blood volume (1) 
Recovery(%)= X 100 
Number of transfused platelets (1011) 
A low 1 h recovery was defined as a recovery of <20%. In the few patients of whom 
the length or body weight was not determined a low recovery was determined as an 
increment of<l5 x 109/l. 
For the detection of in vivo binding of immunoglobulins (IVBI) to platelets by the 
platelet immunoflourescence test (NBI-PIFT) the results of three suspensions per test 
were compared. The first platelet suspension was obtained by taking 5 m1 of EDT A-
anticoagulated blood before the patient received the platelet transfusion (suspension I). 
The second platelet suspension was obtained by using 1 m1 of the leftover donor 
platelets from the transfusion bag (suspension II). The third platelet suspension was 
obtained by taking 5 m1 of EDT A-anticoagulated blood from the patient 1 h after the 
platelet transfusion (suspension III). The platelet count was measured in suspension I 
and III. The three cell suspensions were left overnight at 4°C. 
Platelet-rich plasma (PRP) was obtained by centrifuging the blood containing the 
platelet suspensions I and III at 400 g for 10 min. All centrifugation steps were carried 
out at 20°C in a temperature controlled centrifuge (Rotixa RP, Hettich, Germany). The 
platelet suspensions I, II and III were washed twice in EDTA-PBS-BSA (0.027 M 
NarEDTA in 0.013 M phosphate-buffered 0.0145 M NaCl, pH 7.4, containing 0.2% 
bovine serum albumin), resuspended in EDTA-PBS-BSA and adjusted to a 
concentration of 100 x 106/ml. To 50 f..Ll of each platelet suspension 50 f..Ll of a diluted 
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mixture of fluorescein-conjugated goat anti-IgG (FITC) (NORDIC, Tilburg, The 
Netherlands) was added, mixed and incubated for 30 min in the dark at room 
temperature. Then the suspension was washed three times by adding 0.85 ml EDTA-
PBS-BSA and by centrifuging at 250 g for 7 min. To sort erythrocytes and cell 
remnants 10 f.ll LDS-PI ( 5 f.Ll PI stock, 4 mg propidium iodide in 1 ml PBS (Sigma 
Company, St. Louis, U.S.A.), together with 5 f.Ll LDS stock, 0.2 mg LDS 751 in 1 ml 
methanol (Applied Laser Technology, Maarheze, The Netherlands), in 10 ml EDTA-
PBS-BSA) was added before the platelet fluorescence was measured by flow 
cytometry. All tests were performed in duplicate. 
FRovv 
Five-parameter flow cytometry was performed on a F ACScan (Becton Dickinson 
Immunocytometry Systems, San Jose, U.S.A.), which was equipped with an air-cooled 
argon laser emitting 488 nm at 15 mW. Forward light scatter (FSC) was detected by a 
solid-state silicon detector, sideways light scatter (SSC) by one photomultiplier tube, 
FITC by a second photomultiplier tube and a 530 nm bandpass filter, PE by a third 
photomultiplier tube and a 585 nm bandpass filter (FL2), Laser Dye Solution (LDS-
751) by a third photomultiplier tube and a >650 nm bandpass filter (FL3). LDS, which 
stains DNA and RNA was used to eliminate the erythrocytes from the analysis. From 
every test-tube 8000 events (during flow cytometry a live-gate is used to select 
platelets by their FSC, SSC and FL3 characteristics) were collected, of which the data 
were stored in list mode and analysed using Consort 30 Software (B.D.I.S.). 
During the analysis LDS-PI (FL3) was used to diminish background interference of 
DNA and RNA remnants12, and the platelets were discriminated from granulocytes 
and lymphocytes by their FSC and SSC characteristics (Figure 1). 
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Of each transfusion a combined histogram was made in 'overlay histograms' of the 
logarithmical pattern obtained from platelet suspension I, II and III and visually 
scored. 
Indirect PIFT. 
To demonstrate HLA and other platelet-reactive antibodies we used a combined 
platelet and lymphocyte immunofluorescence test (indirect PIFT and LIFT) with flow 
cytometric analysis, according to Sintnicolaas et al. 8 and Gratama et al. 13 . 
Statistical methods. 
To test the correlation between the results of the IVBI-PIFT and those of the indirect 
PIFT and between the IVBI-PIFT and the platelet recovery, the Pearson chi-squared 
test was used. 
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Results 
of the 
By comparing the results of suspensions I, II and III from each platelet transfusion, 
four different patterns were seen (Figure 2). Pattern 1 shows an identical histogram of 
the suspensions before and after the transfusion compared to the histogram of the 
platelets from the transfusion bag (negative control). Pattern 2 shows a similar shift to 
the right of both the histograms obtained before and after platelet transfusion 
compared to the histogram of the platelets from the transfusion bag. Pattern 3 shows a 
shift to the right of the histogram obtained before transfusion compared to the 
histogram obtained after transfusion (and the negative control). In a variant of pattern 
3 (pattern 3b) a bimodal distribution of the histogram before transfusion is seen. 
Pattern 4 shows a shift to the right of the histogram obtained after transfusion 
compared to the histogram obtained before transfusion (and the negative control). Of 
this pattern also a bimodal distribution of the histogram after transfusion was seen 
(pattern 4b ). 
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In vivo 
We tested 164 random transfusions and compared each of the four different patterns 
described above with the results of the indirect PIFT from the serum drawn before the 
transfusion studied (Table I). The indirect PIFT was scored negative if <30% of the 
panel cells reacted positive, and the indirect PIFT was scored positive if 60% or more 
of the panel cells reacted positive. Not shown are the transfusions that reacted positive 
against 30-60% of the panel donors (antibodies with restricted specificity). The serum 
from patients whose transfusion showed pattern 1 (no Ig binding before or after 
transfusion) was negative in 92% by the Indirect PIFT. The remaining patterns scored 
positive as follows: pattern 2 (Ig binding before the transfusion), 65%, for pattern 3 (Ig 
binding before the transfusion but less binding after transfusion) 84%, and for pattern 
4 (preferential binding to the transfused platelets) 63%. The difference between pattern 
1 (a negative indirect PIFT) versus pattern 4 (a positive indirect PIFT) was significant 
(P=0.001). This was also true if pattern 1 and pattern 3 (both indicating no binding of 
IgG preferentially to the transfused platelets) were taken together (P=0.002). 
Table 1. 
Indirect PIFT < 30% Indirect PIFT > 60% 
n n 
Pattern 1 60 5 
Pattern 2 19 10 
Pattern 3 22 4 
Pattern 4 12 7 
Total 113 26 
or< 60~!1; 
reeov,e:ry 
We compared the four different patterns obtained from 164 random platelet 
transfusions with the platelet recovery after 1 h (Table 2). Pattern 1 was seen in 50/72 
transfusions (69%) with a recovery >20%. Pattern 2 was seen in 54%; pattern 3, 89%; 
and pattern 4, 33%. The difference in the distribution of pattern 1 and pattern 4 with a 
recovery of more or less than 20% respectively was significant (P=0.002), and this 
was also the case if pattern 1 and pattern 3 were taken together (P= 0.0002). 
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Table 2. I\TBI-PIFT versus recovery 
Recovery > 20% 
n 
Pattern 1 50 
Pattern2 23 
Pattern 3 23 
Pattern4 8 
Total 104 
Recovery ~ 20% 
n 
22 
19 
3 
16 
40 
Comparison between the four different pat/ems obtained in the JVBJ-PIFT and !he 
reco-very 1 h. Shown are the number 
HLA-matched transfusions in alloimmunized 
Table 3 shows the results of 34 HLA-matched platelet transfusions in immunized 
patients. All of these HLAmatched transfusions had a recovery > 20% or the platelet 
concentration increased to> 15 x 109/1 platelets. The degree of HLA matching with 
regard to the class 1 antigens (A and B locus) was scored according to Duquesnoy et 
al14: identical: all four antigens in the donor were identical to the recipient; 
compatible: three or less antigens were detected in the donor, all present in the 
recipient; crossreacting: antigens in the donor if not identical, cross-reactive with the 
recipient. 
Of 29 HLA-matched transfusions the ABO blood group of the platelet donor was 
known and ABO incompatibility was present in seven transfusions. None of these 
transfusions had pattern 1, one had pattern 2, one had pattern 3 and five had pattern 4. 
Table 3. HLA-matched transfusions in a!loimmunized 
Identical Compatible Crossreacting Total 
Pattern 1 1 6 2 9 
Pattern 2 2 8 1 11 
Pattern 3 1 3 1 5 
Pattern4 0 3 6 9 
Total 4 20 10 34 
Frequency of the four different pat!ems uhiained in the IVBJ-PJFT of 3-1 HLA-ma!ched 
b)' the degree class I match. 
60 
In vivo of immunoglobulins to transfused 
Discussion 
The use of platelet transfusions continues to increase15 .16, but the reason for enhanced 
destruction of transfused platelets often remains difficult to determine. 
Alloimmunization is one of the factors that can cause shortened survival of transfused 
platelets. Several tests are used to detect alloimmunization. The LCT detects 
antibodies against HLA epitopes17. Platelet-specific antibodies can be measured in the 
PIFT8, MAIPA7 or ELISA5·6. All these tests use panel cells. The correlation of the 
results of these tests with the platelet recovery is poor. Several reasons for this 
phenomenon can be noted: in these tests panel cells are used and not the transfused 
platelets, binding under in vitro circumstances is measured, platelet-bound immune 
complexes may be missed, drug-induced antibodies, which may also unfavourably 
affect platelet survival, are not measured, and the sensitivity of the different tests 
(mostly not quantified) may not be predictive for the rapidity of destruction of the 
platelets, as not only the amount of antibody but also the (sub )class may play a role. 
And last, but not least, non-immunological factors for shortened survival of platelets, 
such as bleeding and hepatosplenomegaly cannot always be recognized and eliminated 
in a clinical study. Here we describe a technique which has theoretical and practical 
advantages compared to the methods mentioned above. Firstly, Ig binding to the 
transfused platelets under in vivo circumstances is measured. Secondly, comparison of 
the Ig binding before and after transfusion discriminates between pre-existent higher 
Ig binding, e.g. by immunecomplexes, autoantibodies or drug-induced antibodies on 
one hand (patterns 2 and 3) and preferential binding to the transfused platelets (pattern 
4) as can be seen if alloantibodies are present on the other hand. Practical advantages 
compared to the standard methods are that the test can be performed within 4 h, no 
panel platelets are needed, and no extra amount of blood has to be drawn from the 
patient. Interpretation of the results is based on the comparison of the flow cytometric 
patterns obtained from the PIFT before and after transfusion using the pattern of the 
PIFT of the platelets from the transfusion bag as a negative control. In this series four 
different patterns were observed, a fifth pattern (shift to the right of the histogram of 
the platelets from the transfusion bag compared to the histograms of preand post-
transfusion platelets) was not seen and would make the test uninterpretable. We have 
chosen in this study for a visual scoring, because bimodal distributions were 
sometimes seen in patterns 3 and 4, which made validation of a quantitative approach 
more difficult and only possible in a larger study. For the evaluation of the IVBI-PIFT 
we compared the different patterns to the results of the indirect PIFT and the recovery 
in random transfusions. The comparison of the IVBI-PIFT and the indirect PIFT 
showed a correlation between pattern 1 and 3 (no preferential binding to the transfused 
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platelets) and a negative indirect PIFT on one hand and pattern 4 (binding to the 
transfused platelets) and a positive indirect PIFT on the other. In pattern 2 (pre-existent 
Ig binding) the correlation is less clear. In these cases binding of alloantibodies cannot 
be excluded as there was already a shift to the right. Discrepancies between the IVBI-
PIFT and the indirect PIFT can be explained by a difference in substrate (transfused 
platelets versus panel platelets), a difference in environment (in vivo and in vitro), and 
a difference in the reading of the tests (visual or quantitative). The recoveries of the 
transfusions with patterns 1 and 3 were significantly better than those of the 
transfusions with pattern 4, which is to be expected, since pattern 4 is explained by 
binding of alloantibodies to the transfused platelets. However, pattern 1 was also seen 
with a recovery <20%, pointing to destruction or loss by other than immunological 
factors. An other explanation is that pattern 1 also resulted :from a destruction of the 
transfused platelets within 1 h of transfusion (recovery 0%). However, pattern 4 was 
observed while the platelet transfusion resulted in a recovery > 20%. This implicated, 
and was also deduced :from the in vitro tests, that in vivo binding of antibodies to 
transfused platelets does not necessarily lead to enhanced destruction. Differences in 
the amount of bound IgG or subclass make-up are explanations for this phenomenon. 
Pre-existent IgG binding to platelets may be compatible with a normal 1 h survival, 
but a shortened survival over a longer period cannot be excluded. All four patterns 
were encountered in the HLA-matched transfusions, all of which had a recovery of 
>20%. Pattern 4 may be caused by the presence of crossreacting HLA antibodies, 
platelet-specific antibodies or ABO antagonism. In conclusion, the technique 
described here detects whether in vivo Ig was bound to the platelets before transfusion 
and if possible changes occurred after the platelet transfusion. If the test is used as a 
screening test to evaluate the cause of refractoriness, it may discriminate between 
alloimmunization and other immunological mechanisms that can interfere with platelet 
survival. 
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against platelets after transfusion 
Bronno van tler 
Wlllenz Gratanta 
Jrlars B. van 't Veer 
Clinical 57B: 40-46 
" J 
Abstract 
We described a technique, in v1vo binding of immunoglobulins in the platelet 
immunofluorescence test (IVBI-PIFT), that detects IgG bound in vivo to transfused 
platelets. The visually scored results of this technique, however, are susceptible to 
interobserver variation. Here we describe a more objective method to generate results 
in the IVBI-PIFT. 
and materda!s 
We studied 201 samples in 120 patients with hematological malignancies in the IVBI-
PIFT. Histogram subtraction, fluorescence (anti-IgG-FITC) histogram before platelet 
transfusion subtracted from the histogram after platelet transfusion, was compared to 
visual scoring (pattern 1: no enhanced fluorescence before and after transfusion; 
pattern 2: enhanced fluorescence both before and after platelet transfusion; pattern 3: 
enhanced fluorescence before transfusion; pattern 4: enhanced fluorescence after 
transfusion, interpreted as alloimmunization). Following histogram subtraction, the 
number of remaining events (EPS) and the mean amount of fluorescence of these 
remaining events (MCPS) were used and compared with the visual scoring and with 
platelet survival after transfusion. 
ResQJ]ts 
In 26 (13%) of the 201 samples studied in the IVBI-PIFT less than 3 of 5 observers 
agreed on the visually scored pattern. In the 175 (87%) remaining samples histogram 
subtraction showed a significant differentation between pattern 4 and patterns 1 and 2 
by using EPS, while patterns 4 and 3 were distinguished by using the MCPS. The 
combination of EPS and MCPS differentiated best between pattern 4 and patterns 1, 2 
and 3 (sensitivity 73%, specificity 96%, positive predictive value 79% and negative 
predictive value 95%). Predictive value for platelet recovery after 1 and 16 hours of 
both pattern 4 from the visual scoring method and the results of histogram subtraction, 
however, was poor. 
Conclusion 
We describe an objective method of histogram subtraction that correlates well with the 
visual scoring method of the IVBI-PIFT. 
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Introduction 
Patients who receive platelet transfusions are at risk of alloimmunization against HLA 
antigens or platelet-specific antigen1'2. These antibodies may interfere with the 
survival of the transfused platelets3A and may cause febrile transfusion reactions. The 
presence of alloantibodies against platelet and leucocyte antigens are routinely 
measured by incubation of the serum of patients with a panel of donor cells (platelets, 
mononuclear cells and granulocytes). Several methods have been described to detect 
the presence of these alloantibodies: the Lymphocytotoxic Test (LCT)5-7, microscopic 
Platelet Suspension Immunofluorescence Test (PSIFT)8, Enzyme-Linked 
Immunosorbent Assay (ELISA)9- 12, Monoclonal Antibody-specific Immobilization of 
Platelet antigens Assay (MAIPA)13-15, monoclonal 125I-labeled anti-IgG assay (125I-
MA)16, flow cytometric Platelet and Lymphocyte Immunofluorescence Test (PIFT 
respectively LIFT)17- 21 , 51Cr platelet lysis assal2 and Platelet Radioactive 
Antiglobulin Test (PRAT)23 . Although the sensitivity of these methods may differ, 
they all are based on the binding of antibodies under in vitro circumstances and to 
panel cells. In vivo circumstances, e.g. platelet-bound immune complexes or drug-
dependent antibodies which may also adversely affect platelet survival, are not 
evaluated by these tests. Testing against panel cells rather than against platelets of the 
transfused donor(s), incubation under in vitro circumstances and the inability to detect 
platelet-bound immunoglobulins (Ig) not related to alloantibody binding may be 
technical causes for the discrepancies that are found between the laboratory results and 
platelet recovery after transfusion in the clinic. Previously we have described a test 
that detects IgG bound to (transfused) platelets in vivo, the In Vivo Binding of 
Immunoglobulins in the Platelet Immunofluorescence Test (IVBI-PIFTf4. In this work 
the results of the IVBI-PIFT were visually scored by a single blinded observer. We 
demonstrated that preferential binding of immunoglobulins after platelet transfusion 
(pattern 4) was associated with significantly lower platelet recoveries than when n,o 
binding of immunoglobulins after platelet transfusion took place (pattern 1 ). The 
introduction of the IVBI-PIFT in our clinic revealed a considerable inter-observer 
variability for the visual scoring of of the 4 different patterns. Here we evaluate the use 
of histogram subtraction as an objective alternative for the subjective visual 
comparison of paired histograms, and correlated the results of both methods of data 
interpretation with the corresponding platelet recoveries at 1 and 16 hours after 
transfusion. 
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Methods and materials 
From October 1994 until August 2000 201 paired serum samples (before and after 
transfusion) were studied in 120 random patients, mean 1.7 transfusions per patient 
(range 1-7), who were treated for a malignant lymphoma or leukemia in our hospital. 
Patients received a platelet transfusion of random donors prophylactically (i) when 
platelet count was less than 10 x 10911, (ii) before an intervention or (iii) because of 
clinical manifest bleeding at higher platelet counts. The serum samples were collected 
before and one hour after the platelet transfusion. 
Iv"Bl-PIFT 
The NBI-PIFT method has been described elswhere24. In short: after the collection of 
whole blood, before and after platelet transfusion, the results of three platelet 
suspensions after incubation with a mixture of fluorescein-conjugated goat anti-IgG 
(FITC) were used: I: before transfusion, II: the transfusion bag and III: 1 hour after 
transfusion. Per suspension a histogram, showing the distribution of IgG-fluorescence 
on a logarithmic scale, was obtained by collecting 4-parameter flow cytometry data 
from 8,000 platelets. Of each transfusion an overlay histogram was composed from the 
fluorescence of platelet suspensions I, II and III. All tests were performed in duplicate. 
subtraction 
The histograms of the IgG-fluorescence of suspension I (prior to transfusion) was 
subtracted from the histogram of suspension III (post transfusion). This was done by 
subtracting the number of platelets for each fluorescence channel separately (linear 
scale of256 histogram channels). If differences between the corresponding channels of 
histogram I and III resulted in negative values these were replaced by zero events in 
the subtraction histogram (Figure 1 ). 
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Histogram II was used as a negative control (see below). This leaves a subtraction 
histogram that can be characterised by the number of remaining events (=total number 
of platelets of all fluorescence channels after this subtraction) and the mean 
fluorescence of the remaining events. First, "Events post subtraction" (EPS) was 
defined as the average of all remaining events of both (duplicate) subtraction 
histograms. Second, "Mean channel post subtraction" (MCPS) was defined as the 
average ofthe mean channel values ofboth (duplicate) subtraction histograms. 
Visual 
Patterns were scored independently and blinded by 5 observers according to the 
following definitions: 
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Pattern 1: similar shapes of histograms of the suspensions I, II and III (interpretation: 
no alloimmunization). Pattern 2: strongly resembling shifts to the right of both the 
histograms of suspension I and III relative to suspension II (interpretation: binding of 
IgG not related to alloimmunization). Pattern 3: a shift to the right of the histogram of 
suspension I relative to suspension III (interpretation: preferential binding of IgG to 
own or previously transfused platelets). Pattern 4: a shift to the right of the histogram 
of suspension III relative to suspension I (interpretation: alloimmunization) (Figure 
2i4. When 3 or more of all 5 observers indicated the same pattern for both (duplicate) 
overlay histograms per platelet transfusion, this was considered as the consensus 
pattern and was used for further analysis. 
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Pliate!et transfusion :results 
A successful platelet transfusion was defined as a recovery of platelets after 
transfusion of20% or more after 1 hour or 10% or more after 16 hours25•26: 
Platelet increment (10911) x blood volume (1) 
%recovery= X 100 
Number of transfused platelets (1011) 
Statistical methods. 
EPS and MCPS as continous variables were compared with the consensus patterns 1, 
2, 3, and 4 using the Kruskal-Wallis test. Pearson's chi-squared test or Fisher's exact 
test, whichever appropriate, was used to compare the EPS and MCPS, after 
dichotomization into the lower two-thirds and the higher one-third, with the 4 
consensus patterns. Univariate logistic regression was used to calculate P-values for 
differences in recovery for the visual and histogram subtraction method with 
adjustment for multiple transfusions in single patients. All P-values are two-sided and 
P-values s; 0.05 were considered statistically significant. 
Results. 
VnsuaJ vs. EPS and MCPS results 
In 201 transfusions the results of the NBI-PIFT were both visually scored and 
generated by histogram subtraction. In 26 (13%) of the transfusions studied in the 
IVBI-PIFT less than 3 of 5 observers agreed on the pattern so that no consensus was 
reached. The comparison of the histogram subtraction results with the visually scored 
patterns of the NBI-PIFT was, therefore, performed in 17 5 transfusions administered 
to 111 patients. 
Expectedly, the median number of EPS was significantly higher for transfusions 
showing pattern 4 (alloimmunization) as compared to those with pattern 1 and 2 (no 
alloimmunization) 1480, 615 and 566, respectively (Figure 3A), but no difference was 
found with transfusions showing pattern 3, of which the median EPS was 1222. The 
median value ofMCPS was significantly higher in pattern 4 than in pattern 3, 49 and 7 
respectively (Figure 3B), but no difference was found with transfusions showing 
pattern 1 and 2, MCPS being 23 and 46, respectively. 
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Dichotomization of the transfusions into a upper one-third (N = 58) with EPS 2: 1040 
and the lower two-third (N = 117) with EPS < 1040 revealed the following 
correlations (Table 1). The proportion of transfusions with EPS 2: 1040 was 
significantly higher for pattern 3 and 4 than for pattern 1 and 2 (i.e., 52 of72 [72%] vs. 
6 of 103 [6%] transfusions, respectively, P < 0.0001). 
dichotomnzation into a fioveer thvo-third and a 
EPSt 
< 1040 
2: 1040 
MCPS 
< 37 
2:37 
Pattern 1 
n=82 
79 
3 
60 
22 
7
- l<J < 0. 0001 jOr pa!tern 3 and -lrs. 
2') 3 and 4 
Pattern 2 
n =21 
18 
3 
10 
11 
1 and] 
/ P < ]JalleiJJ 3 rs.JJa!tern -! 
Pattern 3 
n=42 
14 
28 
39 
3 
Pattern 4 
n=30 
Total 
n = 175 
6 117 
24 58 
8 117 
22 58 
The difference between pattern 3 and 4 on the one hand and patterns 1 and 2 on the 
other, is caused by the fact that the positions of the data in histograms I and III are 
divergent for patterns 3 and 4, and to a large extent overlapping for patterns 1 and 2 
(Figure 2). In contrast, the proportion of transfusions with MCPS 2: 37 was clearly 
higher in pattern 4 than for pattern 3 (i.e., 22 of 30 [73%] vs. 3 of 42 [7%] 
transfusions, respectively, P < 0.0001). This difference is caused by the fact that the 
posstransfusional histogram (III) is situated far more to the right than the 
pretransfusional histogram (I) in pattern 4, whilst the reverse is true for pattern 3 
(Figure 2). 
vs. EPS combined with MCPS 
A combination of EPS and MCPS was used to generate more distinction between a 
positive or negative test result. The proportion of transfusions that demonstrated EPS 2: 
1040 and MCPS 2: 37, these values were described above after dichotomization, was 
significantly higher for pattern 4 (63%) than for pattern 1 (2%), 2 (14%), and 3 (5%) 
(P < 0.001) (Table 2). This resulted in a sensitivity of 63%, a specificity of 95%, a 
positive predictive value of 73% and a negative predictive value of 93% in 
differentiating pattern 4 from pattern 1, 2 and 3. 
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Table 2. Combination 
Pattern 1 Pattern 2 
n = 82 n =21 
.EPS ~ 1040 AND MCPS ~ 37t 
< 1040 80 18 
~ 1040 2 3 
MCPS ~ 1100 AND MCPS ~ 3o+ 
< 37 80 19 
~37 2 2 
1, 2, 3 and 4 
Pattern 3 
n=42 
40 
2 
40 
2 
Pattern 4 
n =30 
11 
19 
8 
22 
Total 
n = 175 
149 
26 
147 
28 
l'wo conzbinations f!fcul-c~ffJ70intsjOr _~_~]JS and 1\IC~J)S conzparer.l to Jlattern~v !, 2. 3 and -1. 
other 
EPS::O: 10..f.OANDMCPS:;o:37 
EPS::O: 1100 AND !HCPS:;o: 30 
AND A! CPS 2: 37" ·No= all 
The combination of EPS and MCPS was investigated further in order to find a cut-off 
point that showed the best combination of sensitivity, specificity, positive predictive 
value and negative predictive value. The best cut-off point was found in the 
combination of EPS ~ 1100 and MCPS ~ 30, resulting in a sensitivity of 73%, a 
specificity of 96%, a positive predictive value of 79% and a negative predictive value 
of 95%, for differentiating pattern 4 from patterns 1, 2 and 3 (Table 2). 
Visual subtraction vs. recovery 
The visual scoring method demonstrated no larger proportion of poor platelet recoveries 
after 1 and 16 hours for pattern 4 compared to the recoveries of pattern 1, 2 and 3 (P = 
0.89 and P = 0.95, respectively). The proportion of poor platelet recoveries after 1 and 16 
hours of all patterns differed significantly (P = 0.02) and borderline significantly (P = 
0.06), respectively. This was mainly caused by the correlation of pattern 2 with poor 
platelet recovery after both 1 and 16 hours. 
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Table 3. Visual of and subtraction 2: HOO AND 
vs. the number of successful transfusions after 6 hours 
Recovery after 1 hourt 
n(%) 
Recovery after 16 hours:t:* 
n (%) 
Visual scoring 
Pattern 1 
Pattern2 
Pattern3 
Pattern4 
~20% 
42 (51%) 
2 (11%) 
21 (50%) 
13 (43%) 
<20% 
40 (49%) 
19 (89%) 
21 (50%) 
17 (57%) 
~10% 
50 (64%) 
7 (35%) 
27 (75%) 
18 (62%) 
Histogram subtraction results (EPS 2: 1100 AND MCPS 2: 30) 
No 66 (45%) 81 (55%) 84 (61%) 
Yes 12 (43%) 16 (57%) 18 (69%) 
<10% 
28 (36%) 
13 (65%) 
9 (25%) 
11 (38%) 
53 (39%) 
8 (31 %) 
Recovery c~:fier 1 Jumr: P = 0.02fi;r all pat!ems, P = 0.89 jor pattem .:/compared with rhe 
n7\'lfJUT'I7171 Sllbfmclion 
all pattems. P = 0.95 
pattem 1, pat/em 2. 6 
subtraction and 2 
Subsequently, a positive result of the histogram subtraction (EPS 2: 1100 and MCPS 2: 
30) did not demonstrate an association with poor platelet recovery after 1 and 16 hours 
(P = 0.85 and P = 0.42, respectively). 
Discussion 
Of all platelet transfusion 24 to 44% do not result in the expected platelet 
increment3'27 . Because platelet transfusion failure is often multicausal in patients with 
hematological diseases a test that reliably detects alloimmunization can be a step 
forward in selecting patients in need of HLA-matched or cross-matched platelet 
transfusions. Recently we have shown that pattern 4 of the IVBI-PIFT significantly 
correlates with a low recovery of a subsequent platelet transfusion in patients at risk 
for alloimmunization24. The results of the IVBI-PIFT, however, were visually scored, 
a method subjected to inter-observer variation. 
In this study the inter-observer variation of the visually scoring ofthe patterns, defined 
as less than 3 of5 observers reporting the same pattern, was 13% (26 serum samples), 
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which was in accordance to our experience during clinical practice. In order to study 
the association of the histogram subtraction with the visual scoring method we 
compared the results of histogram subtraction with the "golden standard" visual 
scoring method, in which 3 or more of the 5 observers agreed on the visually scored 
pattern, and excluded these 26 transfusions from further study. We can not exclude 
that this exclusion may be selective. 
In order to objectivate the results of the IVBI-PIFT histogram subtraction was 
introduced by subtracting the fluorescence histogram of a serum sample before 
transfusion from the fluorescence histogram after the platelet transfusion. We 
previously have studied the effect of subtracting the mean or median of the histograms. 
This did not lead to a reliable substitution of the visual scoring method (data not 
published), because of biphasic curves before or after transfusion or because of a 
substantial difference in the range of the channel numbers with events before or after 
transfusion. Because of these difficulties we studied the subtraction of the number of 
events per channel number in 175 samples in which also consensus could be reached 
by the visual scoring method. This histogram subtraction resulted in the variables EPS 
and MCPS. The EPS 2: 1040 clearly demonstrated a significant differentiation between 
pattern 3 and 4 on one hand and 1 and 2 on the other hand. Subsequently pattern 3 and 
4 could be differentiated by MCPS 2: 37. 
We set out to generate a positive or negative test result of the IVBI-PIFT by 
combining the EPS and MCPS. When the combination of the dichotomization cut-off 
for EPS and MCPS was used (EPS 2: 1040 and MCPS 2: 37) a good differentiation 
between pattern 4 and patterns 1, 2 and 3 could be achieved. Other cut-off points were 
also tested, which resulted in a best cut-off point characterised by EPS 2: 1100 and 
MCPS 2: 30. This cut-off point showed a better sensitivity, positive predictive value 
and negative predictive value than the original cut-off point while maintaining the 
same specificity. Still 8 (27%) transfusions demonstrating pattern 4 were negative in 
the histogram subtraction method, and 6 (4%) transfusions demonstrating pattern 1, 2 
or 3 were positive in the histogram subtraction method. This cut-off point has no 
universal meaning because it is sensitive to laboratory dependent factors such as 
temperature, incubation time, laser emitting wave length and fluorescence antibody 
concentration, so it should be validated for each laboratory. 
Finally, in order to validate the technique the results of the visual scoring method and the 
histogram subtraction method were compared to platelet recovery after 1 and 16 hours of 
the studied platelet transfusion. No significant correlation could be demonstrated between 
pattern 4 of the visual scoring method and recovery after 1 and 16 hours. Pattern 2, 
however, did demonstrate a significant negative correlation with platelet recovery both 
after 1 and 16 hours, but the numbers are small. This may indicate the importance of 
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immune complexes as a causative agent in enhanced destruction of transfused platelets. 
Pattern 4, defined as increased IgG present on transfused platelets, was interpreted as 
compatible with alloimmunization and may be used to select patients for HLA-matched 
platelet transfusions. Here we demonstrate, however, that binding of IgG to transfused 
platelets does not necessarily lead to enhanced donor platelet destruction. The majority of 
discrepancies between test results and platelet recovery are probably caused by non-
immunological factors causing enhanced platelet destruction present at the time of 
transfusion28. 
In conclusion we demonstrated that histogram subtraction of the IVBI-PIFT by 
combining EPS and MCPS is a reliable and objective substitution for visually scored 
consensus patterns. In this study, however, no correlation was demonstrated between 
pattern 4 of the visual scoring method or a positive histogram subtraction result and 
platelet recovery after 1 and 16 hours. 
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Abstract 
Allo-antibodies against HLA-antigens can be reduced by applying leucodepletion to 
transfusions. Because the importance of immunological and non-immunological 
causes of poor platelet transfusion results using leucodepleted transfusions is not clear 
we conducted a prospective study in an unselected patients population receiVmg 
leucodepleted transfusions. 
In 97 patients with hematological malignancies 181 random leucodepleted platelet 
transfusions were studied for immunological causes of poor platelet transfusion results 
by calculating the odds ratio of 4 different screening tests for a low platelet recovery. 
Non-immune causes were also studied by calculating the odds ratio of the most 
prevalent non-immune causes for a low platelet recovery. 
No single screening test showed an association with recovery after 1 and 16 hours 
following a platelet transfusion. The combination of a positive ELISA and PIFT or a 
combination of a positive LIFT and PIFT, demonstrating an association with a low 
platelet recovery after 16 hours, was present in 2% of all platelet transfusions. Of non-
immune causes splenomegaly and storage time of platelets of more than 3 days were 
associated with low platelet recovery after 1 hour and 16 hours being present in 29% 
and 47% of all platelet transfusions, respectively. 
Conchnsions 
Immunological causes account for a small proportion of poor platelet transfusion 
results compared to non-immunological causes in a non-selected patient population 
receiving leucodepleted transfusions. 
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Introduction 
Patients with hematological malignancies may have prolonged periods of 
thrombocytopenia caused by bone marrow involvement or treatment. Platelet 
transfusions, mostly from random donors, are given beneath a platelet count of 10 x 
109/1 to reduce the risk of bleeding1-3. Many platelet transfusions, however, do not 
result in the expected platelet recovery because of immunological factors in 18-70% 
(anti-HLA antibodies, anti-HPA antibodies; ABO-mismatch, circulating immune 
complexes)4-19and non-immunological factors in 33-67% (splenomegaly, bone marrow 
transplantation, Amphotericin B, Ciprofloxacin, Tacrolimus, Cyclosporine, 
Vancomycin, Fluconazol, hyperbilirubinemia; total body irradiation; disseminated 
. 1 1 . d d d' fi . )9 11 13-17 19-71 mtravascu ar coagu anon, a vance 1sease status, ever, seps1s, etc. · · · - . 
Sensitization by random donor platelet transfusions against HLA and platelet specific 
antigens is one of the causes that can be measured and circumvented by the use of 
platelets compatible for the antigens involved. Leucodepleted transfusions have shown 
to diminish the prevalence of sensitization against HLA antigens, the most frequent 
immunological cause of platelet refractoriness14·22- 25 . Several tests are used to 
demonstrate the presence of allo-antibodies against platelet antigens but the prevalence 
of positive test results in an unselected patient population receiving leucodepleted 
transfusions is not clear6'7'26-34. Also non-immunological factors that can diminish 
platelet recovery in an unselected patient population receiving leucodepleted platelet 
transfusions are not well-defined. In order to clarify these issues we conducted a 
prospective study in which both immunological causes, as measured by four different 
tests, and the most prevalent non-immunological causes were related to platelet 
recovery. 
Methods and Materials 
Patients 
From December 1998 until August 2000 181 serum samples collected from randomly 
selected platelet transfusions from 97 random patients were tested, mean 1.9 
transfusions per patient (range 1-8) who were treated for a malignant lymphoma or 
leukemia in our referral hospital (Table 1).The serum samples were collected before 
patients received a random donor platelet transfusion when platelet count was less than 
10 x 109/1 to prevent bleeding, or at higher counts before an intervention or because of 
clinical manifest bleeding. The median platelet count before transfusion was 11 x 10911 
(range 4-60 x 109/1). 
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Table 1. Patient characteristics 
Characteristics Category Number 
Sex Male 61 
Female 36 
Age in years Median 46 
Range 16-76 
Diagnosis ALL 4 
AML 43 
CLL 1 
CML 9 
MM 6 
NHL 18 
HD 4 
MDS 9 
Other "' .) 
Therapy Chemotherapy 59 
Auto BMT/SCT 10 
Allo BMT/SCT 23 
Other 5 
.~LL = acwc ~vmphoblasuc leukemia; .cliYfL = acute myeloid leukemia; CLL ~, chronic 
leukemia; CA1L = chronic myeloid leukemia; A1lvl = multiple myeloma; NHL = 
non-Hodgkin 's HD = Hodgkin's disease: jvJDS = s~vmlromes: 
Awo B!vfTISCT = autologous bone marrow stem cell 
· J.llo BMT SCT = allogeneic hone marrow 
Platelet concentrates 
Platelet concentrates were obtained from the Sanquin Blood Bank South West Region 
and were prepared from the blood of 5 HLA-unmatched ABO-matched volunteer 
donors. The average content of the platelet concentrates was 4 x 1011 platelets in 250 
mL The platelet concentrates were filtered by a PLX-5 Asahi filter (Baxter, La Chatre, 
France) to deplete the transfusion from leucocytes. The average leukocyte number was 
0.05 x 106 per platelet concentrate (range 0.00-0.20 x 106). In patients receiving a bone 
marrow or peripheral stem cell transplantation the platelet concentrates were irradiated 
by 25 Gy in order to prevent graft versus host disease (GvHD) by transfused 
lymphocytes35 . The platelet concentrates were stored at 22 °C until used for 
transfusion. Also erythrocyte concentrates were always leucocyte depleted and 
irradiated for the same reasons as stated above. 
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Platelet transfusion. results 
A successful platelet transfusion was defined as a recovery of platelets after 
transfusion of 20% or more after 1 hour or 10% or more after 16 hours1736. 
Platelet increment (109 11) x blood volume (1) 
%recovery= X 100 
Number of transfused platelets (1011) 
Methods used for the detection of antibodies 
I. Enzyme Linked Immunosorbent Assay (ELISA) 
QuikScreen TM was used according to manufacturer's instruction (GTI, Brookfield, WI, 
USA) by incubating patient's serum with HLA class I antigens obtained from a large 
pool of platelets from white, black and Hispanic blood donors immobilized in a 
microwell strip. After adding alkaline phosphatase-conjugated goat-antihuman 
immunoglobulin G (IgG) and a substrate of alkaline phosphatase p-nitrophenyl 
phosphate (PNPP) the adsorbance was read at 405 nm. A result was considered to be 
positive when adsorbance exceeded the adsorbance of the negative control more than 2 
times. All tests were performed in duplicate; if the results of duplicate tests differed 
more than 20%, the result was rejected This test detects antibodies against HLA-
antigens. 
II. Lymphocyte Cytotoxic Test (LCT) 
After centrifuging at 1000 G (Rotixa RP 4200, Hettich, Germany) with 2.5 ml of 
Lymphoprep (Pocas, Oslo, Norway) and washing 2 times with 11 ml 1% bovine serum 
albumine in PBS (1% BSA-PBS) the mononuclear cell fraction from 5 different 
donors was separately suspended in 1 ml RPMI1640 (Hyclone, Logan, Utah, 
U.S.A.)/10% BCS (Bio Whittaker, Verviers, Belgium). Covered by a layer ofMedinol 
oil! f.Ll of this cell fraction with a concentration of3 x 106/ml was incubated with 1 f.ll 
of patient serum for 30 minutes at room temperature and then 5 f.Ll of rabbit 
complement was added to each well separately for the 5 different donors. After 
incubating for 45 minutes 2 f.Ll of eosine was added for 3 minutes after which 10 f.ll of 
formaldehyde was added. The wells were covered and left over night at 4 °C . The next 
day dead cells were judged by phase contrast microscopy in triplet. If 2 or 3 of the 
triplet showed a more than 50% lysis the reaction against the donor was considered to 
be positive. If 2 or more of 5 donors showed a positive reaction the patient was 
considered immunized against a broad range of HLA-antigens. This test detects 
lymphocytotoxic antibodies, mainly against HLA-antigens. 
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IlL Platelet and Lymphocyte Immunofluorescence Test (PIFT and LIFT) 
Tbis modified method was used as described elsewhere37 . In short, four parameter 
flow cytometry was performed on a platelet and lymphocyte population from a panel 
of 5 donors after incubation with patient's serum and a diluted mixture of 
fluorescence-conjugated goat anti-IgG. A donor was determined positive when the 
fluoresence showed more than 17% and 36% of all platelets (PIFT) and lymphocytes 
(LIFT), respectively, exceeding a specific marker. A patient was considered 
immunized against a broad range of HLA-antigens if 40% or more of all donors 
showed a positive result. A result was rejected when duplo results differed more than 
10%. The PIFT measures all causes of IgG bound to platelets (antibodies against 
HLA- and platelet-specific antigens and immune complexes). The LIFT measures 
mainly antibodies against HLA-antigens as previously described38•39. 
Non-immune factors 
Of all transfusions the following patient related factors were scored: sex, diagnosis, 
therapy, splenomegaly, fever (>38.2 °C), disseminated intravascular coagulation 
(DIC), graft versus host disease (GvHD), Amphotericin B administration and storage 
time of platelet transfusions from acquisition to donation (Dtime - Atime)· 
St3ltistical 
The endpoints of tbis study were platelet recovery after transfusion of 20% or more 
after 1 hour and 10% or more after 16 hours. The percentage of platelet transfusions 
with successful recovery was calculated for the different subgroups, and univariate 
logistic regression was used to calculate P-values for differences in recovery between 
the subgroups with adjustment for multiple transfusions in single patients. All P-values 
are two-sided and P-values:::; 0.05 were considered statistically significant. 
Results 
Immune factors 
A total of 181 platelet transfusions were studied in 97 patients. Test results were 
complete 181 times (100%) in the PIFT and LIFT, 178 times (98%) in the LCT, because 
of technical failure, and 175 times (97%) in the ELISA, because of more than 20% 
variation in duplo results. A recovery ofless than 20% after 1 hour or less than 10% after 
16 hours was seen in 72 (40%) and 67 (37%) transfusions, respectively. The recovery 
after 1 hour of less than 20% showed a positive test result of the ELISA in 12 (17%), 
LCT in 5 (7%), LIFT in 12 (17%) en PIFT in 8 (11 %) sera (Table 2A). 
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Table 2. lJniv:cu·iate 
a. 
ELISA 
Negative 
Positive 
LCT 
Negative 
Positive 
LIFT 
Negative 
Positive 
PIFT 
b. 
Negative 
Positive 
ELISA 
Negative 
Positive 
LCT 
Negative 
Positive 
LIFT 
Negative 
Positive 
PIFT 
Negative 
Positive 
In1n1une and non-i;nmune causes of lo\v recn·veries 
of recovery- ?: 20% a~ 
transfusions in 
Total 
n 
151 
24 
162 
16 
151 
30 
164 
17 
Total 
n 
151 
24 
162 
16 
151 
30 
164 
17 
Recovery ~ 20% 
n (%) 
93 (62%) 
12 (50%) 
95 (59%) 
11 (69%) 
91 (60%) 
18 (60%) 
100 (61%) 
9 (53%) 
Recovery ~ 10% 
n (%) 
95 (63%) 
14 (58%) 
99 (61%) 
13 (81%) 
98 (65%) 
16 (53%) 
107 (65%) 
7 (41%) 
OR (95%CI) P-value 
0.24 
1 
0.6 (0.3-1.4) 
0.45 
1 
1.6 (0.5-4.8) 
0.98 
1 
1.0 (0.5-2.1) 
0.46 
1 
0.7 (0.3-1.7) 
OR (95%CI) P-value 
0.65 
1 
0.8 (0.4-1.9) 
0.12 
1 
2.8 (0.8-9.9) 
0.28 
1 
0.6 (0.3-1.5) 
0.06 
1 
0.4 (0.1-1.0) 
n = rmmher (?ftran~fitsions; OR = odd>' ratio; 95%CI = 95% confidence interval 
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The recovery after 16 hours of less than 10% showed a positive ELISA in 10 (15%), 
LCT in 3 (5%), LIFT in 14 (21%) and PIFT in 10 (15%) sera (Table 2B). No statistically 
significant correlation between test results and recovery after 1 or 16 hours could be 
demonstrated (Table IIA and IIB). 
Positive tests when recovery after 1 hour was more than 20%, was found in 12 (11 %), 11 
(10%), 18 (17%) and 9 (8%) sera in ELISA, LCT, LIFT and PIFT respectively and after 
16 hours in 14 (13%), 13 (12%), 16 (14%) and 7 (6%) sera. In order to increase the 
specificity of tests a combination of HLA-antibody measuring tests (ELISA, LCT and 
LIFT) and PIFT was investigated. No correlation was found between a recovery after 1 
hour ofless than 20% and a positive ELISA, LCT or LIFT in combination with a positive 
PIFT. The only statistically significant association was demonstrated between a recovery 
after 16 hour of less than 10% and a positive ELISA and PIFT, P = 0.04, or a positive 
LIFT and PIFT, P = 0.03 . 
In 124 transfusions (69%), in which all tests were found to be negative, a recovery of 
less than 20% after 1 hour and less than 10% after 16 hours was found in 50 ( 40%) and 
50 (40%), respectively. In 43 (86%) of the 50 transfusions with negative tests and low 
recovery after 1 hour one or more non-immunological causes of low recovery 
(splenomegaly, fever, Amphotericine B administration, DIC, more than 3 days 
between platelet acquisition and donation) were present. In 39 (78%) of the 50 
transfusions with negative tests and low recovery after 16 hour one or more non-
immunological causes of low recovery were present. 
Non-immune factors 
Several non-immune factors showed an association with a low platelet recovery (Table 
3A and IIIB). 
Splenomegaly showed a correlation withlowplateletrecoveryboth 1 hour (P < 0.01) and 
16 hours (P = 0.02) after platelet transfusion. Presence of CML diagnosis also correlated 
with a low platelet recovery after 1 hour (P < 0.01) and 16 hours (P = 0.02) when 
compared with AML diagnosis. However, in 15 of 21 transfusions in patients with CML 
splenomegaly was present. Allogeneic stem cell transplantation correlated well with a 
low platelet recovery after 1 hour (P = 0.01) and 16 hours (P = 0.05). Also in 12 of 16 
transfusions in patients with allogeneic stem cell transplantation splenomegaly was 
present. Female sex correlated with high platelet recovery after 1 hour (P = 0.05) but not 
after 16 hours (P = 0.68). Further study of this issue showed that splenomegaly was 
almost solely present in male patients ( 44 male patients vs. 8 female patients). When 
patients with splenomegaly were left out of the analysis no association could be 
demonstrated between female sex and high platelet recovery after 1 hour anymore. 
Longer storage time of platelet concentrates, especially when platelet concentrates were 
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stored more than 3 days, showed a low platelet recovery after 1 hour (P = 0.01) and after 
16 hours (P = 0.03). Administration of Amphotericin B was associated with a high 
platelet recovery after 1 hour (P = 0.05) but not after 16 hours (P = 0.87). Also other 
therapies, donor lymphocyte infusion (DLI), canine antithymocyte globulin (ATG) or 
other immunotherapy, showed a correlation after 1 hour with low platelet recovery (P = 
0.04), but this was not observed after 16 hours (P = 0.10). Other non-immune factors we 
studied (fever, DIC and GvHD) showed no correlation with platelet recovery. 
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Table 3. Univariate and 
fadors 
GvHDwere 
for transfusions in 
a. 
Item Total Recovery ?: 20% OR (95%CI) P-value 
n n (%) 
Sex 0.05 
Male 112 60 (54%) 1 
Female 69 49 (71%) 2.1 (1.0-4.5) 
n· . 1 1agnos1s 0.006 
AML 91 60 (66%) 1 
ALL 8 ,., (38%) 0.3 (0.1-1.5) .) 
CML 21 5 (24%) 0.2 (0.1-0.4) 
MM 6 5 (83%) 2.6 (0.3-23.5) 
NHL 23 17 (74%) 1.5 (0.5-4.6) 
HD 5 3 (60%) 0.8 (0.1-6.2) 
MDS 20 13 (65%) 1.0 (0.2-4.2) 
Other 6 3 (50%) 0.5 (0.2-1.5) 
Therapy2 0.004 
Chemo 102 70 (69%) 1 
AutoBMT 14 12 (86%) 2.7 (0.5-13.7) 
AlloBMT 59 26 (44%) 0.4 (0.2-0.8) 
Other therapy 6 1 (17%) 0.1 (0.0-0.9) 
Splenomegaly 0.005 
No 129 88 (68%) 1 
Yes 52 21 (40%) 0.3 (0.1-0. 7) 
Amphotericin B 0.05 
No 164 95 (58%) 1 
Yes 17 14 (82%) 3.4 (1.0-11.5) 
Dtime - Atime 3 0.01 
~3 days 93 64 (69%) 1 
> 3 days 85 44 (52%) 0.5 (0.3-0.9) 
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b. 
Item Total Recovery 2: 10% OR(95%CI) P-value 
n n (%) 
Sex 0.68 
Male 112 69 (62%) 1 
Female 69 45 (65%) 1.2 (0.6-2.5) 
Diagnosis1 0.23 
AML 91 61 (67%) 1 
ALL 8 6 (75%) 1.5 (0.2-11.2) 
CML 21 7 (33%) 0.2 (0.1-0.8) 
MM 6 5 (83%) 2.5 (0.3-22.5) 
NHL 23 17 (74%) 1.4 (0.4-4.6) 
HD 5 2 (40%) 0.3 (0.0-2.6) 
MDS 20 12 (60%) 0.7 (0.2-2.4) 
Other 6 3 (50%) 0.5 (0.2-1.4) 
Therapy2 0.11 
Chemo 102 72 (71%) 1 
AutoBMT 14 9 (64%) 0.8 (0.2-2.9) 
AlloBMT 59 31 (53%) 0.5 (0.2-1. 0) 
Other therapy 6 2 (33%) 0.2 (0.0-1.4) 
Splenomegaly 0.02 
No 129 89 (69%) 1 
Yes 52 25 (48%) 0.4 (0.2-0.9) 
Amphotericin B 0.87 
No 164 103 (63%) 1 
Yes 17 11 (65%) 1.1 (0.4-2.9) 
Dtime - Atime3 0.03 
::; 3 days 93 65 (70%) 1 
> 3 days 85 47 (55%) 0.5 (0.3-0.9) 
)J = nzanher zrans_f:usi ons with sper.:(fi ed fest results: ()R = odLi-.,· ratio: 95%Cl ~" 95'J6 
with AJvfL: CLL is 
] 
are 
3 Time he/ween 
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In 42 transfusions (23%), in which no non-immune factors were present, a platelet 
recovery ofless than 20% after 1 hour and less than 10% after 16 hours were found in 
8 (19%) and 11 (26%), respectively. In the 8 transfusions with no non-immune factors 
and low platelet recovery after 1 hour ELISA, LCT, LIFT and PIFT were positive in 0, 
1, 0 and 0 sera, respectively. In the 11 transfusions with no non-immune factors and 
low platelet recovery after 16 hour no positive tests were found. 
Discussion 
In our study in 97 patients with hematological diseases about 40% of platelet transfusions 
ul d . 1 1 1 hi h . . 'th li 8 9 11 13 16 17 21 res te ill a ow p ate et recovery, w c IS ill agreement W1 terature ' ' ' ' ' ' . 
Alloimmunisation, defined as positivity in one or more tests, could be demonstrated in 5-
21% of platelet transfusions with a low recovery after 1 or 16 hours. This low percentage 
was expected because of a low prevalence of alloimmunisation in the patient population 
we studied. The low prevalence of alloimmunisation was caused by the absence of 
selection of patients, and the leucodepletion of the transfusions. In our study only 10 of 
97 patients were measured more than 3 times. Other studies, that show data from 
. highl 1 d . 11 30 1 . d f . 15 18 32 d sometunes a y se ecte patients- ' over onger peno s o tune ' ' , emonstrate 
higher rates of alloimmunisation. The usage of leucodepleted blood products also 
diminishes the prevalence of alloimmunisation24'25 in contrast with the usage of non-
1 d 1 d bl d d d . bli h d di 3-9 11 13 16 18 19 Al euco ep ete oo pro ucts use ill most pu s e stu es ' ' - - - . so 
difference in the definition of alloimmunisation may play a role. 
No clear correlation could be demonstrated between alloimmunisation demonstrated by 
positivity of a single test and low recovery of a subsequent platelet transfusions after 1 
and 16 hours. On the other hand we showed that alloimmunisation was present in 6-14% 
of platelet transfusions with a good recovery. This discrepancy can be caused by the 
inability of the immunoglobulins, that cause the positive test results, to activate the 
complement or bind to the macrophage system in these patients. Also immunoglobulins 
with restricted specificity may cause positive test results against panel cells but do not 
react with the platelets from the 5 different donors of which the transfusion exists. 
Otherwise in the 11 platelet transfusions with a low recovery and no non-immune causes 
alloimmunisation could be demonstrated in only 1, leaving 10 platelet transfusions 
without explanation. This may be explained by other non-immune causes of low platelet 
recovery we did not measure in this study or by a lack of sensitivity in the tests we 
studied. In the literature LCT is the most studied test in demonstrating alloimmunisation 
showing a good correlation with low platelet recovery6•8•26 . The LCT, however, in our 
hands is less sensitive than the ELISA and LIFT, the correlation between these two tests 
92 
Immune and non-immune causes of low recoveries 
being high25 . Other tests that have demonstrated a correlation with platelet recovery are 
PIFT7, 51Cr platelet lysis assay7 and ELISA18. These studies however were not designed 
to demonstrate a correlation between a single test and recovery in a subsequent platelet 
transfusion in a non-selected patient population using leucodepleted blood products. 
Combining the ELISA with PIFT or LIFT with PIFT did demonstrate a correlation with 
recovery of a subsequent platelet transfusions after 16 hours, but not after 1 hour. It 
seems un~ikely that the presence of antibodies against platelet specific antigens next to 
anti-HLA antibodies are resposible for this finding. Positivity in two tests, one measuring 
HLA-antibodies and the other HLA-antibodies and platelet specific antibodies, increases 
specificity and in that way diminishes false positive results. In most studies several 
combination of tests have demonstrated a correlation between platelet refractoriness and 
11 . . . 91113-15?9303? H th d' d'd 1 k d 1 d 1 1 a mmmurusatwn · · ~ ' ' -. owever ese stu 1es 1 not use eu o ep ete p ate et 
transfusions or were not designed to demonstrate a correlation with a subsequent platelet 
transfusion. 
Of the non-immune factors splenomegaly, mak sex, CML, allogeneic stem cell 
transplantation and other therapies, DLI, ATG or other immunotherapy, were found to 
have a negative effect on platelet recovery after 1 hour in a univariate analysis. Low 
platelet recovery after 16 hours was correlated with splenomegaly, storage time of more 
than 3 days, CML and allogeneic stem cell transplantation. However further investigation 
showed splenomegaly to be a confounding factor in sex, CML and allogeneic stem cell 
transplantation. A correlation of platelet recovery with CML and allogeneic stem cell 
transplantation were also found by others9•11•15•21 but no comment was made as towards 
splenomegaly as a confounding factor. 
Immune causes of platelet refractoriness are infrequently encountered in a non-selected 
patient population receiving leucodepleted transfusions. Randomly executed tests, that 
detect alloantibodies, are not predictive for platelet recovery in these patients. Non-
immune causes, known to influence platelet recovery, are frequently present, of which 
splenomegaly and a storage time of more than 3 days are the main causes of a low 
platelet recovery. 
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Abstract 
Alloantibodies against platelets can be detected by different laboratory tests. Most of 
these tests use panel cells or antigens as a target. In relation to these tests a crossmatch 
test of transfused platelets and patient's serum may be viewed of as the standard for 
detecting donor platelet destruction by alloimmunization. 
In 95 randomly selected thrombocytopenic patients with hematological malignancies 
receiving leukodepleted blood products 184 serum samples were studied in an in vitro 
crossmatch test according to the technique of the platelet immunofluorescence test 
(crossmatch-PIFT), in an in vivo crossmatch detecting binding of immunoglobulins in 
vivo to transfused platelets (in vivo-PIFT), in the indirect PIFT using 5 random donors 
as a target (panel-PIFT) and in an enzyme linked immunosorbent assay using 
immobilized HLA-antigens of 100 standardised donors (ELIHLA). The results of all 
these methods were related to the recovery at 1 and 16 hours post transfusion. 
Results 
The results of the crossmatch-PIFT were not associated with platelet recovery at 1 and 
16 hours after transfusion. Even in a patient subgroup, in which predefined clinical 
factors were excluded, no association with platelet recovery was found. The results of 
the crossmatch-PIFT correlated with those of the in vivo-PIFT (P = 0.02), however, 35 
(19%) discrepant results were established between these tests. The results of the 
crossmatch-PIFT were not related to the panel-PIFT (P = 0.25), but did relate to those 
of the ELIHLA (P = 0.02) still revealing 36 (20%) discrepant results. Neither the in 
vivo-PIFT, the panel-PIFT nor the ELIHLA was associated with platelet recovery after 
1 hour, whilst only a positive panel-PIFT was associated with poor platelet recovery at 
16 hours after transfusion (P = 0.03). 
In a population at low risk for alloimmunization the correlation of test outcome and 
platelet recovery is poor. None of the tests, crossmatch tests nor screening tests, 
showed to be superior in this population. 
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Introduction 
Patients with hematological malignancies who receive intensified chemotherapy often 
need platelet support to prevent bleeding complications. Twenty-four to 44% of 
platelet transfusions fail to produce satisfactory responses because of non-immune 
factors (63-67%), immune factors (18-25%) or both1-4 . In order to distinguish immune 
from non-immune factors different serological tests are routinely used. Examples of 
these tests are lymphocytotoxicity (LCTt7, immunofluorescence (IFT)8-13 , enzyme-
linked immunosorbent assays (ELISA)14-17, or monoclonal antibody-specific 
immobilization of platelet antigens assays (MAIPAi8- 20. In all these tests patient's 
serum is incubated with donor panel cells as a target in order to demonstrate the 
presence of alloimmunization. More recently other techniques have been described, 
which use a broad range of readily available HLA-antigens as a target. Examples of 
the latter tests are flow cytometry of latex beads coated with HLA class I antigens21•22 
and an ELISA tests with a broad range of immobilized HLA class I antigens 
(ELIHLAi3-27. We recently demonstrated the limited correlation of tests using donor 
panel cell or antigens, such as the LCT, platelet immunofluorescence test (PIFT), the 
lymphocyte immunofluorescence test (LIFT) and the ELIHLA, with the outcome of 
platelet transfusions in patients receiving leukodepleted platelet transfusions27. For this 
reason we developed a test that measured physiologic circumstances of in vivo binding 
of antibodies to transfused platelets, the in vivo binding of immunoglobulin G (IgG) in 
the platelet immunofluorescence test (IVBI-PIFT, renamed in vivo-PIFT for clarity in 
this studyi8. This test can be considered as an in vivo crossmatch test. 
In view of these data the question arises if there is superiority in vitro crossmatch 
testing in relation to in vivo crossmatch testing (in vivo-PIFT) and screening tests using 
panel cells (panel-PIFT and ELIHLA) in predicting transfusion outcome. In this way 
the importance of difference in target cells and in in vitro or in vivo binding of 
immunoglobulins to transfused platelets was assessed in relation to test results and to 
platelet transfusion outcome. 
Methods and Materials 
Serum 
We studied 184 serum samples from 95 randomly selected patients, mean 1.9 
transfusions per patient (range 1-8), who were treated for a malignant lymphoma or 
leukemia in our hospital. One patient was treated with rabbit antithymocyte globulins; 
none with human intravenous immunoglobulins. Patients received a leukocyte 
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depleted platelet transfusion, a suspension of 5 random ABO-matched donors, (i) 
prophylacticly when platelet count was less than 10 x 10911, (ii) before an intervention 
or because of clinical manifest bleeding at higher platelet counts. The serum samples 
were collected before and 1 and 16 hours after platelet transfusion. The median platelet 
count before platelet transfusion was 11 x 10911 (range 4-60 x 109 11). 
Platelet concentrates were obtained from the Sanquin Blood Bank South West Region 
(Rotterdam, the Nethe~lands) and were prepared from the blood of 5 HLA-unmatched 
ABO-matched volunteer donors. The average content of the platelet concentrates was 
4 x 1011 platelets in 250 ml. The platelet concentrates were filtered by a PLX-5 Asahi 
:filter (Baxter, La Chatre, France) to deplete the transfusion from leukocytes. The 
average leukocyte number was 0.05 x 106 per platelet concentrate (range 0.00-0.20 x 
106). In patients receiving a stem cell transplantation the platelet concentrates were 
irradiated with 25 Gy in order to prevent graft versus host disease (GvHD) by 
transfused lymphocytes29 . The platelet concentrates were stored at 22 °C until used for 
transfusion. Also erythrocyte concentrates were always leukocyte depleted and for the 
same reasons irradiated as mentioned above. 
tests 
Crossmatch-PIFT 
The crossmatch-PIFT was performed according to a modified method of the indirect 
PIFT, as described elswhere11. 13• 28 , and the transfused platelets as target antigens. 
From the platelet transfusion bag 100 ~ of suspension was washed twice with a 
buffer, 10 g ethyleendiamine-tetra-acetate (EDTA), 8.5 g NaCl, 1.61 g Na2HP04.2H20 
and 0.2 g NaH2P04.2H20 in 1 liter Millipore H20, titrated up to pH= 7.35 with 10 
mmol NaOH and mixed with 9 ml bovine serum albumin 22%, (EDTA-PBS 0.2% 
BSA) at 1800 G for 10 minutes. After removing the supernatant the cell pellet was 
resuspended to a platelet suspension of 100 x 106 cells/ml. To 50 Ill of the platelet 
suspension 50 Ill of serum was added and incubated at room temperature in the dark 
for 30 minutes. After washing for 3 times with 850 Ill EDT A-PBS 0.2% BSA at 1800 
G for 5 minutes, 50 ~ of fluorescence-conjugated goat anti-human IgG (FITC) 
(Nordic, Tilburg, The Netherlands) was added and incubated at room temperature in 
the dark for 30 minutes. After washing for 3 times with 850 ~EDT A-PBS 0.2% BSA 
at 1800 G for 5 minutes 10 Ill LDS-PI (5 ~ LDS stock [0.2 mg laser dye stock solution 
751 in 1 ml methanol] (Applied Laser Technology, Maarheze, the Netherlands) 
together with 5 Ill PI stock [4 mg propidium iodide in 1 ml PBS] (Sigma Chemicals, St 
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Louis, MO, USA) in 10 ml EDTA-PBS 0.2% BSA) was added to the suspension and 
incubated for 15 minutes. 
After adding 50 111 of EDTA-PBS 0.2% BSA 4-parameter flow cytometry was 
performed collecting 5,000 events, using a live gate to select the platelets. In this way 
a histogram was made that showed the FITC-fluorescence on a logarithmic scale. Of 
every studied platelet transfusion the platelets were also incubated with previously 
defined negative and positive sera. The average percentage of platelets from the 
negative control exceeding a predefined fluorescence marker in 100 samples was 15% 
with a standard deviation of 11%. We subtracted this average plus 1 standard 
deviation, together 26%, from the percentage platelets exceeding the predefined 
marker in the tested serum sample. All tests were performed in duplicate, so that the 
final crossmatch-PIFT results were generated using the average percentage of platelets 
exceeding the predefined marker of these 2 duplicate results corrected by the average 
plus 1 standard deviation from the negative control (26% in this series). The 
crossmatch-PIFT detects most causes of IgG binding to platelets (antibodies against 
HLA-class I antigens, against platelet specific antigens and autoantibodies). 
In vivo-PIFT 
The in vivo-PIFT was executed by collecting blood before and one hour after platelet 
transfusion in duplicate according to the technique of the In Vivo Binding of 
Immunoglobulins in the Platelet Immunofluorescence Test (IVBI-PIFT/8. After 
several centrifuging steps, as described elswhere28 , three platelet suspensions were 
used: (I) from the blood drawn before transfusion, (II) from the platelets out of the 
transfusion bag as an internal control and (III) from the blood drawn after transfusion. 
These three suspensions were separately incubated with a diluted mixture of 
fluorescence-conjugated goat anti-human IgG (FITC) (Nordic, Tilburg, The 
Netherlands), after which 4-parameter flow cytometry was performed acquiring 8,000 
platelets per suspension. An overlay histogram was generated from the list mode data 
on FITC fluorescence of platelet suspensions I, II and III. This combined histogram 
was used for visual scoring. These scores were categorised as pattern 1 (no 
alloimmunization), pattern 2 (binding of IgG not related to alloimmunization), pattern 
3 (preferential binding of IgG to own or previously transfused platelets) and pattern 4 
(alloimmunization) (Figure 1). Thus, pattern 4 was interpreted as positive, indicating 
alloimmunization, while patterns 1, 2 and 3 were classified as no alloimmunization. 
More standardized results of the in vivo-PIFT could be generated by a histogram 
subtraction method 29. The histograms of the IgG-fluorescence of suspension I (prior 
to transfusion) was subtracted from the histogram of suspension III (post transfusion). 
This was done by subtracting the number of platelets for each fluorescence channel 
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separately (linear scale of 256 histogram channels). If differences between the 
corresponding channels of histogram I and III resulted in negative values, these were 
replaced by zero events for those channels in the subtraction histogram (Figure 1 ). 
Figure 1. Results of the m vivo-PIFT 
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Histogram II was used as internal controL This leaves a subtraction histogram that can 
be characterised by (i) the number of remaining events ( = total number of platelets of 
all fluorescence channels after this subtraction) and (ii) the mean fluorescence of the 
remaining events. First, "Events post subtraction"(EPS) was defined as the average of 
all remaining events of both (duplicate) subtraction histograms. Second, "Mean 
channel post subtraction" (MCPS) was defined as the average of the mean channel 
values of both (duplicate) subtraction histograms (Figure 1 ). Finally, results of this 
subtraction were defined as positive when EPS 2: 1100 and MCPS 2: 30; all other 
results were classified negative. The in vivo-PIFT detects all causes of IgG binding to 
platelets (antibodies against HLA-class I antigens, against platelet specific antigens, 
autoantibodies and immunecomplexes). 
Panel-PIFT 
This assay was performed as a modified method from a PIFT assay described 
elsewhere28 . In short, 4-parameter flow cytometry was performed after incubating 
patient's serum with platelets from 5 random donors separately, obtained from the 
Sanquin Blood Bank South West Region, followed by a second incubation with a 
diluted mixture of fluorescence-conjugated goat anti-human IgG. The platelets from 
the 5 random donors were collected the day before, separated from other blood 
components and washed two times. A panel cell suspension was considered to be 
positive when the fluoresence demonstrated more than 17% of all platelets exceeding 
predefined fluorescence marker (previously determined by more than 100 negative 
controls) 11 •27. The final results of the panel-PIFT were generated as the average 
percentage of positive donors of duplicate tests. A patient was considered immunized 
if 40% or more of all donors showed a positive result. The panel-PIFT measures most 
causes of IgG bound to platelets (antibodies against HLA- and platelet-specific 
antigens and autoantibodies). 
Enzyme Linked Immunosorbent Assay (ELIHLA) 
QuikScreen™ was used according to manufacturer's instructions (GTI, Brookfield, 
WI, USA) by incubating patient's serum with HLA class I antigens obtained from a 
platelet pool of about 100 donors consisting of white, black and Hispanic blood 
donors, immobilized in a microwell strip10. After adding alkaline phosphatase-
conjugated goat-antihuman immunoglobulin G (IgG) and a substrate of alkaline 
phosphatase p-nitrophenyl phosphate (PNPP) the adsorbance was read at 405 nm. 
Final results were generated by the average of duplicate results. A result was 
considered to be positive when adsorbance exceeded the adsorbance of the negative 
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control more than 2 times. This ELISA detects antibodies of the lgG-class against 
HLA-class I antigens. 
Pliateiet transfusion n::suits 
A successful platelet transfusion was defined as a recovery of platelets after 
transfusion of (i) 20% or more after 1 hour or (ii) 10% or more after 16 hours31-33 
according to the following formula: 
Platelet increment (1 09/1) x blood volume (1) 
%recovery= X 100 
Number of transfused platelets (lOll) 
Non-immune factors 
For every platelet transfusion the presence of non-immune factors affecting survival of 
transfused platelets was investigated (diagnosis, therapy, splenomegaly, fever (>38.2 
0C), disseminated intravascular coagulation, graft versus host disease, Amphotericin B 
administration and storage time of platelet transfusions from acquisition to donation). 
Previously, we have demonstrated in the same patient population that only the 
presence of splenomegaly and a platelet transfusion storage time of more than 3 days 
correlated with poor platelet recovery33 . We performed a subgroup analaysis m 
transfusions with the presence of the latter two non-immunological factors. 
Statistical methods 
Results of the crossmatch-PIFT were compared with the results of the in vivo-PIFT 
using Pearson's chi-squared test, while Fisher's exact test was used to compare the 
results of the crossmatch-PIFT with the results of the panel-PIFT and ELIHLA. 
Univariate logistic regression with adjustment for patients with multiple transfusions 
was used to investigate the association between platelet recovery after 1 and 16 hours 
and the results of the in vivo-PIFT, the crossmatch, the panel-PIFT and the ELIHLA. 
All P-values are two-sided and P-values ::; 0.05 were considered statistically 
significant 
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Results 
Crossmatch-PIFT and recovery 
In the 184 studied serum samples the crossmatch-PIFT showed a positive result in 26 
(14%) and a negative result in 158 (86%). Of the transfusions with a positive 
crossmatch-PIFT a poor platelet recovery was found in 14 (54%) and 12 (46%) at 1 
and 16 hours after transfusion, respectively. The transfusions with a negative 
crossmatch-PIFT demonstrated a poor recovery in 63 (40%) and 53 (36%, in 11 
transfusions no recovery after 16 hours was available) transfusions at 1 and 16 hours 
after transfusion. A positive crossmatch-PIFT did not predict a poor platelet recovery 
neither after 1 hour (odds ratio [OR]= 0.57, 95% confidence interval [CI] = 0.23-1.38, 
P = 0.21) nor after 16 hours (OR= 0.66, 95% CI = 0.28-1.54, P = 0.33). 
Of 67 platelet transfusions without the presence of previously determined non-immune 
factors that correlated with poor platelet recovery (i.e., splenomegaly and storage time 
of platelets more than 3 daysi3 17 (25%) platelet transfusions demonstrated a recovery 
of less than 20% after 1 hour. In these 17 platelet transfusions a positive crossmatch-
PIFT was demonstrated in only 3 platelet transfusions (18%). Next to this, 15 
transfusions (22%) demonstrated a recovery of less than 10% after 16 hours in the 67 
transfusions without predetermined non-immune factors. A positive crossmatch-PIFT 
was demonstrated in 1 transfusion (7%) of these 15 transfusions. A positive 
crossmatch-PIFT did not predict a poor platelet recovery in this subgroup analysis 
neither after 1 hour (OR= 0.64, 95% confidence interval [CI] = 0.14-2.93, P = 0.56) 
nor after 16 hours (OR= 2.73, 95% CI = 0.29-26.1, P = 0.38). 
Crossmatch-PIFT versus in vivo-PIFT 
The difference in in vitro or in vivo binding of immunoglobulins was studied in the 
184 transfusions by relating the results of the crossmatch-PIFT to those of the in vivo-
PIFT. The results of the crossmatch-PIFT corresponded well with the in vivo-PIFT (P 
= 0.02) (Table 1). 
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Table 1. The results of 
in vivo-PIFT 
Negative 
Positive 
Panel-PIFTt 
Negative 
Positive 
ELIHLA* 
Negative 
Positive 
'p = ().()] 
-.Zl)= 0.25 
" P= 0.0] 
erossmatch-PIFT :related l:o 
Crossmatch-PIFT 
Negative Positive 
n =158 n=26 
142 19 
16 7 
146 22 
12 4 
141 19 
17 7 
resuJts of the vivo-
Total 
n = 184 
161 
23 
168 
16 
160 
24 
Nevertheless the in vivo-PIFT was positive in 16 (9%) transfusions in which the 
crossmatch-PIFT was negative, whereas the crossmatch-PIFT was positive in 19 
(10%) transfusions in which the in vivo-PIFT was negative. 
In 7 transfusions with a positive result of both in vivo-PIFT and crossmatch-PIFT a 
poor platelet recovery after 1 and 16 hours was found in 4 and 3 of transfusions, 
respectively (Table 2). 
Table 2. Studied serum divided into groups on orr 
results of crossmatch-PIFT and vivo-PIFT related to the 
recove!j after 1 and 16 hours the studied PH''~"-' tR-ansfusion 
Crossmatch- in vivo-PIFT Total Recovery1h < 20% Recovery16h < 10% 
PIFT n n (%) n (%) 
Positive Positive 7 4 (57%) 3 (43%) 
Positive Negative 19 10 (53%) 9 (47%) 
Negative Positive 16 4 (25%) 2 (13%)t 
Negative Negative 142 59 (42%) 51 (39%i 
., 1 recoretT 16 hours was not 1.77011'71 
16 hour were not known 
In the 19 transfusions with a negative in vivo-PIFT and a positive crossmatch-PIFT a 
poor platelet recovery was observed in 10 and 9 of transfusions after 1 and 16 hours, 
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respectively. In 16 transfusions with a positive in vivo-PIFT and a negative 
crossmatch-PIFT a poor platelet recovery was demonstrated in 4 and 2 of transfusions 
after 1 and 16 hours, respectively. Finally, in the 142 transfusions with a negative in 
vivo-PIFT and a negative crossmatch-PIFT a poor platelet recovery was found in 59 
(42%) and 51 (39% of 132) of transfusions after 1 and 16 hours. Overall, the in vivo-
PIFT did not predict a poor platelet recovery at 1 hour (OR= 1.41, 95% CI = 0.55-
3.59, P = 0.48) nor at 16 hours (OR= 2.24, 95% CI = 0.77-6.54, P = 0.14) after 
platelet transfusion. 
Crossmatch-PIFT -:versus 
The comparison between crossmatch testing and screening tests was studied by 
relating the results of the crossmatch-PIFT to those of the panel-PIFT in the 184 
studied platelet transfusions. The results of the crossmatch-PIFT corresponded poorly 
with those of the panel-PIFT (P = 0.25) (Table 1). In 12 transfusions the crossmatch-
PIFT was negative and the panel-PIFT positive, whilst the crossmatch-PIFT was 
positive and the panel-PIFT negative in 22; a total of 34 (18%) discrepant results. A 
positive panel-PIFT did not predict a poor recovery after 1 hour (OR= 0.70, 95% CI = 
0.29-1.65, P = 0.41) either, but had some predictive power for poor platelet recovery 
after 16 hours (OR= 0.32, 95% CI = 0.12-0.89, P = 0.03). In 4 transfusions, in which 
both crossmatch-PIFT and panel-PIFT showed positive results, 3 and 4 of transfusions 
demonstrated poor recoveries after 1 and 16 hours, respectively (Table 3). 
Table 3. Studied serum into groups 
u-esuh:s of c:rossn1atch-PIFT and 
transfusion rest1it after 
Crossmatch- panel-PIFT Total Recovery1h < 20% Recoveryi6h < 10% 
PIFT n n (%) n (%) 
Positive Positive 4 3 (75%) 4 (100%) 
Positive Negative 22 11 (50%) 8 (36%) 
Negative Positive 12 5 (42%) 6 (50%) 
Negative Negative 146 58 (40%) 47 (35%)t 
T o.f 11 trans_fitsions no recoFery jneas'ure£l (q?er 16 hours 
In the 22 transfusions with a positive crossmatch-PIFT and a negative panel-PIFT poor 
platelet recovery after 1 and 16 hours was demonstrated in 11 and 8 of transfusions, 
respectively. Of the 12 transfusions with a negative crossmatch-PIFT and a positive 
panel-PIFT 5 and 6 demonstrated a poor platelet recovery after 1 and 16 hours, 
respectively. Finally, the 146 transfusions with negative test results in both 
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crossmatch-PIFT and panel-PIFT were followed by poor platelet recoveries after 1 and 
16 hours in 58 (40%) and 47 (35% of 135) of transfusions, respectively. 
Crossmatch-PIFT versus ELIHLA 
In order to study whether difference with crossmatch testing could be minimized by 
using a screening test with a larger number ofHLA-antigens as a target, we related the 
results of the crossmatch-PIFT with those of the ELIHLA in 184 transfusions. There 
was a statistically significant association between crossmatch-PIFT and ELIHLA 
result (P = 0.02) (Table 1). However, in 17 transfusions the crossmatch-PIFT was 
negative and the ELIHLA positive, whereas the crossmatch-PIFT was positive and the 
ELIHLA negative in 19; a total of 36 (20%) discrepant results. A positive ELIHLA 
was not associated with a poor recovery, neither after 1 hour (OR= 0.68, 95% CI = 
0.31-1.49, P = 0.34) nor after 16 hours (OR= 0.75, 95% CI = 0.33-1.74, P = 0.51). In 
7 transfusions, in which both crossmatch-PIFT and ELIHLA showed positive results, 5 
and 3 of transfusions showed poor transfusions results after 1 and 16 hours, 
respectively (Table 4). 
Table 4. Studied serum divided into 4 groups on 
results of crossmatch-PlFT andl ELIHLA related to 
transfusion result after 1 and 16 hours 
Crossmatch- ELIHLA Total Recoverylh < 20% Recoveryl6h < 10% 
PIFT n n (%) n (%) 
Positive Positive 7 5 (71%) ,., (43%) .) 
Positive Negative 19 9 (47%) 9 (47%) 
Negative Positive 17 7 (41%) 7 (44%)t 
Negative Negative 141 56 (40%) 46 (35%)~ 
'cifl trcmsji1sion no recoveJy was measured ofter 16 hours 
iJO recovery was measured c?fter 16 hours 
In the 19 transfusions with a positive crossmatch-PIFT and a negative ELIHLA poor 
platelet recoveries after both 1 and 16 hours were observed in 9 of transfusions. Of the 
17 transfusions with a negative crossmatch-PIFT and a positive ELIHLA a poor 
platelet recovery after 1 and 16 hours was demonstrated in 7 and 7 (of 16 transfusions) 
of transfusions, respectively. Finally, of the 141 transfusions with negative test results 
in both crossmatch-PIFT and ELIHLA a poor platelet recovery after 1 and 16 hours 
was found in 56 (40%) and 46 (35% of 131) of transfusions, respectively. 
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Discussion 
We have reported that the results of widely used screening tests that detect antibodies 
against platelets, do not correlate with the recovery of donor platelets in a non-selected 
patient population receiving leukodepleted blood products34. Not only can positive test 
results be seen in platelet transfusions with good recoveries but also negative test 
results can be encountered in platelet transfusions with poor recoveries even in the 
absence of non-immune factors that may jeopardize platelet recovery. 
In order to clarify the lack of correlation between alloantibody tests and platelet 
recovery, we studied the relation between the crossmatch-PIFT and the in vivo-PIFT 
(previously named IVBI-PIFTi8. Possible differences of in vivo and in vitro binding 
of IgG to platelets are: (I) differences in the concentration of the alloantibodies; (II) 
differences in temperature during incubation (37 °C versus room temperature); (III) 
presence of interfering proteins in the serum; (IV) presence of non-specific binding of 
immunoglobulins such as immune complexes (V); length of incubation (in vitro 30 
minutes versus 1 hour in vivo); and (VI) the removal of alloantibody-coated platelets 
from the circulation. We demonstrated that the results of in vitro and in vivo 
incubation of the platelets were significantly associated (P = 0.02), although discrepant 
results were observed in 36 (20%) of cases. In order to study whether the results of the 
in vivo binding test might be more predictive than those of in vitro binding tests for 
platelet recovery, we performed subset analysis on the 4 groups as defined by the 
results of in vivo and in vitro assays. In the 7 transfusions with positive results for both 
in vivo and in vitro incubations about half demonstrated a poor recovery after 1 and 16 
hours. Not all transfusions demonstrated a poor recovery, which may be caused by a 
density of alloantibodies too low to trigger physiological destruction mechanisms 
and/or by differences in IgG subclasses. In the 19 transfusions with negative in vivo 
and positive in vitro incubations a poor recovery was found in about half of the studied 
platelet transfusions. This result may be explained by the removal of alloantibody 
coated platelets from the circulation, the temperature dependency of the antibodies to 
bind to platelets or false positivity of in vitro IgG binding assays caused by technical 
reasons (e.g. cut-off too low). In the 16 transfusions with a positive in vivo and a 
negative in vitro result only a minority of transfusions exhibited poor recoveries after 1 
and 16 hours (25% and 13%, respectively). This emphasizes the fact that IgG bound to 
transfused platelets not necessarily leads to enhanced platelet destruction, be it 
alloantibodies, immune complexes or other non-specific binding of immunoglobulins 
to the platelets. Finally, about 40% of 142 transfusions, that showed negative results 
for both type of tests, demonstrated a poor platelet recovery after 1 and 16 hours. 
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These poor platelet recovenes may be largely caused by non-Immune factors 
jeopardizing survival of transfused platelets. 
A second reason for this discrepancy may be the difference in target antigens. No 
statistically significant association between the crossmatch-PIFT and the panel-PIFT 
was established. The discrepancy may be explained by the difference in antigenic 
make-up of the panel cells used in these two tests, the crossmatch-PIFT uses platelets 
of the 5 donors from the transfusion bag whilst the panel-PIFT uses platelets of 5 
randomly selected donors, respectively. Also technical reasons may attribute to this 
difference such as the fact that the crossmatch-PIFT measures the fluorescence of a 
mixed platelet suspension of all 5 donors where as the panel-PIFT measures the 
:fluorescence of a platelet suspension of 5 donors separately. The crossmatch-PIFT did, 
however, demonstrate a statistically significant association with the ELIHLA, that uses 
100 random donors as a target in the ELISA technique. Nevertheless, a substantial 
number of discrepant results (36 of 184 transfusion) was observed. These 
discrepancies may be caused by difference in antigenic make-up of the target antigens 
used in both assays and/or a different sensitivity of the two techniques. Both tests, 
however, failed to show a correlation with platelet recovery. 
Positive test results of all 4 tests failed to demonstrated a significant correlation with 
poor platelet recoveries of subsequent leukodepleted platelet transfusions after 1 hour. 
Only the panel-PIFT demonstrated a significant association with the recovery after 16 
hours. The fact that the test results did not correlate with recovery may be caused by 
(i) the interference of concomitant non-immune causes of poor platelet recovery5•33, 
(ii) by the tests being too frequently positive or not specific enough in detecting 
alloantibodies in relation to in vivo alloimmune platelet destruction, and/or (iii) by a 
low incidence of alloimmunization in our patient population receiving leukodepleted 
platelet transfusions. In addition, in a subgroup analysis in transfusions with a poor 
recovery in the absence of predefined non-immunological factors a positive 
crossmatch-PIFT could be demonstrated in only 12% and 7% 1 and 16 hours after 
transfusion, respectively. This emphasizes the fact that alloinlmunization, as 
demonstrated by laboratory techniques, accounts for only a small amount of 
transfusion failures in patients receiving leukodepleted blood products35 . The 
explanation that this crossmatch is insensitive, is unlikely on the basis of a substantial 
number of false positive tests. 
We conclude that crossmatch testing is not superior to in vitro tests that use panel cells 
in relation to platelet recovery in patients receicing leukodepleted blood products. 
Differences between in vitro and in vivo binding of immunoglobulins to transfused 
platelets nor antigen composition differences between transfused and panel cells could 
clarify the lack of correlation of the crossmatch test with platelet recovery. 
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Abstract 
Alloantibody tests demonstrate immunological causes of insufficient increments in 
random platelet transfusions. The value of a positive or negative test result rn 
predicting outcome of HLA-matched transfusions in patients refractory to 
leukodepleted random platelet transfusions has not been assessed. 
Methods and materials 
We retrospectively evaluated outcome of :first HLA-matched platelet transfusions in 72 
patients with haematological diseases in two ways: First the strategy according to 
which the patient was selected for HLA-matched platelet transfusions was analysed. 
The strategies were: (I) results of alloantibody tests were not available; (II) result of 
alloantibody test was positive; (III) inspite of a negative alloantibody test. Second the 
outcome of the :first HLA-matched transfusion was investigated in relation to the 
results of alloantibody tests irrespective the strategy. 
Results 
No significant association was found between the decision strategy and the outcome of 
the :first HLA-matched platelet transfusions. Positive alloantibody tests, however, 
predicted a better outcome of the :first HLA-matched platelet transfusion (P = 0.04 and 
P = 0.03 after 1 and 16 hours, respectively). 
Conclusion 
In patients refractory to random platelet transfusions positive alloantibody tests predict a 
better outcome of HLA-matched platelet transfusions. Patients with negative alloantibody 
tests, however, may benefit from HLA-matched platelet transfusions. 
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Introduction 
Patients with hematological illnesses and thrombocytopenia following cytotoxic 
therapy frequently require platelet transfusions in order to prevent or treat bleeding 
complications. Usually pooled platelet suspensions from random donors are used. 
Most of these random platelet transfusions are matched for the ABO-blood group 
because high titers of antibodies against ABO may enhance platelet destruction and 
matching for ABO-blood group is relatively easy1- 3. Donor platelets, however, are not 
routinely matched for human leukocyte antigens (HLA) or human platelet antigens 
(HPA), because of the low prevalence of antibodies against HLA- or HPA-antigens 
and difficulties in finding HLA- or HPA-matched platelet suspensions4-6. Antibodies 
against HLA- and HPA-antigens can cause platelet refractoriness and febrile 
transfusion reactions. In order to establish whether poor platelet recovery is caused by 
immunological (antibodies against HLA- or HPA-antigens) or by non-immunological 
factors (e.g. splenomegaly, older transfused platelets, fever, drugs, bleeding) a variety 
of tests are used to demonstrate the presence of alloantibodies7-32. These tests have 
been demonstrated to be of use in predicting a loss of response to random donor 
platelet transfusions in alloimmunized patients. The value of alloantibody testing in 
predicting the success of an HLA-matched platelet transfusion in patients refractory to 
random donor platelet transfusions, however, has not been established. 
In order to evaluate the importance of alloantibody tests in assigning patients to liLA-
matched transfusions we conducted a retrospective study in which three decision 
strategies (associated with distinct clinical contexts) and the results of alloantibody 
tests were assessed with regard to the platelet recovery of the first HLA-matched 
platelet transfusion. The effect of patient variables and transfusion characteristics that 
may have influenced platelet recoveries were studied as well in all HLA-matched 
platelet transfusions the included patients received. 
Methods and Materials 
Patients 
From January 1997 to January 2002 89 patients received 619 HLA-matched platelet 
transfusions at the hematological department of the Erasmus MC - University Medical 
Center. Seventeen patients (19%), receiving 59 HLA-matched platelet transfusions, 
were excluded from the analysis because of a non-hematological diagnosis in 9 
(testicular carcinoma in 1, ovarian carcinoma in 3 and surgery in 5) and missing data 
in 8 patients. Finally 560 HLA-matched platelet transfusions (91 %) in 72 patients 
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(81 %), average 8 HLA-matched platelet transfusions per patient (range 1-36), were 
studied (Table 1). 
Table 1. Patient characteristics 
Characteristics Category Number 
Sex Male 22 
Female 50 
Diagnosis ALL 4 
AML 29 
CLL 1 
CML 4 
MM 8 
NHL 2 
MDS 10 
AA 9 
ITP ,.., .) 
Other 2 
Treatment Chemo-/other therapy 49 
Auto SCT 5 
AlloSCT 18 
.4L = amie Zvmphoblastic leukemia; A.ivfL = acute myeloid leukemia; CLL ~, chronic 
NHL= 
stem cell Allo 
Patients, demonstrating a platelet recovery (defined below) after 1 hour of less than 
20% in at least two consecutive platelet transfusions (refractory) and in whom an 
immune mediated cause was presumed (non-immunological causes of platelet 
refractoriness were absent, patients developed chills or fever following random platelet 
transfusions), were selected for HLA-matched platelet transfusions. Three clinical 
contexts that led to the decision of HLA-matched platelet transfusions were 
distinguished: (I) transfusion without alloantibody test result (LIFT or MAIP A result 
became known after the HLA-matched platelet transfusion); (II) transfusion with 
information on a positive alloantibody test result; (III) transfusion inspite of a negative 
alloantibody test result (an empiric HLA-matched platelet transfusion was given). 
Outcome of these three transfusion strategies were compared retrospectively. 
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concentrates 
Platelet concentrates were obtained from the Sanquin Blood Bank South West Region 
and were prepared as an apheresis product from a single HLA-matched volunteer 
donor consisting of a wide range of platelets per transfusion (82 - 1173 x 1 09). The 
HLA-match was classified as compatible, when donor and recipient shared all HLA-A 
and B antigens or when the donor expressed less HLA-A and B antigens than the 
recipient It was designated as crossreacting, when cross-reactive HLA-mismatches 
between the donor and recipient HLA-A and B antigens were presenr. The platelet 
concentrates were filtered through a PLX-5 Asahi filter (Baxter, La Chatre, France) to 
deplete the suspension from leucocytes. The average leukocyte number was 0.05 x 106 
per platelet concentrate (range 0.00-0.20 x 106). In patients receiving a hematopoietic 
stem cell transplantation the platelet concentrates were irradiated with 25 Gy in order 
to prevent graft versus host disease (GvHD) by transfused lymphocytes33 . The platelet 
concentrates were stored at 22 °C under continuous agitation for a maximum of five 
days. Also erythrocyte concentrates were always leukocyte depleted and irradiated for 
the same reasons as stated above. 
Pftateliet transfusion results 
Platelet increment (1 09 11) x blood volume (1) 
%recovery= X 100 
Number of transfused platelets (1011) 
A successful platelet transfusion was defined as a recovery of platelets of 20% or more 
after 1 hour or 10% or more after 16 hours after transfusion34'35 . 
Tests 
Assays for HLA-antibodies 
I. Indirect Lymphocyte Immunofluorescence Test (LIFT) 
A slightly modified method was used according to the method described 
elsewhere11 •19•28 . In short four parameter flow cytometry was performed on a 
lymphocyte population from a panel of 5 donors after incubation with patient's serum 
and a diluted mixture of fluorescence-conjugated goat anti-immunoglobulin G (IgG). 
The donor panel was simultaneously incubated with a positive and negative control 
serum in order to prevent inter assay variation. The patient was considered to be 
sensitized against a donor if the fluorescence showed more than 36% of all 
lymphocytes exceeding a standard threshold (determined by more than 100 negative 
controls). A patient was considered immunized against a broad range ofHLA-antigens 
9 
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( alloimmunized) if 40% or more of all 5 donors showed a positive result. The LIFT 
measures mainly antibodies against HLA-antigens. 
II. Monoclonal Antibody-specific Immobilization of Platelet Antigens (MAIPA) 
This test was performed according to Kiefel with slight modifications 14. In short, 
platelet rich plasma (PRP) was stored and frozen after fixation with 
paraformaldehyde10 from a pool of 100 donors. After defrosting PRP the platelets were 
solubilized with TBS-Nonidet P40 (BDH, Poole, Dorset, England) after successive 
incubation with patient's serum and a monoclonal mouse anti-human antibody against 
the MHC-class I molecule (Dako, Glostrup, Denmark). The solubilized platelets were 
added to the wells of a microtiter plate that was covered with a polyclonal rabbit anti-
mouse immunoglobulin (Dako ). After incubation and washing the microplates a horse 
radish peroxidase conjugated-rabbit anti-human antibody against immunoglobulin G 
was added. Again after incubating and washing ABTS-peroxide (Roche, Basel, 
Switzerland) was added and the extinction was measured. The extinction of a negative 
panel serum was subtracted from the extinction of patient's serum. When this 
subtraction exceeded 150 (two times the standard deviation, as was previously 
determined by more than 20 negative donors) the patient was considered immunized 
against a broad range of HLA-antigens (alloimmunized). This test detects antibodies 
against HLA-antigens. 
Indirect Platelet Immunofluorescence Test CPIFT) 
This method was used with slight modifications from description elswhere in two 
different techniques10' 19 . In short, four parameter flow cytometry was performed on a 
panel platelet population after incubation with patient's serum and fluorescence-
conjugated goat anti-IgG. The panel platelet population was derived from fresh whole 
blood of 5 donors separately19 or from platelets (stored and frozen as PRP) after 
fixation with paraformaldehyde10 of a pool of 100 donors. In the first technique a 
donor was considered to be positive when the fluoresence showed more than 17% of 
all platelets exceeding a standard threshold (established in more than 100 negative 
controls). A patient was considered immunized against a broad range ofHLA-antigens 
if 40% or more of all donors showed a positive result. In the second technique a 
patient was considered immunized against a broad range of HLA-antigens if more than 
20% of all platelets exceeded a specific threshold (previously determined on 20 
negative controls). The PIFT measures all causes oflgG bound to platelets (antibodies 
against HLA- and platelet-specific antigens, autoantibodies and possibly immune 
complexes). 
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Patient variables and transfusion characteristics 
The recovery after 1 and 16 hours of all HLA-matched platelet transfusions the study 
group received were compared to patient variables sex, diagnosis and therapy 
(described in Table 1) and transfusion characteristics ABO-match and HLA-match. 
Statistical methods .. 
The association between strategies and recovery after the first transfusion or the test 
results and recovery after the first transfusion was investigated using Fisher's exact 
test in case of discrete variables, and the Kruskal-Wallis test in case of continuous 
outcomes. Univariate logistic regression with adjustment for patients with multiple 
transfusions was used to evaluate the association between the patient and transfusion 
characteristics and the recovery in all transfusions. All P-values are two-sided and a 
significance level a= 0.05 was used. 
Results 
results ofthe group 
Test results in 72 patients were as follows: in 13 patients PIFT and HLA-tests (LIFT or 
MAIPA) were negative, in 51 patients PIFT and HLA-tests were positive. In 5 patients 
the PIFT was positive and the HLA-tests were negative, in 3 patients the PIFT was 
negative and theHLA-tests were positive. 
to HLA-matched transfusions to 
Of the 72 patients 17 received HLA-matched transfusions following strategy I (decision 
for transfusion without information of an alloantibody test result), 39 following strategy 
II (decision based on a positive alloantibody test) and 15 following strategy III (decision 
inspite of a negative alloantibody test) (Table 2). In one patient it was not clear whether 
the decision was based upon a positive test result. This patient has been excluded from 
this analysis, but is included in the analysis on test results irrespective the strategy. The 
average recoveries· of the first HLA-matched platelet transfusion did not differ 
significantly between the three strategies. The average recoveries (± standard deviation) 
of the transfusions after 1 hour were 42% (± 18%), 47% (± 26%) and 35% (± 27%) for 
strategies I, II and III (P = 0.17) and the average recoveries after 16 hours were 20% (± 
20%), 32% (± 25%) and 17% (± 14%) (P = 0.1 0), respectively (Table 2). Successful 
transfusions for strategies I, II and III were noted in 94%, 85% and 73% after 1 hour (P = 
0.27) and 76%, 77% and 67% after 16 hours (P = 0.71), respectively. 
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Table 2. Dedsnon 
Item 
Positive HLA-test 
Recovery1hour 
Recoveryl6hours 
Successful transfusionslhour 
Successful transfusionsl6hours 
recovery 
n= 17 
I 
14 
42%± 18% 
20%±20% 
16 (94%) 
13 (76%) 
Strategy 
n=39 
II 
39 
47%±26% 
32%±25% 
33 (85%) 
30 (77%) 
n= 15 
m 
0 
35%±27% 
17%± 14% 
11 (73%) 
10 (67%) 
P-value 
0.17 
0.10 
0.27 
0.71 
i.Y not j;/(_:lnded in this zabel becau5:e the decision szra1eg;' 1ras no! 
clear. 
Of the 72 patients HLA-tests had been positive in 54 patients (14 strategy I, 39 strategy II 
and 1 not clear). In 18 patients (3 strategy I and 15 strategy III) no HLA-alloantibodies 
could be detected in these techniques (LIFT and MAIPA). The average platelet recovery 
of the first HLA-matched platelet transfusion in patients with a positive HLA-test after 1 
hour was 47% (± 24%) and in patients with a negative test 35% (± 25%) (P = 0.04). The 
average platelet recovery after 16 hours of the first HLA-matched platelet transfusion in 
patients with a positive test was 31% (± 24%) and 15% (± 14%) in patients with a 
negative test (P = 0.03) (Table 3). Successful transfusions for patients with a positive and 
negative test were present in 87% and 78% after 1 hour (P = 0.45) and in 80% and 61% 
after 16 hours (P = 0.13), respectively. 
122 
Item 
Recovery !hour 
Recoveryl6hours 
Successful transfusionslhour 
Successful transfusionsl6hours 
HLA-test P-valu.e 
n=54 
Positive 
47%±24% 
31%±24% 
47 (87%) 
43 (80%) 
n= 18 
Negative 
35%±25% 0.04 
15%± 14% 0.03 
14 (78%) 0.45 
11 (61 %) 0.13 
1 aru.:{ l6 hours arzd the nunzber 
and 16 hours 
In this series a positive PIFT was found in 56 patients and a negative PIFT in 16 patients. 
The average platelet recovery after 1 hour of the first HLA-matched platelet transfusions 
in patients with a positive PIFT was 46% (± 25%) and in patients with a negative test 
38% (± 24%) (P = 0.14). After 16 hours the average platelet recovery of the first HLA-
matched platelet transfusion in patients with a positive PIFT was 30% (± 24%) compared 
to 17% (± 14%) in patients with a negative test (P = 0.08). Successful transfusions for 
patients with a positive and negative PIFT were present in 86% and 81% of cases after 1 
hour (P = 0.70) and in 79% and 75% of cases after 16 hours (P = 0.21), respectively. 
In the 3 patients with a positive HLA-test and a negative PIFT a successful increment 
was established in 100% of first HLA-matched transfusions both after 1 and 16 hours. 
Among the 5 patients in whom a negative HLA-test and a positive PIFT was found 80% 
of first HLA -matched transfusions resulted in a successful recoveries at 1 and 16 hours 
after transfusion. 
With regard to the recovery values after 1 and 16 hours of the 560 HLA-matched 
transfusions no differences were noted between male and female patients. There was 
no apparent impact of diagnosis or treatment (chemotherapy compared to autologous 
or allogeneic stem cell transplantation) on the values of platelet recovery either. ABO-
blood group incompatibility did not predict platelet recovery, although a trend 
towards lower recovery 16 hours after transfusion (P = 0.07) was evident (83% of 
successful outcomes in ABO compatible HLA-matched transfusions compared with 
69% in ABO incompatible HLA-matched transfusions, in 7 transfusions the ABO-
match was not known). In 145 transfusions with a cross-reactive HLA-mismatch 77% 
of successful outcomes were established after 1 hour, which was significantly less (P = 
0.04) than the 88% of successful outcomes in 404 HLA-compatible transfusions. No 
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difference in recovenes after 16 hours between cross-reactive and compatible 
transfusions was found, 82% of successful transfusions in compatible transfusions and 
77% in incompatible transfusions (P = 0.44). In 11 of the 560 transfusions no HLA 
match could be found retrospectively. 
Discussion 
Alloantibody measurement in the serum of patients not responding to random donor 
platelet transfusions has become common practice. Several studies have demonstrated 
that alloantibody tests predict for insufficient increment of random non-leucodepleted 
platelet transfusions4-6. We and others could not find a correlation between test result 
and platelet recovery of random transfusions3&-38. The importance of these tests in 
predicting the success of HLA-matched platelet transfusions, in patients refractory to 
leucodepleted random donor platelet transfusions, has not been studied. 
In the retrospective study reported here 3 decision strategies (not based on an available 
alloantibody test result; based on a positive alloantibody test; and inspite of a negative 
alloantibody test) of selecting patients for HLA-matched transfusions were compared. 
We could not demonstrate a difference between these 3 strategies with regard to the 
increment of the first HLA-matched platelet transfusion. A trend, however, towards a 
lower average transfusion result was observed for strategy III. We may have been 
unable to demonstrate a significant difference between these 3 strategies due to the 
limited number of patients accrued during the 5 year period. In addition, a supprisingly 
82% of the 17 transfusions following strategy I demonstrated a positive HLA-test in 
retrospect, and thus patients of both strategy-groups I and II showed serological 
evidence of alloimmunisation in majority. 
In the second part of the analysis the results of a positive or negative HLA-test was 
related to the recovery of the first HLA-matched transfusion. Significantly better 
average recoveries of the first HLA-matched platelet transfusion were observed in the 
patient group with a positive HLA-test. This underscores the importance of patient 
selection with the help of an HLA-test for HLA-matched transfusions in a population 
receiving leucodepleted blood products. However, 7 of 54 patients with a positive 
HLA-test showed a poor recovery of the first HLA-matched transfusion suggesting a 
possible role of non-immune factors. These factors had not been specified or 
recognised by the treating physician as the cause of refractoriness, and therefore their 
nature remains unclear. On the other hand it is of note that 14 of 18 patients who 
demonstrated a negative HLA-test showed positive response to HLA-matched 
transfusions. The adequate recovery of HLA-matched platelet transfusions in the 
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absence of documented HLA sensitization cannot easily be explained but it is possible 
that transient non-immunological factors have played a role in the lack of response of 
these patients to the random platelet transfusions earlier. In addition, it is conceivable 
that the restricted sensitivity of HLA-tests in detecting alloantibodies is too restricted 
in a proportion of patients. Finally in vivo absorption of alloantibodies to transfused 
platelets at the time of serum sampling for the alloantibody test might have interfered. 
The results ofHLA-tests and PIFT demonstrated a considerable overlap. Therefore the 
added value of PIFT in the series as a predictor of immunization was limited. The 
PIFT did not demonstrate a significant correlation between test result and the average 
recovery of the first HLA-matched platelet transfusion, although a trend towards 
poorer recoveries in patients with a negative PIFT was noted. The 11% (8/72) of 
discrepant results between HLA-tests and PIFT may be explained by the fact that 
HLA-tests only measure alloantibodies against HLA-antigens and the PIFT detects 
also other alloantibodies (platelet-specific, autoantibodies and possibly immune 
complexes). In addition HLA-antigen expression on platelets is less than that on 
lymphocytes, which are used as targets in the LIFT. This may explain why the HLA-
tests demonstrated a stronger association with increment of HLA-matched platelet 
transfusions than the PIFT. Furthermore, the incidence of platelet specific antibodies 
with or without the presence ofHLA antibodies is in our and others experience low39. 
Platelet specific antibodies, therefore, are not expected to influence the outcome of this 
analysis. 
In looking for other factors interfering with platelet recovery we considered the total 
560 HLA-matched transfusions in the study group. No differences in platelet 
recoveries were found in relation to sex, diagnosis or therapy. We were not able to 
demonstrate a significant effect of ABO-incompatibility upon platelet recovery of 
HLA-matched transfusions. Although the study was not assigned to primarily address 
this issue, this is in contrast to other reports on random platelet transfusions1- 3,4°. Our 
patients received random ABO-matched platelet transfusions prior to HLA-matched 
transfusions. In this way a boost to ABO-antigens may have been avoided. We 
demonstrated a significantly better recovery after 1 hour of a compatible HLA-match 
in contrast to a cross-reactive HLA-match. This emphasizes the importance of the 
effort that has to be undertaken to find the best match for a patient immunized against 
a broad range ofHLA-antigens. 
In conclusion a positive HLA-test predicts for better overall recovery ofHLA-matched 
platelet transfusions in patients refractory to random donor platelet transfusions. 
Patients refractory to random donor platelet transfusions with a negative HLA-test and 
without non-immunological factors present, however, may benefit from HLA-matched 
transfusions in a significant proportion of cases, although the average recovery is 
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considerably lower. In these patients or in patients in whom no results of HLA-tests 
are available an empiric HLA-matched platelet transfusion may be considered. 
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General summary 
Introduction 
Platelet transfusions from voluntary donors are indispensable for preventing bleeding in 
patients who are thrombocytopenic due to their hematologic disorder (e.g. acute 
leukemia) or to marrow suppressive treatment (radiation, chemotherapy). A considerable 
proportion of platelet transfusions, however, fail to produce a good recovery after 
transfusion. One of the causes of enhanced donor platelet destruction results from 
antibody formation by the recipient against antigens present on transfused platelets. The 
frequency of alloantibody mediated destruction of donor platelets has been considerably 
diminished since the application of leukodepletion to all blood products, which is a 
standard procedure in many countries including the Netherlands. 
In this thesis we describe and compare different tests to detect alloantibodies to platelets. 
We study the correlation of the results of these tests and the platelet transfusion outcome, 
and estimate the frequencies of alloantibody formation (in serum) as well as non-
immunological factors that have been implicated in reduced survival of transfused 
platelets. These studies were conducted in patients who recieve leukodepleted blood 
products. The results of these studies lead to a reappraisal of the clinical value of platelet 
antibody detection. 
Alloantibody detecting tests based on in vitro incubation 
The lymphocyte, platelet and granulocyte immunofluorescence test (LIFT, PIFT and 
GIFT, respectively) using a cell panel from 5 random donors and a simultaneous four-
channel flowcytometric technique in order to detect IgG and IgM antibodies bound to 
platelets, lymphocytes and neutrophils have been described in chapter 2. The 
usefulness of the LIFT and the PIFT was illustrated by the description of a patient who 
developed IgM and IgG alloantibodies against platelets and lymphocytes. Repeated 
platelet transfusion failures were noted in the presence of these alloantibodies reacting 
in the LIFT and PIFT (most probably alloantibodies against a broad range of HLA-
class I antigens). The alloantibodies could be circumvented with the use of HLA-
matched single donor platelet transfusions in this patient. All the patients who showed 
alloantibodies of the IgM -class also demonstrated alloantibodies of the IgG-class. The 
technique of simultaneous four-channel detection ofigG antibodies bound to platelets, 
lymphocytes and neutrophils by flowcytometry was shown to be more sensitive than 
the lymphocyte cytotoxic test (LCT). We standardised test results by introducing a 
defined threshold above which a test was regarded as positive. The threshold was 
established by measuring the fluorescence of a number of negative sera. 
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In chapter 3 we studied the correlation between the results of the LCT, LIFT and 
PIFT, all using donor panel cells, in 192 prospectively and randomly selected serum 
samples. The routine measurement of the GIFT, described in chapter 2, was 
discontinued because of the large inter-assay variation, the significant background of 
autofluorescence from the neutrophils and its minimal clinical added value (the 
prevalence of antibodies against neutrophils is very low and is rarely related to platelet 
refractoriness). The results of the LIFT, PIFT and LCT correlated significantly with 
each other (P < 0.005). The LIFT, however, more frequently produced positive test 
results in relation to the PIFT and the LCT. Each of the 3 tests were found 
occasionally to assess alloantibodies against lymphocytes or platelets that might have 
been missed by any of the other two tests. In this chapter the results ofLCT, PIFT and 
LIFT were also compared to those of a commercially available ELISA technique using 
a broad range of immobilized HLA-class I antigens (ELIHLA). The results of the 
LIFT and ELIHLA demonstrated a highly significant correlation (x2 = 63.7; P < 
0.001). In addition, the results of the ELIHLA and the PIFT or LCT significantly 
correlated as well (x2 = 42.3; P < 0.001 and 
x2 = 8.6; P = 0.003, respectively). But the ELIHLA more frequently produced positive 
test results as compared to the PIFT and the LCT. 
Detection of in vivo bound antibodies to platelets 
In chapter 4 we have described a newly developed test, the in vivo binding of 
immunoglobulins in the platelet immunofluorescence test (IVBI-PIFT). This technique 
compares the fluorescence histogram oflgG bound in vivo to platelets before a platelet 
transfusion with the fluorescence histogram after the platelet transfusion. We 
described 4 distinct patterns of fluorescence in the combined histograms (before and 
after transfusion). Pattern 1 (no shift of the fluorescence histogram both before and 
after platelet transfusion) was interpreted as no alloimmunization or complete 
elimination of transfused platelets from the circulation within 1 hour. Pattern 2 
(enhanced fluorescence of platelets before and after transfusion as compared to that of 
the platelets in the transfusion bag) was assumed to represent aspecific binding of 
immunoglobulins to platelets (e.g. due to immune complexes and autoantibodies). 
Pattern 3 (greater fluorescence before platelet transfusion) was interpreted as aspecific 
binding of immunoglobulins or alloantibodies against formerly transfused platelets 
(e.g. HLA-antibodies or platelet specific alloantibodies against formerly transfused 
platelets). Finally, pattern 4 (increased fluorescence after platelet transfusion) was 
assumed to reflect the condition of alloantibodies against the transfused platelets (e.g. 
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HLA-antibodies or platelet specific alloantibodies). These patterns were related to the 
results of the indirect PIFT, which measures IgG-binding to panel platelets in vitro. 
Positive results of the indirect PIFT were more frequently associated with transfusions 
that demonstrated pattern 4 (enhanced binding of IgG to platelets after transfusion) in 
relation to pattern 1 (no enhanced binding of IgG to platelets after transfusion), P = 
0.001. Poor platelet recoveries were more frequently seen in association with pattern 4 
as compared to pattern 1 (P = 0.002). As expected, patterns 2 and 3 did not relate with 
results ofthe indirect PIFT nor with transfusion response in vivo. 
The results of the IVBI-PIFT had been scored visually by a single blinded observer in 
the previous study. In order to eliminate interobserver variability of the visual scoring 
of the histograms, according to the 4 different patterns in the IVBI-PIFT, we 
developed a histogram subtraction method in 201 random serum samples (chapter 5). 
A histogram was created by subtracting the number of platelets per fluorescence 
channel (256 channels in toto) of the histogram before transfusion from those of the 
histogram after transfusion. Finally, the net histogram was constructed solely of the 
channels with a positive number of platelets of the remaining histogram. This 
histogram was characterized by the average number of remaining platelets in duplicate 
tests, Events Post Subtraction (EPS), and the average mean value of the curve of the 
remaining platelets in duplicate, Mean Channel Post Subtraction (MCPS). The 
interobserver disagreement rate in the IVBI-PIFT, defined as less than 3 of 5 blinded 
observers with identical visual scoring, was 13% (26/201) in our study. In the 
remaining 175 serum samples in which 3 or more blinded observers agreed on the 
score, named the consensus visual score, the pattern-score was compared to the results 
of the histogram subtraction. Pattern 4 appeared distinguishable from patterns 1 and 2 
with EPS (P < 0.0001). Pattern 4 could be distinguished from pattern 3 with the MCPS 
(P < 0.0001). The combination of EPS (~ 1100) and MCPS (~ 30) reliably predicted 
pattern 4 in relation to patterns 1, 2 and 3 (P < 0.001). However, the platelet 
transfusions associated with pattern 4 by the consensus visual scoring method nor the 
histogram subtraction method predicted for platelet recovery at 1 and 16 hours 
following transfusion. 
Predictive value of alloantibody detecting tests 
The relative importance of immunological and non-immunological factors in relation 
to the survival of transfused platelets in randomly selected patients was examined in 
chapter 6. We prospectively studied the results of 4 alloantibody tests (ELIHLA, 
LCT, LIFT and PIFT) and their relation with the platelet recoveries in 181 transfusions 
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from 97 patients. Various established non-immunological factors that might have 
influenced the survival of transfused platelets were taken into account. None of the 4 
tests appeared to correlate with platelet recoveries at 1 or 16 hours after transfusion. 
Only the combination of ELIHLA and PIFT or that of LIFT and PIFT demonstrated a 
statistically significant association with platelet recoveries at 16 hours (P = 0.04 and P 
= 0.03, respectively). The non-immunological factors under consideration were: 
diagnosis, therapy, splenomegaly, fever (>38.2 °C), disseminated intravascular 
coagulation, graft versus host disease, use of Amphotericin B and storage time of 
platelet transfusions from acquisition to donation. Significantly reduced platelet 
recoveries were apparent only in relation to splenomegaly (P < 0.01 at 1 hour and P = 
0.02 at 16 hours after transfusion) and in relation to platelet transfusions that had been 
stored for more than 3 days (P = 0.01 at 1 hour and P = 0.03 at 16 hours after 
transfusion). 
In chapter 7 we set out to further explore the lack of a relation between alloantibody 
tests and platelet transfusion outcome. Since we regarded the crossmatch test as the 
"golden standard" with regard to alloantibody testing (transfused platelets incubated 
with patient's serum in the PIFT technique, named crossmatch-PIFT) we related the 
results of this assay with the transfusion outcome. We did not find a positive 
relationship between a positive crossmatch-PIFT and poor platelet recoveries at 1 and 
16 hours after a random donor platelet transfusion. A subgroup analysis in platelet 
transfusions in absence of the non-immunological factors that might have influenced 
platelet transfusion results (splenomegaly and storage time of platelets of more than 3 
days) revealed a positive crossmatch-PIFT in 12% of transfusions with a poor outcome 
(based on recovery estimate) at 1 hour and in 7% of transfusions with a poor response 
at 16 hours. The results ofthe crossmatch-PIFT (in vitro incubation of patient's serum 
with transfused platelets) correlated with those of the IVBI-PIFT (in vivo binding of 
alloantibodies to transfused platelets, which serves as an in vivo correlate of the 
crossmatch), P = 0.02. In addition, the results of the crossmatch-PIFT (using 
transfused platelets as a target) were compared to those of 2 screening tests using 
donor panel antigens as a target (panel-PIFT and ELIHLA). The results of the 
crossmatch-PIFT and the panel-PIFT did not correlate (P = 0.25). This was in contrast 
to a significant positive relationship between the results of the crossmatch-PIFT and 
the ELIHLA (P = 0.02). None of the two alloantibody tests using donor panel cells as 
a target predicted platelet recoveries at 1 and 16 hours after transfusion correctly. 
The predictive value of alloantibody tests with regard to outcome of HLA-matched 
platelet transfusions was studied in a selected patient population, refractory to random 
platelet transfusions and with no apparent involvement of non-immunological factors 
(chapter 8). The platelet recoveries at 1 and 16 hours after the first HLA-matched 
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platelet transfusions in 72 patients were analysed according to the clinical decision by 
which the patient had been assigned to HLA-matched platelet transfusions. The 
decisions were taken in the following context: (I) results of alloantibody tests were not 
(yet) available when the patient was assigned to HLA-matched platelet transfusions; 
(II) the alloantibody test had been positive; and (III) the alloantibody test had been 
negative. No significant relationship was found between the context in which the 
decision for HLA-matched platelet transfusions was made and the outcome of the 
transfusion. However, in patients selected for HLA-matched transfusions according to 
strategy III there was a trend towards a poorer recovery at 1 and 16 hours after 
transfusion. The recoveries of the :first HLA-matched transfusion were also 
investigated in relation to the results of alloantibody tests irrespective of the strategy. 
The latter comparison demonstrated that a positive alloantibody test predicted a better 
average response to the :first HLA-matched platelet transfusion (assessed at 1 hour, P = 
0.04, and 16 hours after transfusion, P = 0.03). In order to evaluate other influences on 
the efficacy ofHLA-matched platelet transfusions, we studied the effect of a variety of 
patient and transfusion factors in relation to the response to 560 HLA-matched 
transfusions in the 72 patients. No differences in platelet transfusion response were 
observed for gender, diagnosis or therapy (chemotherapy compared to autologous or 
allogeneic stem cell transplantation). ABO-blood group incompatibility tended 
towards lower recoveries at 16 hours after transfusion, P = 0.07 (83% of successful 
outcomes in ABO compatible HLA-matched transfusions compared with 69% in ABO 
incompatible HLA-matched transfusions), but not at 1 hour. A cross-reactive (the 
donor expresses HLA-class I antigens that are not present in the acceptor) HLA-match 
demonstrated a significantly lower recovery after 1 hour, P = 0.04, than a compatible 
(all HLA-class I antigens of the donor are present in the acceptor) HLA-match; no 
difference was observed after 16 hours. 
Conclusions of the studies of this thesis 
2 
In this chapter we describe a double colour :flowcytometric technique in which 
simultaneously alloantibodies from the IgG- and IgM-class can be detected. In the 
studied patient population IgM alloantibodies were not found in the absence of 
alloantibodies from the IgG-class. 
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3 
The results of 4 different screening tests for alloimmunization based on different 
serological principles (LCT, PIFT, LIFT and ELIHLA) are significantly correlated. 
The LIFT and ELIHLA are more frequently positive than the LCT and PIFT, thus 
being more sensitive for the detection ofHLA-antibodies. 
4 
A method of a modified PIFT in which the in vivo binding of IgG preferentially to the 
transfused platelets can be measured (named NBI-PIFT) is described. The results of 
this method are correlated with those ofthe in vitro binding oflgG in the indirect PIFT 
and with the outcome of the studied platelet transfusions. 
5 
A histogram subtraction method is described to objectivate the visual score of the 
NBI-PIFT as used in chapter 4. 
6 
The different alloantibody assays, which showed a good intercorrelation with respect 
to serological results (chapter 2), did tum out to be predictive for platelet transfusion 
outcome when used as screening tests in an unselected population in need for platelet 
transfusions. Reasons for the absence of this correlation are given and non-
immunological factors that jeopardize platelet survival were identified. 
7 
The results of a platelet crossmatch test in the PIFT technique are significantly related 
to those of the NBI-PIFT and ELIHLA, but not to those of the indirect PIFT. The 
results of these 4 tests (crossmatch-PIFT, IVBI-PIFT, ELIHLA and indirect PIFT), 
however, do not predict the outcome of a subsequent platelet transfusion in a non-
selected patient population. 
8 
HLA-matched platelet transfusions in patients who are refractory to random donor 
platelet transfusions and in whom non-immunological factors for enhanced platelet 
destruction are excluded have a significantly higher average recovery if the patients 
have a positive alloantibody test in relation to those with a negative test result. 
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Inleiding 
Trombocytopenie is frequent aanwezig bij patienten met hematologische ziekten en 
wordt veroorzaakt door: (i) de hematologische ziekte (verdringing van het gezonde 
beenmerg door de maligne aandoening of een primaire aplasie ), (ii) de therapie 
( chemotherapie, immunotherapie, bestraling, omgekeerde afstoting of 
transplantaatfalen na een beenmerg of perifere stamceltransplantatie ), (iii) het 
toegenomen verbruik van trombocyten (diffuse intravasale stolling, actief bloedverlies 
of autoantistoffen), of (iv) een abnormale distributie van trombocyten ( splenomegalie ). 
Indien het trombocytenaantal lager is dan 10 x 109 per liter worden profylactisch 
trombocytentransfusies toegediendom bloedingen te voorkomen1'2 . Deze transfusies 
bestaan uit een mengsuspensie van de trombocyten van 5 willekeurige donoren. 
Vierentwintig tot 44% van de profylactische trombocytentransfusies zijn niet 
succesvol als gevolg van immunologische en/of niet-immunologische factoren3 - 6. 
Indien immunologische of niet-immunologische oorzaken van een lage 
trombocytenopbrengst persisteren, IS de patient refractair geworden voor 
trombocytentransfusies van 5 willekeurige donoren. De immunologisch veroorzaakte 
refractaire status berust op de vorming van antistoffen tegen klasse I humane 
leukocyten antigenen (HLA-klasse I), antistoffen tegen trombocytspecifieke antigenen, 
op autoantistoffen of op circulerende immuncomplexen7'8. Het ns1co op 
alloimmunisatie tegen HLA-klasse I antigenen neemt toe naar gelang de hoeveelheid 
leukocyten per transfusieproduct. Een andere risicofactor voor alloimmunisatie is een 
eerder doorgemaakte zwangerschap6'9' 10. Onder de niet-immunologische oorzaken van 
een refractaire status worden vele klinische factoren geschaard die de overleving van 
getransfundeerde trombocyten negatief bemvloeden. Voorbeelden van niet-
immunologische oorzaken van een refractaire status zijn splenomegalie, medicatie, 
koorts, diffuse intravasale stolling en actiefbloedverlies3. 
Verschillende testen, die antistoffen tegen HLA-antigenen aantonen, worden toegepast 
om alloimmunisatie als oorzaak van een refractaire status te onderscheiden van de 
aanwezigheid van niet-immunologische factoren. In dit proefschrift is onderzoek 
gedaan naar de waarde van verschillende testen die alloantistoffen tegen HLA-
antigenen bepalen. De waarde van deze testen is afgemeten aan de overeenkomst met 
referentietesten. Ook is de voorspellende waarde van testuitslagen voor het resultaat 
van trombocytentransfusies bestudeerd. De verschillende studies zijn verricht bij 
patienten die aileen ge:filtreerde bloedprodukten hebben ontvangen. Het gevolg van de 
leukodepletie van bloedprodukten is de reductie van alloimmunisatie als oorzaak van 
de refractaire status voor trombocytentransfusies9•11-21 . 
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Onderlinge vergelijking van verschillende alloantistoftesten 
In hoofdstuk 2 wordt een flowcytometrische techniek beschreven waarmee 
tegelijkertijd IgG en IgM antistoffen tegen trombocyten, lymfocyten en granulocyten 
kan worden vastgesteld, de PIFT, LIFT en GIFT, respectievelijk. Een afkappunt voor 
positiviteit van de PIFT, LIFT en GIFT (afzonderlijk IgG en IgM) werd bepaald met 
behulp van een panel van 10 niet gei:mmuniseerde don oren. Op deze manier kunnen de 
resultaten van deze testen worden geobjectiveerd. Tevens wordt een patient 
beschreven met een refractaire status voor ongetypeerde trombocytentransfusies. Bij 
deze patient werden IgG en IgM antistoffen aangetoond in de PIFT en LIFT 
(antistoffen tegen HLA-klasse I antigenen). De refractaire status voor 
trombocytentransfusies bleek te kunnen worden doorbroken door HLA-
overeenkomstige trombocytentransfusies toe te dienen. In alle bestudeerde patienten 
die alloantistoffen van de IgM-klasse lieten zien, werden ook alloantistoffen van de 
IgG-klasse gevonden. 
De gevoeligheid en betrouwbaarheid van een commercieel verkrijgbare ELISA-
techniek met een breed scala van HLA-antigenen (ELIHLA) wordt vastgesteld in 
hoofdstuk 3. Hierin worden de resultaten van de ELIHLA vergeleken met de uitslagen 
van de LCT, PIFT en LIFT. Een statistisch significante correlatie wordt gevonden 
tussen de uitslagen van alle 4 de testen. De LIFT en de ELIHLA zijn het best met 
elkaar gecorreleerd. Tevens lijken deze 2 testen het meest frequent positief te zijn als 
uiting van alloimmunisatie tegen HLA-klasse I antigenen. 
Aangezien het verband tussen de resultaten van verschillende in vitro testen en de 
trombocytenopbrengst in vivo frequent niet overeenkomen, wordt in hoofdstuk 4 een 
door ons ontwikkelde techniek beschreven. In deze techniek, de IVBI-PIFT genoemd, 
wordt de in vivo binding van IgG aan getransfundeerde trombocyten vastgesteld. Het 
fluorescentie histogram van de trombocyten na transfusie ge'incubeerd met een anti-
IgG-antistof (verbonden met een fluorochroom) wordt vergeleken met hetzelfde 
histogram voorafgaande aan de trombocytentransfusie. Hierbij worden de trombocyten 
uit de transfusiezak als negatieve controle gehanteerd. Er werden 4 verschillende 
patronen onderscheiden: patroon 1 laat geen toegenomen fluorescentie van de 
trombocyten zien (geen immunisatie of volledige destructie van getransfundeerde 
trombocyten binnen het uur); patroon 2 laat een toegenomen fluorescentie van de 
trombocyten voor en na transfusie zien in vergelijking met de trombocyten uit de 
transfusiezak (aspecifieke binding van antistoffen aan trombocyten, bijv. circulerende 
immuuncomplexen); patroon 3 laat een toegenomen fluorescentie voorafgaande aan de 
transfusie zien (antistoffen tegen voorgaande transfusies); en patroon 4 toegenomen 
fluorescentie na transfusie (ge'interpreteerd als alloimmunisatie ). Het patroon 4, 
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toegenomen fluorescentie na de trombocytentransfusie, werd ge'interpreteerd als een 
positieve testuitslag van de IVBI-PIFT. In dit hoofdstuk wordt aangetoond dat patroon 
4 (alloimmunisatie) vaker met een positieve indirekte PIFT overeenkomt (P = 0.001) 
dan patroon 1 (geen alloantistoffen tegen trombocyten). Tevens wordt bij 
trombocytentransfusies met patroon 4 vaker een slechte trombocytenopbrengst 
aangetroffen dan bij transfusies met patroon 1, 67% (16/24) versus 31% (22/72) van de 
transfusies, respectievelijk (P = 0.002). 
Na introductie van de IVBI-PIFT in onze kliniek b1eek de visuele patroonscore 
onderhevig te zijn aan inter-individuele variatie tussen verschil1ende observatoren. In 
hoofdstuk 5 wordt een methode beschreven, waarbij de visue1e patroonscore 
vervangen wordt door een geobjectieveerde uits1ag van de IVBI-PIFT, de zogenaamde 
histogram-subtractie methode. In dit hoofdstuk bleek de visuee1 gescoorde patronen in 
26 van de 201 (13%) trombocytentransfusies niet overeen te komen tussen 5 
observatoren. De techniek van histogram-subtractie in de IVBI-PIFT is a1s vo1gt: het 
aanta1 trombocyten per fluorescentiekanaa1 (256 fluorescentiekana1en per histogram) 
voor en na de trombocytentransfusie worden van elkaar afgetrokken. Een nieuw 
histogram wordt gemaakt van de resterende trombocyten van die fluorescentiekana1en 
met meer dan of evenveel trombocyten na transfusie als voor transfusie, de overige 
fluorescentiekana1en worden op 0 trombocyten gedefinieerd. Uiteindelijk wordt van 
dit resulterende histogram het gemidde1d aanta1 trombocyten (EPS) en het gemidde1de 
fluorescentie kanaa1 (MCPS) van de dup1o-meting gegenereerd. Het blijkt dat EPS 
goed differentieerde tussen patroon 4 en patroon 1 en 2, terwij1 MCPS goed 
differentieert tussen patroon 4 en patroon 3. De combinatie van EPS 2: 1100 en MCPS 
2: 30 onderscheidt het best tussen patroon 4 en de overige patronen (P < 0.001 voor het 
verschil). De visue1e score en de histogram subtractie is echter niet gecorreleerd met 
de trombocytenopbrengst 1 en 16 uur na transfusie. Dit komt waarschijnlijk door de 
aanwezigheid van eerder genoemde niet-immuno1ogische factoren en de lage 
prevalentie van immuno1ogische factoren. 
V oorspellende waarde van alloantistoftesten 
Het belang van immuno1ogische en niet-immunologische factoren a1s verklaring voor 
een slechte trombocytenopbrengst wordt beschreven in hoofdstuk 6. In dit hoofdstuk 
wordt aangetoond dat er geen verband tussen de resultaten van 4 verschillende 
antistofmetende testen (LCT, ELIHLA, PIFT en LIFT) en een s1echte trombocyten 
opbrengst na 1 en 16 uur in onze popu1atie kon worden gevonden. Aileen een 
combinatie van een positieve ELIHLA en PIFT of een combinatie van een positieve 
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LIFT en PIFT lieten een relatie zien met een slechte trombocytenopbrengst 16 uur na 
een trombocytentransfusie, P = 0,04 en P = 0,03 respectievelijk. Deze combinatie van 
positieve testen was aanwezig in slechts 2% van de trombocytentransfusies. Van de 
niet-immunologische factoren was splenomegalie gecorreleerd met een slechte 
trombocytenopbrengst na 1 en 16 uur (P = 0,05 en P = 0,02, respectievelijk) evenals 
een bewaartijd van de trombocytentransfusies van meer dan 3 dagen (P = 0,01 en P = 
0,03, respectievelijk). Opvallend was dat een significant slechtere 
trombocytenopbrengst werd gezien bij transfusies van patienten met chronische 
myeloi:de leukemie (CML), allogene stamceltransplantatie (alloSCT) en van het 
mannelijk geslacht. Deze correlatie werd met name veroorzaakt door de aanwezigheid 
van splenomegalie als interfererende factor en kon in een multivariate analyse niet 
worden bevestigd. Geconcludeerd wordt in dit hoofdstuk dat de alloantistoftesten niet 
betrouwbaar de trombocytenopbrengst kunnen voorspellen in een niet-geselecteerde 
pati entenpopulati e. 
Om te onderzoeken waarom de correlatie tussen alloantistofmetende testen en 
trombocytenopbrengst slecht is, wordt in hoofdstuk 7 als "gouden standaard" een 
trombocytenkruisproef vergeleken met de uitkomst van verschillende testen en de 
trombocytenopbrengst. De trombocytenkruisproefbestaat uit een in vitro incubatie van 
het serum van de patient met de getransfundeerde trombocyten, waarbij eventuele 
binding wordt gemeten in de PIFT -techniek. In dit hoofdstuk wordt beschreven dat er 
ook geen correlatie bestaat tussen de trombocytenkruisproef en de 
trombocytenopbrengst. Van de transfusies met een slechte transfusieopbrengst in de 
afwezigheid van eerder gedefinieerde klinische factoren (splenomegalie en een 
trombocytenbewaartijd van meer dan 3 dagen) blijkt slechts 12% na 1 uur en 7% na 16 
uur een positieve trombocytenkruisproefte hebben. De teleurstellende correlatie tussen 
trombocytenkruisproef en trombocytenopbrengst wordt verder onderzocht door het 
verband te bestuderen: tussen (i) in vitro en in vivo binding van alloantistoffen aan 
getransfundeerde trombocyten en tussen (ii) trombocytenkruisproef en 
screeningstesten die een ander donoren panel hanteren. De in vitro en in vivo binding 
van IgG aan getransfundeerde trombocyten (trombocytenkruisproef versus IVBI-
PIFT) zijn statistisch geassocieerd (P = 0,02). Er wordt echter geen relatie gevonden 
tussen de kruisproef en de panel-PIFT, P = 0,25. Wel wordt een associatie tussen de 
resultaten van de kruisproef en de ELIHLA aangetoond (P = 0.02). De resultaten van 
de kruisproef, de IVBI-PIFT, de panel-PIFT noch de ELIHLA laten een verband met 
de trombocytenopbrengst zien. Hieruit wordt geconcludeerd dat het niet zinvol is sera 
te screenen op de aanwezigheid van alloantistoffen bij alle patienten die een 
trombocytentransfusie krijgen. 
De relevantie van het toepassen van alloantistoftesten op een geselecteerde 
patientenpopulatie, die refractair zijn voor ongetypeerde trombocytentransfusies, 
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wordt beschreven in hoofdstuk 8. In dit hoofdstuk wordt van aile patienten, die in het 
ErasmusMC van januari 1997 tot januari 2002 een HLA-overeenkomstige 
trombocytentransfusie ontvingen, de trombocytenopbrengst van de eerste HLA-
overeenkomstige trombocytentransfusie verge1eken met de resultaten van 
alloantistoftesten. In eerste instantie worden 3 omstandigheden betreffende het 
(beschikbare) resultaat van een alloantistof test, alvorens werd besloten tot een HLA-
overeenkomstige transfusie, in verband gebracht met de trombocytenopbrengst van 
deze eerste HLA-overeenkomstige transfusie. Deze omstandigheden waren: (I) geen 
resultaat van een alloantistofmetende test was beschikbaar, (II) een positieve 
alloantistofmetende test was bekend en (III) een negatief resultaat van een 
alloantistofmetende test was bekend. Er werd geen significant verschil gevonden 
tussen de trombocytenopbrengst van de eerste HLA-overeenkomstige transfusie en de 
omstandigheid waarin de van de beslissing voor deze transfusie werd genomen. W el 
werd een tendens tot slechtere trombocytenopbrengst opgemerkt bij strategie III. In 
tweede instantie werden de resultaten van alloantistoftesten vergeleken met de 
trombocytenopbrengst onafhankelijk van de beslissingsstrategie. In deze vergelijking 
bleek een positieve alloantistoftest significant gecorreleerd met een betere 
trombocytenopbrengst 1 en 16 uur na de trombocytentransfusie, P = 0,04 en P = 0,03, 
respectievelijk. Opvallend was dat toch nog 78% en 61% van patienten met een 
negatief testresultaat een goede transfusie opbrengst hadden 1 en 16 uur na de HLA-
overeenkomstige transfusie. Kortom patienten, die refractair zijn voor ongetypeerde 
trombocytentransfusies in afwezigheid van niet-immunologische factoren en die een 
positieve alloantistoftest hebben, laten een betere trombocytenopbrengst van HLA-
overeenkomstige transfusies zien dan patienten met een negatieve test. Maar een 
aanzienlijk deel van de patienten, die refractair zijn voor ongetypeerde 
trombocytentransfusies, met een negatieve alloantistoftest kunnen wel degelijk baat 
hebben bij een HLA-overeenkomstige transfusie. 
In deze patientengroep werden van alle 560 HLA-overeenkomstige transfusies ook 
nog vastgesteld dat compatibele HLA-overeenkomstige transfusies (patient heeft alle 
HLA-klasse I antigenen die de donor heeft) een betere trombocytenopbrengst hadden 
na 1 uur in vergelijking met een kruisreagerende transfusie (patient heeft niet aile 
HLA-klasse I antigenen die de donor heeft), P = 0.04. Dit benadrukt het belang van 
een goed HLA-overeenkomstigheid tussen donor en ontvanger. Hiemaast werd een 
trend tot een s1echtere trombocytenopbrengst na 16 uur bij ABO-incompatibele HLA-
overeenkomstige transfusies waargenomen, P = 0.07. 
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Er zijn vele technieken beschikbaar, die ailoantistoffen tegen trombocyten detecteren. 
In studies, waarbij de patienten geen leukocytenarme bloedprodukten kregen is 
aangetoond dat de trombocytenopbrengst samenhangt met het testresultaat. Aangezien 
de waarde van de verschiilende testen niet duidelijk was in patienten die ge:filtreerde 
bloedprodukten ontvangen, hebben wij verschiilende testen in deze patientengroep 
onderzocht. Wij vonden dat, ook al kwamen de resultaten van de meeste testen goed 
met elkaar overeen, de voorspeilende waarde van aile onderzochte testen ten opzichte 
van de trombocytenopbrengst zeer beperkt is. Het lijkt daarom niet zinvol om 
ailoantistof testen uit te voeren bij aile patienten die ge:filtreerde bloedprodukten 
ontvangen. Wellijkt het zinvol de testen te selecteren voor patienten die refractair zijn 
en bij wie geen niet-immunologische factoren aanwezig zijn die de verkorte 
overlevingsduur van trombocyten kunnen verklaren. Omdat bij de vergelijking van de 
verschiilende testen onderling geen van de serologische testen superieur bleek te zijn, 
adviseren wij de test te hanteren, die de minste vals positieve resultaten geeft en die 
het meest eenvoudig is om uit te voeren. In onze studies was dat de ELIHLA. 
Indien patienten refractair voor trombocytentransfusies zijn en indien er geen 
immunologische oorzaken aanwezig zijn die de trombocytenopbrengst bei:nvloeden 
bevelen wij aan een proeftransfusie met HLA-overeenkomstige trombocyten toe te 
dienen en een ailoantistofrnetende test uit te voeren. De HLA-overeenkomstige 
trombocytentransfusie heeft dan 94% en 76% (hoofdstuk 8) kans op een goede 
transfusie opbrengst 1 en 16 uur na de transfusie. Mocht de test negatief zijn dan kan 
bij een volgende transfusie het geven van ongetypeerde trombocyten opnieuw worden 
overwogen. Bij een positieve test mag men aannemen dat ailoimmunisatie de oorzaak 
is van het slechte transfusieresultaat van ongetypeerde trombocyten, tenzij ook HLA-
overeenkomstige transfusies geen goede opbrengsten geven. Men kan in het laatste 
geval de aanwezigheid van plaatjesspeci:fieke antistoffen overwegen die niet met de 
ELIHLA gemeten kunnen worden. Deze situatie is in de praktijk echter zeer zeldzaam. 
Een voorstel voor de transfusie-strategie indien is besloten tot het toedienen van een 
HLA-overeenkomstige trombocytentransfusie is weergegeven :figuur 1. Enkele 
belangrijke beslispunten zijn verder toegelicht in de legenda. 
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De verschillende onderzoeken in dit proefschrift leiden tot de volgende conclusies: 
1. Verschillende alloantistofmetende testen laten een goede overeenkomstigheid in de 
resultaten zien. Wij raden daarom aan om de meest eenvoudige test te gebruiken, 
welke in onze onderzoeken de ELIHLA was. 
2. Het regelmatig testen van de sera van ongeselecteerde patienten, die gefiltreerde 
bloedprodukten ontvangen, op de aanwezigheid van alloantistoffen is niet zinvol, 
aangezien de uitslagen niet de trombocytenopbrengst voorspellen. 
3. Dit geldt niet zonder meer voor het uitvoeren van deze testen bij een 
patientengroep die refractair is voor ongetypeerde trombocytentransfusies in de 
afwezigheid van niet-immunologische factoren. De gemiddelde opbrengst van 
HLA-overeenkomstige trombocytentransfusies is binnen deze populatie beter bij 
patienten met een positieve alloantistoftest. Een goed transfusieresultaat bij 
patienten met een negatieve alloantistoftest is echter zeker niet uitgesloten. 
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General discussion 
Jj 
The problematic place of alloantibody tests in clinical practice 
In 2003 an international forum has addressed the value and applicability of 
alloantibody tests in general1. The forum emphasized the large differences that exist 
between countries in their policy of alloantibody detection (used test, frequency of 
alloantibody detection and when to applicate HLA-matched transfusions) (Tabell). 
Table 1. The vah.1e o:f to an international forum 
Country Preferred alloantibody The predictive value of alloantibody Standard 
test tests (in relation to platelet leukodepletion 
refractoriness) 
France ELlliLA Good Yes 
Denmark LCT Possible No 
Poland LCT and LIFT Not clear No 
Austria MAIPA Possible Yes 
Japan LCT Good Yes 
USA ELlliLA Not clear No 
Finland FlowPRA Not clear No 
Spain LCT Good Yes 
Germany LCT and ELISA Possible Yes 
Netherlands ELlliLA Not clear Yes 
England LCT and ELISA Not clear Yes 
ELJHLA = Ell::yme linked imrmmosorbent human leukocyze antigen assay (Quikscreen"' 1), 
E;JJSA =, Enzyme-linked inmwnosorbent assay. = Platelet radioactive 
detection LCT= 
nnmu1u>Hnnrt>w·.i>m'P test. J\LUPA =Monoclonal antibody-
Secondly, the presumed predictive value of alloantibody tests as interpreted by experts 
from these 11 countries was widely variable. Three experts reported a good correlation 
between alloantibody test results and platelet recovery, 3 experts reported a possible 
correlation, and 5 experts could not provide evidence for a correlation. Apparently 
there is a lot of disagreement with regard to the utility of these tests in clinical practice. 
Alloantibody testing: the questions 
In order to clarify the obscurity of this issue we studied the place of alloantibody tests 
in clinical practice in this thesis. We focus on two aspects of alloantibody testing 
against platelets: technical aspects and clinical value. Technical aspects concerned 
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comparison of techniques based on three different principles: complement lysis (LCT), 
immunofluorescence (PIFT and LIFT) and the enzyme linked immunosorbent assay 
(ELISA). The LCT, the oldest and best validated technique, is used in many 
laboratories worldwide. Newer techniques like immunofluorescence read by 
flowcytometry, and ELISA have the advantage of greater sensitivity and more 
objective reading of the results. We studied the correlation of the results of different 
screening tests and modified the techniques in certain studies with the intention of 
mimicing the in vivo situation. Thus we wished to assess whether any of the tests 
would be superior in measuring alloantibodies against platelets. In order to assess the 
clinical value of alloantibody testing against platelets we correlated the test results 
with the in vivo recovery of platelets after transfusion. 
Alloantibody tests 
tests 
Overall we found a good correlation between the results of the various alloantibody tests. 
Discrepancies in the results in individual cases were noted. We assume that these 
discrepancies might have been caused by: (i) differences in the specificity of the 
alloantibodies that are detected, (ii) differences in the target antigens in the panel 
(qualitatively an quantitatively), and (iii) differences in the test conditions. 
Ad (i) the specificity of the antibody. Antibodies specific exclusively for HLA-antigens 
were detected in the LIFT and an ELISA using HLA-class I antigens from 100 donors as 
a target (ELIHLA). Antibodies against HLA and platelet specific antigens were detected 
in the PIFT-technique and its modifications (IVBI-PIFT and crossmatch-PIFT). In the 
techniques that use immunofluorescence also aspecifically bound IgG, e.g. immune 
complexes, can be found. The role of this aspecifically bound IgG under test 
circumstances is uncertain, but seems to be of minor importance. One of the reasons that 
we did not detect large discrepancies between the tests is that in alloimmunization by 
platelet transfusions the antibodies are most frequently directed against HLA-antigens or 
against HLA and platelet specific antigens simultaneously. Rarely, these antibodies are 
directed against platelet specific antigens alone2•3. 
Ad (ii) antigen composition of the panel. We used fresh cells of 5 random donors as a 
panel in the LCT, LIFT and PIFT. It may be argued that the panel was relatively small 
and discrepancy in test results may be caused by restricted antigen composition of the 
panel. However, comparison of LCT, LIFT and PIFT with ELIHLA, in which a broad 
range ofHLA-antigens of 100 donors is present, showed good correlations. This suggests 
that the distribution of the HLA-antigens on donor cells in a panel of 5 would be 
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representative. Lymphocytes and platelets serving as panel cells both express HLA-
antigens, but platelets express HLA-antigens in a much lower density. This renders the 
LIFT more sensitive for detection ofHLA-antibodies than the PIFT. 
Ad (iii) differences in test conditions between the studied test were numerous. These 
variations include e.g. the use of second antibodies (complement activation, fluorescence 
or light-absorbance), duration of incubation, applied temperature (in vitro versus in vivo), 
number of washing steps, and the way of analyzing the results (automated versus visual). 
By comparing the results of the different tests we could not pinpoint factors that 
positively or negatively influenced the test results. 
the results of dUfferent tests with a reference test 
In spite of serological differences a highly significant correlation was found between 
the results of the different tests. This positive correlation between test results may also 
be explained by the characteristics of the study population. The tested patients had a 
low risk of alloimmunization due to the fact that we did not select patients at high risk 
of sensitization (except in chapter 8) and that patients always received leukodepleted 
blood products. The percentage of negative test results in this population proved to be 
between 85 and 90%. This imbalance in favour of negative results in each of the 
techniques may, therefore, have biased the correlation ofthe test results. 
In order to exclude the influence on the herefore described imbalance in the 
population, we related the test results to a reference test in order to establish its 
reliability. This way of establishing the reliability of serologic tests in detecting 
alloantibodies in relation to a reference test is widely applied in literature, e.g. for the 
LCT4-6, the PIFT and LIFT7-10, the ELISA11 -14, the MAIPA15'16, the monoclonal 125I-
labeled anti-IgG assay C25I-MA) 17, the flowcytometry oflatex beads coated with HLA 
class I antigens18•19 and the commercially available ELISA tests with a broad range of 
HLA class I antigens20-22. In these studies the correlation of a test with a reference test 
is regarded as evidence for the reliability of the particular test, i.e. a good specificity 
and sensitivity in relation to a reference test. In this thesis we used the LCT, 
commonly used in the literature, as a reference test in chapter 2 and 3. The indirect 
PIFT was used in chapter 4, in order to study the impact of micro-environmental 
factors in relation to the NBI-PIFT. The crossmatch-PIFT, finally, was used in 
chapter 7, because it is theoretically the best test in predicting alloantibody mediated 
platelet destruction. 
The ELIHLA appears to perform best as a screening tool for alloimmunization of 
HLA-antigens on the basis of (i) its good correlation with the LCT, the indirect PIFT 
and the crossmatch-PIFT and (ii) its relatively easy applicability and time-sparing 
character in relation to other tests. 
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Clinical value 
A second aspect of alloantibody testing we addressed in this thesis is the predictive 
value of test results for transfusion outcome. Data on this aspect are still scarcely 
documented (see below). Our results revealed an unsatisfactory predictive value of 
each of the screening tests (LCT, LIFT, PIFT, and ELIHLA ). Also the two crossmatch 
tests (crossmatch-PIFT and IVBI-PIFT) failed to reliably predict the transfusion 
outcome. 
This lack of prediction might have been influenced by 2 important factors: (i) the 
concomitent presence of non-immunological factors that jeopardize platelet survival 
following transfusion and (ii) the use of leukodepleted blood products. The impact of 
non-immunological factors upon platelet recovery in vivo in our patient population 
was clearly established for splenomegaly and a storage time of platelet transfusions of 
more than 3 days. Other non-immunological factors described in literature might have 
had a role as well. Due to their relative infrequency they did not have enough power in 
our study to demonstrate a correlation with platelet recovery in a univariate analysis. 
The second factor, the influence of filtration of blood products in order to rigorously 
deplete all blood products from leukocytes, is separately discussed below. 
The value of to literature 
The published data on the value of alloantibody tests in predicting platelet transfusion 
outcome is limited. In the era before the introduction of systemic leukodepletion of 
blood products the probability of alloimmunization was 4- to 8-fold greater than today. 
In those days under those transfusion conditions the LCT has been validated by Bishop 
with regard to the prognostic value for transfusion increment23•24. In a prospective 
study a multivariate analysis that considered both immunological and non-
immunological factors in 941 non-leukodepleted platelet transfusions showed a 
positive correlation of a positive alloantibody test with poor platelet transfusion 
outcome. In contrast, the results of a multivariate analysis by Doughif5 taking into 
account non-immunological factors did not confirm the relationship between the 
results of the LCT and the outcome of 266 non-leukodepleted platelet transfusions. 
The value of alloantibody test results in relation to the outcome of leukodepleted 
platelet transfusions had previously been assessed in only one study until our studies26. 
In the latter study no association between a positive LCT and a poor outcome of 439 
platelet transfusions in 42 patients was found. The study was also analysed according 
to multivariate approach taking into account non-immunological factors. Our study on 
the value of alloantibody tests in predicting response to platelet transfusions was 
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conducted in 181 leukodepleted platelet transfusions in 97 patients27. In our study non-
immunological factors were taken into account in the multivariate analysis. No relation 
was found between the results of the LCT, LIFT, PIFT and ELIHLA and platelet 
recoveries at 1 and 16 hours after transfusion. 
Five longitudinal studies on the prevalence of positive alloantibody tests in patients 
receiving serial leukodepleted platelet transfusions have been described3'28-31 . Fabris 
demonstrated a positive ELISA test detecting alloantibodies against HLA-class I 
antigens in 4 (67%) of 6 refractory patients as compared to no alloantibodies in 19 
non-refractory patients28. Non-immunological factors were not significantly different 
in the 2 groups. A positive MAIPA and/or a positive LCT was demonstrated by Kurz 
in 44 (54%) of 81 patients refractory to random platelet transfusions29 . Non-
immunological factors, however, were not taken into account in this study. A 
prospective study by Legler in 145 patients demonstrated 40 (28%) refractory patients. 
Of these refractory patients a positive test was found in 7 (5%) in the absence of non-
immunological factors3. A case-control study by Alcorta demonstrated a positive LCT 
in 16 (31 %) of 52 refractory patients in relation to 1 (2%) of 52 non-refractory 
patients. This difference was statistically significant in a multivariate analysis taking 
into account non-immunological factors30. A prospective study by Novotny 
demonstrated a positive PIFT and LCT in 31 (3 9%) of 79 patients refractory to random 
donor platelet transfusions in relation to 17 (15%) of 115 non-refractory patients 
without taking non-immunological factors into account31 . 
of on for aUoantibodies 
Leukodepletion of blood products has been shown to be of major importance with 
respect to reduction of the incidence of alloimmunization. Platelet refractoriness may be 
reduced from approximately 24% without leukodepletion to 3% with rigorous 
leukodepletion as we discussed in the introduction32-4° (chapter 1 ). This reduction in the 
incidence of platelet refractoriness was recently confirmed by a study from Seftel. In this 
study the frequencies of alloimmunization and refractoriness to random platelet 
transfusions before and after the introduction of leukodepletion to blood products in 
Canada were compared41 . A decrease in alloimmunization from 19% to 7% and in 
alloimmune platelet refractoriness from 14% to 4% were found. 
In our studies all blood products were leukodepleted, henceforth the incidence of 
alloimmunization was expected to be low. For this reason an increased rate of false 
positive and false negative test results of alloantibody tests was to be expected in our 
study population. 
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False 
Because of the reduced incidence of alloimmunization following the application of 
leukodepleted blood products the relative contribution of non-immunological factors 
to platelet transfusion failures will increase. As a consequence, a higher rate of false 
negative results of the alloantibody tests is to be expected. In our studies the 
proportion of false negative test results ranged from 31 to 55% in relation to a poor 
recovery at 1 hour after platelet transfusion (Table 2). 
Table 2. False 
Test 
LCT1 
LIFT1 
PIFT1'2 
ELIHLA1'2 
IVBI-PIFT -visuae·4 
IVBI-PIFT -automated2'4 
Crossmatch-PIFT2 
False negative rate 
41% 
40% 
39-41% 
38-41% 
31-55% 
43-55% 
40% 
False positive rate 
69% 
60% 
50-53% 
50% 
33-43% 
43-65% 
46% 
rates are calculawdfor the platelet recoreiy a! l hour 
!he and 
immzau!fluorescence test (LIFT and PJFT, the en:::yme linked inmzww-sorbent 
assay with a large panel of immobili:::cd HLA-antigens 
in !he PJFT according !o the visual scoring cl~vstem 
according to the automated generation 
test to the PLFTwr·mrun,•P 
1 Chapter 6, 2 Chapter 7, 3 
Reduction of false negative test results can be obtained by selecting patients for these 
tests on the basis of the absence of non-immunological factors (patient selection). 
False 
The percentage of false positive test results was estimated by us by combining the rate 
of false positive test results in the hallmark study of Bishop (sensitivity 38% and 
specificity 85% in the LCTi2 and the assumed reduction in refractory patients (for 
detail see introduction to the thesis, chapter 1 ). By combining these two factors the 
false positive rate can be estimated according to the formula42 : 
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(!-sensitivity) x not refractory patients 
False positive= 
(!-sensitivity) x not refractory patients + specificity x refractory patients 
This results in an expected false positivity rate of 91% [0.15 x 207 I (0.15 x 207 + 0.38 
x 7)] ofthe LCT in patients receiving leukodepleted transfusions with less than 5 x 106 
leukocytes per transfusion. This 91% is a high value that is subject to significant error. 
Factors that influence this value are e.g. the selection bias of patients in the studies 
used to determine the reduction in platelet refractoriness or the number of transfusions 
per patient in the study of Bishop23 . 
The percentage of false positive test results of the alloantibody tests in our studies 
ranged from 33 to 69% (Table 2). The high number of false positive tests is of major 
concern and compromises their usefulness as screening tests. As antibodies (lgG) 
bound to the surface of transfused platelets in vivo may not necessarily lead to their 
destruction and in patients not immunized by leucocytes or pregnancy a positive 
alloantibody titer may be low, test positivity in a random population receiving 
leukodepleted blood products may not have clinical consequences. Also variations in 
IgG-subclass composition might explain the high false positive test rate as some 
subclasses are more effective in the destruction than others. A reduction in false 
positive results can be obtained by applying the tests to a selected category of patients 
at high risk of sensitisation, e.g. in those showing a poor recovery after platelet 
transfusion. 
Alloantibody testing: possible answers 
in dinical 
As alloantibody tests do not qualify as a screening test in patients at low risk for 
alloimmunization is there any place for alloantibody testing at all? In chapter 8 we 
demonstrated an increased average platelet recovery after HLA-matched platelet 
transfusions in a selected patient population (refractory to random platelets and in the 
absence of non-immunological factors) who showed positive alloantibody tests. In this 
particular patient group characterized by an increased risk of refractoriness by 
alloimmunization the predictive properties of the alloantibody tests were much better. 
In this way the results of alloantibody tests can lend support to the decision to 
administer HLA-matched platelet transfusions to patients refractory to random donor 
platelets. In addition, the results of alloantibody tests can provide information as to 
whether further investigations with regard to the involvement of platelet-specific 
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alloantibodies are warranted. Finally, a negative alloantibody test might guide the 
transfusion management of a trombocytopenic patient who responded well to HLA-
matched platelets leading to a rechallange with random donor platelets in order to 
exclude transient non-immunological factors. An algorithm for the administration of 
random donor and HLA-matched platelet transfusions on the basis ofthe results of our 
studies is shown in figure 1. Particular decision points in this algorithm are highlighted 
in the text. 
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Figure 1. 
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No at aU'? 
Based on our studies we advocate to test for alloimmunization in selected patients 
only: those being refractory to random platelets and after exclusion of non-
immunological factors. But even among this subgroup the risk of alloimmunization 
may differ considerably. Previous pregnancy has proved to be one of the strongest 
predictors for platelet refractoriness in different studies3.43.44. Also it is conceivable 
that patients with a rare type or mixture of HLA-class I antigens will preferentally 
develop alloantibodies against commonly prevalent HLA-class I antigens in the donor 
population. At this moment a retrospective study is conducted in which we wish to 
identify specific HLA-class I antigens associated with an increased risk of 
alloimmunization. It is also possible that certain combinations ofHLA-class A, Band 
C antigens show a greater tendency for alloimmunization. The latter enhanced 
likelihood of alloimmunization might relate to the amino acid triplet containment of 
exposed parts of the HLA-class I molecules as recently described by Duquesnol5.46. 
Among the large number of possible triplets only a small and particular fraction of 
triplets may be responsible for causing alloimmunization against donor platelets. 
Previous studies have suggested a greater probability of alloimmunization in patients 
with HLA-DR247-49 . This relationship, however, might have been dependent on the 
number of leukocytes in the transfused blood products and could not be confirmed in a 
population receiving leukodepleted blood products50. It is also possible that the 
relationship of alloimmunization with HLA-DR2 does not depend on the low 
frequency of the HLA-antigen itself, but it might be an epiphenomenon of the fact that 
patients with HLA-DR2 appear high producers of immunoglobulins against different 
antigens (high responders), so that screening tests demonstrating alloantibodies more 
often tum positive. 
If in future studies specific HLA-class I antigens, specific combinations of HLA-class 
I antigens or certain amino acid triplets of HLA-class I antigens appear to predispose 
for alloimmunization, these patients might profit from being monitored with 
alloantibody tests. This would hold particularly for female patients after pregnancies. 
In these selected subsets of patients HLA-matched platelet transfusions may be applied 
earlier in the platelet transfusion treatment on the basis of positive alloantibody tests. It 
might perhaps be advantages that these subsets of patients will receive HLA-matched 
platelets on forehand in order to prevent platelet refractoriness, but the availablility of 
sufficient compatible donors is likely to be small. The answers to these questions are 
directly relevant for optimized platelet transfusion support, in which severe bleeding 
complications at the time of refractoriness for random platelets may be prevented. 
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Final conclusions 
In this thesis we investigated a series of tests that detect alloantibodies to platelets. 
These investigations leads us to conclude: 
1. The various tests correlated statistically significantly with each other. In view of 
this we recommend to use the fastest and most easy applicable test (i.e. ELIHLA in 
our studies) 
2. Screening any patients rece1vmg leukodepleted blood products for 
alloimmunization is not useful as the predictive value with regard to the response 
to platelet transfusions is unsatisfactory. 
3. An HLA-matched platelet transfusion m patients refractory to random donor 
platelet transfusions in the absence of non-immunological factors may have a good 
survival even when the alloantibody test result has been negative. The average 
recovery, however, of HLA-matched platelet transfusions is better in patients with 
a positive test. 
4. In refractory patients with a negative test and a good response to HLA-matched 
platelet transfusions a rechallenge with random donor platelets is recommended. In 
refractory patients with a positive alloantibody test and a poor recovery of an HLA-
matched transfusion further investigations with regard to the involvement of 
platelet-specific alloantibodies appear warranted. 
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AA 
AlloBMT/SCT 
ALL 
AML 
ATG 
AutoBMT/SCT 
BDIS 
BSA 
CCI 
CI 
CLL 
CML 
Crossmatch-
PIFT 
DIC 
DLI 
Dtime-Atime 
EDTA 
ELIHLA 
ELISA 
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GAHu 
HD/HL 
HLA 
HPA 
FACScan 
FITC 
FSC 
GIFT 
GvHD 
12si-MA 
IgG 
IgM 
In vivo-PIFT 
IQR 
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Aplastic anemia 
Allogeneic bone marrow or stem cell transplantation 
Acute lymphoblastic leukemia 
Ac.ute myeloid leukemia 
Anti-thymocyte globulin 
Autologous bone marrow or stem cell transplantation 
Becton Dickinson 
Bovine serum albumin 
Corrected count increment 
Confidence interval 
Chronic lymphoblastic leukemia 
Chronic myeloid leukemia 
Cross match of patient's serum and transfused platelets in the PIFT 
technique 
Disseminated intravascular coagulation 
Donor lymphocyte infusion 
Time from acquisition of platelets till donation 
Ethylenediamine tetraacetic acid 
Enzyme linked immunosorbent human leukocyte antigen assay 
(Quikscreen ™) 
Enzyme-linked immunosorbent assay 
Events post subtraction 
Goat-anti human 
Hodgkin's disease or Hodgkin's lymphoma 
Human leukocyte antigen 
Human platelet antigen 
Fluorescence activated cell scan 
Fluorescein isothiocyanate 
Forward light scatter characteristics 
Granulocyte immunofluorescence test 
Graft versus host disease 
Monoclonal 125Iodide-labelled anti-IgG assay 
Immunoglobulin G 
Immunoglobulin M 
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Interquartile range 
ITP 
IVBI-PIFT 
LCT 
LIFT 
LDS 
MAIPA 
MCPS 
MDS 
MM 
NHL 
OR 
Panel-PIFT 
PBS 
PE 
PFA 
PI 
P(S)IFT 
PNPP 
PRA(T) 
PRP 
RAEB-t 
sse 
TO 
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Idiopathic thrombocytopenic purpura 
In vivo binding of immunoglobulins according to the PIFT 
technique 
Lymphocyte cytotoxic test 
Lymphocyte immunofluorescence test 
Laser dye solution 
Monoclonal antibody-specific immobilization of platelet antigens 
assay 
Mean chanell post subtraction 
Myelodysplastic syndromes 
Multiple myeloma 
Non-Hodgkin's lymphoma 
Odds ratio 
Indirect-PIFT (PIFT technique using panel cells from 5 random 
donors) 
Phosphate-buffered saline 
Phycoerythrin 
Paraformaldehyde 
Propidiumiodide 
Platelet (suspension) immunofluorescence test 
Phosphate p-nitrophenylphosphate 
Platelet radioactive antiglobulin (test) 
Platelet rich plasma 
Refractory anemia with excess of blasts in transformation 
Sideward light scatter characteristics 
T ransfusi eop brengst 
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Dankwoord 
Het is vanzelfsprekend dat een promotieonderzoek tijdens een voltijdse opleiding tot 
internist en hematoloog alleen tot stand kan komen dankzij de hulp van vele anderen. 
Ik ben dan ook alle mensen die hebben bijgedragen aan dit proefschrift zeer dankbaar 
voor hun inspanningen en de tijd die zij hieraan besteed hebben. 
Allereerst wil ik professor Lowenberg bedanken voor het feit dat hij mij in staat heeft 
gesteld om op zijn afdeling te promoveren. Tevens is zijn inzicht en schrijfstijl een 
inspiratie geweest voor verschillende delen van dit proefschrift. Zijn belangstelling 
gedurende vele jaren, niet alleen voor de vorderingen omtrent deze onderzoekingen 
maar ook voor mijn opleidingstraject op weg naar de hematologie, heb ik altijd zeer 
gewaardeerd. 
Mars van 't Veer heeft mij al die jaren begeleid en voorzien van denkbeelden, 
arbeidskrachten, hardware en informatie. Zonder zijn bezieling en 
doorzettingsvermogen, als er onverwachte resultaten werden gevonden, had ik het 
zeker niet al die jaren volgehouden. Het laatste jaar moest Mars ook wel eens zuchten 
als zijn E-mail box overladen werd met artikelen of andere stukken uit dit proefschrift. 
Toch wist hij altijd tijd vrij te maken overdag, 's avonds of als het nodig was zelf 's 
nachts. Heel hartelijk dank voor dit alles en ik verheug mij op de vele inhoudelijke 
discussies die wij ongetwijfeld nog zullen hebben in de toekomst. 
De meeste laboratoriumhandelingen zijn verricht door Jos de Veld op het immuno-
hematologisch laboratorium in het ErasmusMC - Daniel den Hoed (voorheen de Dr. 
Daniel den Hoed kliniek). Jos was steeds weer bereid om protocolen in de praktijk te 
brengen en ook de artikelen kritisch door te lezen en van commentaar te voorzien. In 
het immuno-hematologisch laboratorium hebben in de loop van de jaren ook Patricia 
van den Broek, Petra van der Spoel en Nicole Bakker veel testen uitgevoerd en 
geanalyseerd. 
Wim de Vries heeft mij wegwijs gemaakt in de immuno-hematologie op zijn eigen 
onnavolgbare marrier. ·Zijn ideeen omtrent de verschillende technieken van 
alloantistoftesten zijn duidelijk herkenbaar in verschillende hoofdstukken van dit 
proefschrift. Tevens heeft hij kritisch gekeken naar de meerdere artikelen uit dit 
proefschrift. 
De data analyse werd voor het grotendeels verricht door Ronnie van der Holt van de 
afdeling statistiek in het ErasmusMC - Daniel den Hoed. Ook heeft hij steeds met zijn 
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is gekomen. 
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de Erasmus Universiteit te Rotterdam. Een keuze-onderwijs op de afdeling 
hematologie motiveerde hem om te participeren aan een tweeledig keuze-onderzoek in 
1994 in de Dr. Daniel den Hoed kliniek onder begeleiding van Dr. A. Hagenbeek en 
Dr. M. B. van 't Veer. Een van deze twee keuze-onderzoeken ging over de waarde van 
IgM antistoffen tegen trombocyten, waarmee zijn interesse in de betekenis van 
alloantistoffen tegen trombocyten is begonnen. Hij verrichtte zijn co-schappen in 1995 
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doorgebracht op de verschillende afdelingen in het Medisch Centrum Rijnmond Zuid 
locatie Zuider (voorheen Zuider Ziekenhuis). De opleiding tot internist werd in juli 
2001 voortgezet in het ErasmusMC (opleider prof. dr. H. A. P. Pols), alwaar hij 
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